








Quick Reference Guide HEDIS[®] MY 2025



-  Meridian Medicaid
-  Meridian Medicare-Medicaid (MMP)
-  YouthCare (Medicaid)
-  Ambetter (Marketplace)
-  Wellcare (Medicare)
-  Electronic Clinical Data Systems (ECDS)-only HEDIS measure

 For more information, visit www.ncqa.org

HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA). The HEDIS[®] measures and specifications were developed by and are owned by NCQA. NCQA holds a copyright in these materials and may rescind or alter these materials at any time. Users of the HEDIS[®] measures and specifications shall not have the right to alter, enhance, or otherwise modify the HEDIS[®] measures and specifications, and shall not disassemble, recompile, or reverse engineer the HEDIS[®] measures and specifications. Anyone desiring to use or reproduce the materials, subject to licensed user restrictions, without modification for an internal non-commercial purpose may do so without obtaining any approval from NCQA. Use of the Rules for Allowable Adjustments of HEDIS[®] to make permitted adjustments of the materials does not constitute a modification. All other uses, including a commercial use, or any external reproduction, distribution, or publication must be approved by NCQA and are subject to a license at the discretion of NCQA.

HEDIS® MY 2025 Quick Reference Guide

Updated to reflect NCQA HEDIS® MY 2025
Technical Specifications

We strive to provide quality healthcare to our membership as measured through HEDIS® quality metrics. We created the HEDIS® MY 2025 Quick Reference Guide to help you increase your practice's HEDIS® rates and to use to address care opportunities for your patients. Please always follow the state and/or CMS billing guidance and ensure the HEDIS® codes are covered prior to submission.

What is HEDIS®?

HEDIS® (Healthcare Effectiveness Data and Information Set) is a set of standardized performance measures developed by the National Committee for Quality Assurance (NCQA) to objectively measure, report, and compare quality across health plans. NCQA develops HEDIS® measures through a committee represented by purchasers, consumers, health plans, health care providers, and policy makers.

What Are the Scores Used For?

As state and federal governments move toward a quality-driven healthcare industry, HEDIS® rates are becoming more important for both health plans and individual providers. State purchasers of healthcare use aggregated HEDIS® rates to evaluate health insurance companies' efforts to improve preventive health outreach for patients.

Physician-specific scores are also used to measure your practice's preventive care efforts. Your practice's HEDIS® score determines your rates for physician incentive programs that pay you an increased premium — for example Pay for Performance or Quality Bonus Funds.

How Are Rates Calculated?

HEDIS® rates can be calculated in two ways: administrative data or hybrid data. Administrative data consists of claim or encounter data submitted to the health plan. Hybrid data consists of both administrative data and a sample of medical record data. Hybrid data requires review of a random sample of member medical records to abstract data for services rendered but that were not reported to the health plan through claims/encounter data. Accurate and timely claim/encounter data can reduce the need for medical record review. If services are not billed, not billed accurately, or not shared through electronic data feeds, they are not included in the calculation.

How Can I Improve My HEDIS® Scores?

- Submit claim/encounter data for each and every service rendered
- Make sure that chart documentation reflects all services billed
- Bill (or report by encounter submission) for all delivered services, regardless of contract status
- Ensure that all claim/encounter data is submitted in an accurate and timely manner
- Include CPT II codes to provide additional details and reduce medical record requests
- Implement an electronic data feed to capture relevant HEDIS data, such as test results not obtained via claims or services rendered before the member's enrollment, for more accurate reporting

This guide has been updated with information from the release of the HEDIS® MY 2025 Volume 2 Technical Specifications by NCQA and is subject to change.

Contact Information For Provider Services:

- [lmeridian.com](https://www.lmeridian.com) 866-606-3700
- mmp.lmeridian.com 855-580-1689
- [lyouthcare.com](https://www.lyouthcare.com) 844-289-2264
- [ambetterofillinois.com](https://www.ambetterofillinois.com) 1-855-745-5507
- [wellcare.com/en/illinois](https://www.wellcare.com/en/illinois) 1-855-538-0454 (TTY 711)

 For more information, visit www.ncqa.org

Contents

| | | |
|-----------|--|-----------------|
| 2 | What is HEDIS®? | |
| 2 | What Are the Scores Used For? | |
| 3 | How Are Rates Calculated? | |
| 3 | How Can I Improve My HEDIS® Scores? | |
| 4 | Contents | |
| 7 | Partnering with the Health Plan | |
| 7 | Introduction | |
| 8 | Provider Incentive Programs | ● ● ● |
| 9 | HEDIS MY 2025 Summary of Changes | ● ● ● ● ● ● |
| 10 | Electronic Clinical Data Systems (ECDS) | ● ● ● ● ● ● ● ● |
| 12 | Consumer Assessment of Healthcare Providers and Systems (CAHPS®) | ● ● ● ● ● |
| 16 | Critical Incidents (CI) | ● ● ● |
| 17 | Cultural Competence | ● ● |
| 18 | Quality Education Webinar (QEW) | ● ● ● ● ● ● |
| 19 | Access & Availability | ● ● ● ● ● |
| 27 | Caring for and Communicating with Individuals with Intellectual and Developmental Disabilities (IDD) | ● ● ● ● ● ● ● |
| 30 | Early Periodic Screening, Diagnosis, and Treatment (EPSDT) | ● ● |
| 33 | Supplemental Data | ● ● ● ● ● ● |
| 34 | Adult Health | |
| 34 | Adults' Access to Preventive/Ambulatory Health Services (AAP) | ● ● ● ● |
| 35 | Advanced Care Planning (ACP) | ● |
| 35 | Adult Immunization Status (AIS-E) | ● ● ● ● ● ● ● |
| 38 | Appropriate Treatment for Upper Respiratory Infection (URI) | ● ● ● ● ● ● |
| 40 | Glycemic Status Assessment for Patients with Diabetes (GSD) | ● ● ● ● ● ● |
| 40 | Blood Pressure Control for Patients with Diabetes (BPD) | ● ● ● ● ● |
| 41 | Eye Exam for Patients with Diabetes (EED) | ● ● ● ● ● ● |
| 42 | Kidney Health Evaluation for Patients with Diabetes (KED) | ● ● ● ● ● ● |
| 42 | Diabetes Monitoring for People with Diabetes and Schizophrenia (SMD) | ● |
| 43 | Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD) | ● |
| 44 | Cardiac Rehabilitation (CRE) | ● ● ● ● |
| 44 | Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia (SMC) | ● |
| 45 | Colorectal Cancer Screening (COL-E) | ● ● ● ● ● ● ● ● |
| 46 | Care for Older Adults (COA) | ● |
| 47 | Controlling High Blood Pressure (CBP) | ● ● ● ● ● ● |
| 48 | Blood Pressure Control for Patients with Hypertension (BPC-E) | ● ● ● ● ● ● ● ● |
| 49 | Follow-Up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions (FMC) | ● ● ● |
| 50 | Persistence of Beta-Blocker Treatment After a Heart Attack (PBH) | ● ● ● ● ● ● |
| 51 | Pharmacotherapy Management of COPD Exacerbation (PCE) | ● ● ● ● ● ● |
| 52 | Plan All Cause Readmissions (PCR) | ● ● ● ● ● ● |
| 53 | Transitions of Care (TRC) | ● ● ● ● |
| 54 | Use of Imaging Studies for Low Back Pain (LBP) | ● ● ● ● ● ● |

56 Behavioral Health

- 56 Adherence to Antipsychotic Medications for People with Schizophrenia (SAA) ●●●
- 57 Follow-Up After Emergency Department Visit for Mental Illness (FUM) ●●●●
- 59 Follow-Up After Emergency Department Visit for Substance Use (FUA) ●●●●
- 66 Follow-Up After High Intensity Care for Substance Disorder (FUI) ●●●●
- 68 Follow-Up After Hospitalization for Mental Illness (FUH) ●●●●
- 71 Initiation and Engagement of Substance Use Disorder (IET) ●●●●
- 75 Pharmacotherapy for Opioid Use Disorder (POD) ●●●●
- 76 Unhealthy Alcohol Use Screening and Follow-Up (ASF-E) ●●●●
- 77 Screening for Depression and Follow-Up Plan (CDF-AD) ●
- 77 Screening for Depression and Follow-Up Plan (CDF-CH) ●
- 78 Depression Screening and Follow-Up for Adolescents and Adults (DSF-E) ●●●●
- 78 Depression Remission or Response for Adolescents and Adults (DRR-E) ●●●●
- 79 Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E) ●●●●
- 80 Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) ●●

81 General Health

- 81 Appropriate Testing for Pharyngitis (CWP) ●●●●
- 81 Asthma Medication Ratio (AMR) ●●
- 84 Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB) ●●●●
- 86 Social Need Screening and Intervention (SNS-E) ●●●●

92 Pediatric Health

- 92 Childhood Immunization Status (CIS-E) ●●●●
- 98 Follow-Up Care for Children Prescribed ADHD Medication (ADD-E) ●●●●
- 100 Immunizations for Adolescents (IMA-E) ●●●●
- 101 Lead Screening in Children (LSC) ●
- 102 Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E) ●●●●
- 104 Oral Evaluation, Dental Services (OED) ●●●●
- 105 Topical Fluoride for Children (TFC) ●●
- 105 Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) ●●●●
- 106 Well-Child and Adolescent Well-Care Visits (W30 ●●●/WCV ●●●)

107 Pharmacy Measures

- 107 Adherence to Cholesterol Medications (STAT) ●
- 108 Adherence to Diabetes Medications (DIAB) ●
- 109 Adherence to Hypertensive Medications (RASA) ●
- 110 Statin Therapy for Patients with Cardiovascular Disease (SPC) ●●●●
- 111 Statin Therapy for Patients with Diabetes (SPD) ●●●●

113 Women's Health

- 113 Breast Cancer Screening (BCS-E) ●●●●
- 114 Documented Assessment After Mammogram (DBM-E) ●●●●
- 115 Follow-Up After Abnormal Mammogram Assessment (FMA-E) ●●●●
- 116 Cervical Cancer Screening (CCS-E) ●●●●

- 117 Chlamydia Screening in Women (CHL) ●●
- 118 Osteoporosis Management in Women Who Had a Fracture (OMW) ●●
- 118 Osteoporosis Screening in Older Women (OSW) ●●
- 119 Prenatal and Postpartum Care (PPC) ●●
- 121 Prenatal Immunization Status (PRS-E) ●👤
- 122 Prenatal Depression Screening and Follow-Up (PND-E) ●👤
- 122 Postpartum Depression Screening and Follow-Up (PDS-E) ●👤

123 Appendix

- 123 Antidepressant Medication List ●●●●
- 124 Approved Depression Screening Instruments, Codes, and Positive Findings ●●●●
- 125 Follow-Up Visit ●●●●
- 127 Depression or Other Behavioral Health Condition ●●●●
- 132 Exclusions ●●●●
- 142 Point of Service Code Definitions ●●●●

Partnering with the Health Plan



Introduction

This guide contains information about the quality measures for the following Meridian lines of business:

- **Meridian Medicaid Plan (Medicaid)**

The Meridian Medicaid Plan in Illinois provides government-sponsored managed care services to families, children, seniors and individuals with complex medical needs through Medicaid across the state.

- **Meridian Medicare-Medicaid Plan**

The Meridian Medicare-Medicaid Plan (MMP) is a Medicare-Medicaid Alignment Initiative (MMAI) plan for beneficiaries eligible for both Medicaid and Medicare in Illinois.

- **YouthCare (Medicaid)**

The YouthCare HealthChoice Illinois program is a specialized healthcare program built cooperatively with parents and other stakeholders to improve access, continuity of care, and healthcare outcomes for Department of Children and Family Services (DCFS) youth in care and former youth in care.

- **Ambetter of Illinois (Marketplace)**

Ambetter offers quality and affordable health insurance in Illinois that fits various needs and budgets.

- **Wellcare (Medicare)**


Medicare Advantage (MA) plans that offer Medicare Part A, Part B, and Part D benefits.

Provider Incentive Programs ●●●

Partnership for Quality (P4Q) measures are on the provider portal. Visit our [Provider Portal](#) to view the recent P4Q measures available to our Meridian provider partners.

For additional information about provider incentive programs, please contact your organization’s assigned Provider Engagement Administrator or representative. If your practice doesn’t have an assigned representative, please complete the [Provider Relations intake form](#) or consult our [Provider Relations page](#) for additional contact options.

When contacting Provider Relations, please be ready to share the region where your practice is located so you can be directed to the appropriate support teams.



Provider incentive programs apply to non-risk contractual providers only.

HEDIS MY 2025 Summary of Changes ●●●●●

The following changes are effective for Measurement Year (MY) 2025.

This guide has been updated with information from the release of the HEDIS 2025 Volume 2 Technical Specifications by NCQA and is subject to change.

Retired Measures:

- Antidepressant Medication Management (AMM)
- Childhood Immunization Status (CIS)*
- Immunizations for Adolescents (IMA)*
- Cervical Cancer Screening (CCS)*

***Note:** The traditional HEDIS measure is being retired, and the measure is transitioning to Electronic Clinical Data Systems (ECDS) reporting only (CIS-E, IMA-E, and CCS-E will still be reported). There will no longer be a hybrid sample for CIS, IMA, or CCS beginning in MY 2025.

Revised Measures:

Please refer to each measure's listing within the guide for the latest measure description.

- Acute Hospitalization Utilization (AHU)
- Adult Immunization Status (AIS-E)
- Care for Older Adults (COA)
- Potentially Harmful Drug-Disease Interactions with Older Adults (DDE)
- Eye Exam for Patients with Diabetes (EED)
- Follow-Up After Hospitalization for Mental Illness (FUH)
- Follow-Up After Emergency Department Visit for Mental Illness (FUM)

In addition, NCQA has removed the telehealth option for the following measures:


- Well-Care Visits in the First 30 months of Life (W30)
- Child and Adolescent Well-Care Visits (WCV)

New Measures:

All new measures for MY 2025 are reported using the ECDS-only method (see more on page 9).

- Blood Pressure Control for Patients with Hypertension (BPC-E)
Note: This measure is NOT replacing Controlling High Blood Pressure (CBP) in MY 2025
- Documented Assessment After Mammogram (DBM-E)
- Follow-Up After Abnormal Mammogram Assessment (FMA-E)

Electronic Clinical Data Systems (ECDS)

Tip: Look for the  icon to quickly identify HEDIS measures that are only reported using the ECDS method.

ECDS (Electronic Clinical Data Systems) are the network of data containing a patient's personal health information and records of their experiences within the healthcare system. They may also support other care-related activities directly or indirectly, including evidence-based decision support, quality management, and outcome reporting. Data in these systems are structured such that automated quality measurement queries can be consistently and reliably executed, providing results quickly and efficiently to the team responsible for patient care.

Establishing an enterprise network of interoperable electronic data systems will foster a patient-centered, team-based approach to improving healthcare quality and communication across healthcare service providers.

ECDS reporting is part of NCQA's larger strategy to enable a Digital Quality System and is aligned with the industry's move towards greater interoperability of health information. Visit www.ncqa.org/ecds for more information and frequently asked questions about ECDS reporting.

The goal is to promote the integration of clinical information by automatically transferring data for gap closure. ECDS measures allow for plans to view quality care prospectively as opposed to reviewing quality care retrospectively.

ECDS data sources include:

- Enrollment
- Claims
- Encounters
- EHRs
- HIEs
- Registries
- Case Management

Tips for successful gap closure for all measures include:

- Establish electronic data transfers, such as supplemental data files
 - Refer to [Supplemental Data source section](#)
- Include CPT II codes on claims
- Ensure CPT II, LOINC, and SNOMED codes are all linked in your provider EMR system
 - LOINC and SNOMED value sets are transferred electronically, not on claims
- Develop and execute a data strategy prior to HEDIS transitioning to ECDS only

ECDS reporting highlights:

The following measures have transitioned to ECDS-only reporting for MY 2025:

- Cervical Cancer Screening (CCS-E)
- Childhood Immunization Status (CIS-E)
- Immunizations for Adolescents (IMA-E)

Other ECDS measures developed that are currently being measured and reported include:

- Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)
- Adult Immunization Status (AIS-E)
- Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)
- Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)
- Blood Pressure Control for Patients With Hypertension (BPC-E)
- Colorectal Cancer Screening (COL-E)
- Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)
- Depression Remission or Response for Adolescents and Adults (DRR-E)
- Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)
- Postpartum Depression Screening and Follow-Up (PDS-E)
- Prenatal Depression Screening and Follow-up (PND-E)
- Prenatal Immunization Status (PRS-E)
- Social Need Screening and Intervention (SNS-E)

Visit www.ncqa.org/ecds for more information and FAQs about ECDS reporting.

Consumer Assessment of Healthcare Providers and Systems (CAHPS®) ●●●●

Every year, a random sample of patients are surveyed about their experience with their providers, services, and health plan. It is an important component of ensuring that patients are satisfied, not only with their health outcomes but also with their healthcare experience.

The CAHPS survey is applicable to **Meridian**, **Wellcare**, and **YouthCare**. For **Ambetter**, the CAHPS survey is referred to as the Qualified Health Plan (QHP) Enrollee Survey. The CAHPS and the QHP surveys allow patients to evaluate the aspects of care delivery that matter the most to them. At Meridian, we are committed to partnering with our providers to deliver outstanding patient experience.

As a provider, you are the most critical component of that experience. We want to ensure that you know exactly how your patients are evaluating your care. Please take a moment to review and to familiarize yourself with some of the key topics included in the survey.

| Survey Measure | Description | Daily Practice Tips |
|---------------------|---|--|
| Getting Needed Care | This measure assesses the ease with which patients received the care, tests, or treatment they needed. It also assesses how often they were able to get a specialist appointment scheduled when needed. | <ul style="list-style-type: none"> • Office staff should help coordinate specialty appointments for urgent cases • Encourage patients and caregivers to view results on the patient portal when available • Inform patients of what to do if care is needed after hours • Offer appointments or refills via text and/or email • Offer alternative appointment types to expand access to care (e.g., telephone, telehealth, telemedicine, and patient portals) |

| Survey Measure | Description | Daily Practice Tips |
|----------------------|---|--|
| Getting Care Quickly | This measure assesses how often patients got the care they needed as soon as they needed it and how often appointment wait times exceeded 15 minutes. | <ul style="list-style-type: none"> • Ensure a few appointments each day are available to accommodate urgent visits • Offer appointments with a nurse practitioner or physician assistant for short notice appointments • Maintain an effective triage system to ensure that frail and/or very sick patients are seen right away or provided alternate care via phone and urgent care • Keep patients informed if there is a longer wait time than expected and give them an option to reschedule |
| Care Coordination | This measure assesses providers' assistance with managing the disparate and confusing health care system, including access to medical records, timely follow-up on test results, and education on prescription medications. | <ul style="list-style-type: none"> • Ensure there are open appointments for patients recently discharged from a facility • Integrate PCP and specialty practices through EMR or fax to get reports promptly • Ask patients if they have seen any other providers; discuss visits to specialty care as needed • Encourage patients to bring in their medications to each visit • Share test results and explain what they mean • Provide instructions for follow-up questions or concerns |

| Survey Measure | Description | Daily Practice Tips |
|-------------------------------|--|---|
| How Well Doctors Communicate | This measure assesses patients' perception of the quality of communication with their doctor. Consider using the Teach-Back Method to ensure patients understand their health information. | <ul style="list-style-type: none"> • Use body language to show you are engaged and listening to the patient (sit down and face the patient; maintain eye contact) • Don't rush; explain things in a way the patient can understand • Be empathetic with bad news. Be sensitive and acknowledge family members or caregivers in the room with the patient • Summarize the visit and next steps in a way the patient can understand • Let the patient know when you will see them next <p>What is Teach-back?</p> <ul style="list-style-type: none"> • Asking a patient (or family member) to explain in their own words what they need to know or do, in a caring way • A way to check for understanding and, if needed, re-explain and check again |
| Rating of Health Care Quality | The CAHPS® survey asks patients to rate the overall quality of their health care on a 0-10 scale. | <ul style="list-style-type: none"> • Encourage patients to make their routine appointments for checkups or follow up visits as soon as they can – weeks or even months in advance • Ensure that open care gaps are addressed during each patient visit • Make use of the provider portal when requesting prior authorizations |

On the following page are examples of **satisfaction categories and survey questions** for which your patients are asked to respond; provider discussion questions; and Provider Tips. We hope this tool will provide reinforcement opportunities for your relationship with the patients you serve.

| Sample Questions | Provider Tips |
|---|---|
| <p>Health Promotion Discussion Questions</p> <p>Any problems with your work or daily activities due to physical problems?</p> <p>Any problems with your work or daily activities due to stress?</p> <p>Anything bothering you or stressful?</p> <p>Are you sad or depressed?</p> <p>Do you use tobacco? (Always/Sometimes/Never)</p> <p>Do you drink alcohol? (Always/Sometimes/Never)</p> <p>Do you exercise? (Always/Sometimes/Never)</p> <p>Do you take aspirin? (Always/Sometimes/Never)</p> <p>Do you or anyone in your family have high blood pressure, high cholesterol or had a heart attack?</p> <p>Have you had a flu shot in the past calendar year? If not, Why?</p> | <ul style="list-style-type: none"> • Complete and document any health assessment on patient • Discuss with patient the benefits of exercise and encourage them to start, increase or maintain physical activity and document discussion • Discuss the risks of tobacco use and recommend medication to assist in stopping • Discuss issues associated with drinking too much alcohol, if necessary • Discuss the risks and benefits of aspirin to prevent heart attack or stroke • Screen patient for high blood pressure and cholesterol • Recommend and/or administer the flu shot during flu season |
| <p>Medication Discussion Questions</p> <p>Are you currently on any prescription medications from another doctor? If so, what?</p> <p>How long have you been on the medication?</p> | <ul style="list-style-type: none"> • Document all prescription medication patient is taking • Discuss options and reasons to take alternate medications if patient is not getting positive results for symptoms • Discuss reasons with patient why they may need to stop taking a particular medication • Discuss the benefits and risks of taking a medicine • Discuss patient's preference on what medication they feel would be best for them • Review medications prescribed by PCP and specialists and verify results |

| Sample Questions | Provider Tips |
|---|--|
| <p>Access to Care Discussion Questions</p> <p>Are you satisfied with the timeframe it took to schedule your appointment?</p> <p>Were you able to get your appointment as soon as you needed?</p> <p>Are you satisfied with the coordination of care you receive, coordinating visits with specialists, non-emergency transportation (if needed) and providing lab or test results?</p> | <ul style="list-style-type: none"> • Evaluate office procedures to improve getting patients scheduled as quickly as possible for their symptoms • Determine why patient perceives difficulty in getting timely care, if necessary • Educate patient on timeframes for getting appointments according to their symptoms • Assist in coordination of non-emergency transportation, if necessary • Use patient experience surveys or post-visit survey results to identify opportunities for improvement |

Critical Incidents (CI) ●●●

A critical incident (CI) is any alleged or actual event that poses a risk of serious harm, injury, or death of the member.

Critical incidents include, but are not limited to:

- Abuse
- Fraud
- Neglect
- Exploitation
- Behavioral Health Issues
- Unanticipated Death
- Legal/Criminal Activity
- Medication Management
- Restraint/Seclusion/or Other Restrictive Intervention
- Medical Emergency/Injury/Illness
- Missing Person/Elopement
- Environmental/Unsafe Housing/Displacement

Types of abuse can include physical abuse, verbal abuse, sexual abuse, or harassment, and mental or emotional abuse.

Reporting Critical Incidents

1. Identify the appropriate CI type
2. Complete a Critical Incident Reporting Form if incident occurred within the past year
 - Submit within 48 hours of discovering the incident
3. Email Critical Incident Reporting Form to criticalincidents@mhplan.com

The Critical Incident Reporting Form can be found here:

<https://www.ilmeridian.com/providers/resources/forms-resources.html>.

Cultural Competence ●●

Cultural Competence is a set of attitudes, behaviors, and policies that enable people to work effectively in cross-cultural situations. We serve a diverse patient population. The ability to understand and relate to different cultures can help you communicate effectively with your patients. All Meridian network providers are contractually required to complete the online Cultural Competency training annually.

Medicaid and MMP: [lmeridian.com/providers/resources/provider-training/annual-training.html](https://www.lmeridian.com/providers/resources/provider-training/annual-training.html)

Tips for Providing Culturally Competent Care

Consider population-specific conditions: Low-income/low-literacy, race, disability, spirituality, age, sexuality, and gender identity.

Ask about cultural practices: Spiritual traditions, dietary restrictions, and more may impact a patient's clinical experience.

Practice transcultural techniques: Approach a new patient slowly, be respectful, sit in a quiet setting, and sit a comfortable distance away.

Ensure patient's understanding of care: Lack of accessible medication instructions in a patient's language can impact quality of care. Ensure a patient's comprehension by utilizing translated handouts and/or make use of a translator.

Things to Remember

- 1 in 4 Americans live with a disability and are twice as likely to find his or her provider's skills or facilities inadequate.
- 1 in 5 Americans speak a language other than English at home. Language barriers can prevent patients from effectively conveying their ailments and understanding their care plans.
- 3.6 million Americans miss or delay medical care because they lack reliable transportation.
- Invest in Americans with Disabilities Act (ADA)-approved renovations and train staff on disabilities, challenges, and rights.
- Speak slowly, summarize, demonstrate, and use appropriate terminology when providing instructions. Ensure that patients understand the instructions at the end of the visit.
- Call Meridian transportation at 866-796-1165 at least three business days prior to a patient's appointment.

Sources: [CDC.gov](https://www.cdc.gov), [census.gov](https://www.census.gov), [ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov)

Quality Education Webinar (QEW) ●●●●●

To support our providers in their quality improvement efforts, Meridian's Quality Improvement team hosts a series of webinars on topics related to improving patients' quality of care.

We hope these sessions will assist provider teams to improve HEDIS® scores and drive better incentive payments to your practice.

All office staff can attend including providers, administrative staff, and quality teams. Participants can watch the webinars remotely using the Zoom call-in number sent each month via email. If you are interested in receiving a copy of the webinar schedule or to be added to the invite distribution list, please email ILHEDISOps@mhplan.com.

Sample webinar topics include:

- HEDIS® Pay for Quality (P4Q) Program
- HEDIS® Measure & Exclusion Criteria
- Best Practices for Closing Care Gaps
- CAHPS® Survey and Patient Satisfaction
- Overview of the Illinois Lines of Business: Meridian Medicaid Plan, Meridian Medicare-Medicaid Plan, Wellcare, YouthCare, and Ambetter
- Risk Adjustment
- Centene Institute for Advanced Health Education
- Member Outreach with Care Coordination
- Vendor Updates and Outreach

Access & Availability ● ● ● ●

To ensure medical services are available to our members on a timely basis, Primary Care Provider (PCP), behavioral health, and specialist appointment availability standards for Meridian and its family of plans are established and noted in the following section. Information is included for all plans, including the Meridian Medicaid Plan, YouthCare, Meridian Medicare-Medicaid Plan (MMP), Ambetter, and Wellcare.

Each year, our Quality Improvement team conducts a telephone audit using the standards below set forth by NCQA, CMS, and/or State regulations. These audits are conducted to monitor provider compliance with Illinois Medicaid contract requirements. The process of conducting the annual audits is outlined below.

IDENTIFY: Meridian audits a sample of its contracted PCPs, behavioral health practitioners, and specialists.

OUTREACH: Conducted by a third-party vendor via phone, up to three attempts are made to reach a live person.

ANALYZE: Analysis is performed based on all data collected.

REPORT: Letters are mailed to offices indicating the results of the audit. Any offices that did not meet the standards are placed on a corrective action plan and are asked to identify ways to improve their appointment availability.

1. Medicaid Appointment and Timely Access to Care Standards

| Primary Care Appointments | |
|---|---|
| Type of Care/Appointment | Length of Wait Time |
| Preventative/Routine Care (Child < 6 months) | Within two (2) weeks of request |
| Preventative/Routine Care (Child ≥ 6 months) | Within five (5) weeks of request |
| Preventative/Routine Care (Adult) | Within five (5) weeks of request |
| Urgent/Non-Emergent (Medically Necessary) Care | Within twenty-four (24) hours of request |
| Non-Urgent/Non-Emergent Conditions | Within three (3) weeks of request |
| Initial Prenatal w/o Problems (First Trimester) | Within two (2) weeks of request |
| Prenatal (Second Trimester) | Within one (1) week of request |
| Prenatal (Third Trimester) | Within three (3) days of request |
| Office Wait Time | Within thirty (30) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

Medicaid Appointment and Timely Access to Care Standards (continued)

| Behavioral Health Appointments | |
|-----------------------------------|---|
| Type of Care/Appointment | Length of Wait Time |
| Life-Threatening Emergency | Immediate admittance or referred to the Emergency Room |
| Non-Life-Threatening Emergency | Within six (6) hours of request |
| Urgent Care Visit | Within forty-eight (48) hours of request |
| Initial Visit for Routine Care | Within ten (10) business days of request |
| Follow-Up Visit for Routine Care | Within twenty (20) business days of request |
| Office Wait Time | Within thirty (30) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

| Specialty Care Appointments | |
|-----------------------------------|---|
| Type of Care/Appointment | Length of Wait Time |
| Routine Care (Adult) | Within forty-five (45) calendar days of request |
| Routine Care (Child) | Within twenty-one (21) calendar days of request |
| Urgent Care Visit | Within seventy-two (72) hours of request |
| Office Wait Time | Within thirty (30) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

Medical coverage 24 hours a day, 7 days a week

Medicaid Primary Care After-Hours Requirements

Acceptable after-hours access mechanisms include:

- Answering service
- On-call pager/cellular connection
- Call forwarding to practitioner's home/other location
- Published after-hours telephone number and recorded voice message directing patients to a practitioner for urgent and non-life-threatening conditions.

The message should not instruct patients to obtain treatment at the **Emergency Room for Non-Life-Threatening Emergencies** but **MUST** direct patients in a medical emergency to call 911 or go to the nearest Emergency Room/Urgent Care.

Voice Message MUST contain ONE of the following:

- Message forwards to on-call practitioner
- Message forwards to an answering service
- Message gives the on-call practitioner’s number
- Message gives the on-call practitioner’s pager number
- Message refers patient to another office, practitioner, or on-call service

Message may not only direct patients to the Emergency Room. The patient must be able to leave a message for an on-call doctor, speak with an on-call doctor, or be forwarded to an on-call doctor.

2. YouthCare Appointment and Timely Access to Care Standards

| Primary Care Appointments | |
|---|---|
| Type of Care/Appointment | Length of Wait Time |
| Preventative/Routine Care (Child < 6 months) | Within two (2) weeks of request |
| Preventative/Routine Care (Child ≥ 6 months) | Within five (5) weeks of request |
| Preventative/Routine Care (Adult) | Within five (5) weeks of request |
| Urgent/Non-Emergent (Medically Necessary) Care | Within twenty-four (24) hours of request |
| Non-Urgent/Non-Emergent Conditions | Within three (3) weeks of request |
| Initial Prenatal w/o Problems (First Trimester) | Within two (2) weeks of request |
| Prenatal (Second Trimester) | Within one (1) week of request |
| Prenatal (Third Trimester) | Within three (3) days of request |
| Office Wait Time | Within sixty (60) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

| Behavioral Health Appointments | |
|----------------------------------|--|
| Type of Care/Appointment | Length of Wait Time |
| Life-Threatening Emergency | Immediate admittance or referred to the Emergency Room |
| Non-Life-Threatening Emergency | Within six (6) hours of request |
| Urgent Care Visit | Within forty-eight (48) hours of request |
| Initial Visit for Routine Care | Within ten (10) business days of request |
| Follow-Up Visit for Routine Care | Within twenty (20) business days of request |

YouthCare Appointment and Timely Access to Care Standards (continued)

| Behavioral Health Appointments | |
|-----------------------------------|---|
| Office Wait Time | Within sixty (60) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

| Specialty Care Appointments | |
|-----------------------------------|---|
| Type of Care/Appointment | Length of Wait Time |
| Routine Care (Adult) | Within forty-five (45) calendar days of request |
| Routine Care (Child) | Within twenty-one (21) calendar days of request |
| Urgent Care Visit | Within seventy-two (72) hours of request |
| Office Wait Time | Within sixty (60) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

Medical coverage 24 hours a day, 7 days a week

YouthCare Primary Care After-Hours Requirements

Acceptable after-hours access mechanisms include:

- Answering service
- On-call pager/cellular connection
- Call forwarding to practitioner’s home/other location
- Published after-hours telephone number and recorded voice message directing patients to a practitioner for urgent and non-life-threatening conditions.

The message **should not instruct patients to obtain treatment at the Emergency Room for Non-Life-Threatening Emergencies** but **MUST** direct patients in a medical emergency to call 911 or go to the nearest Emergency Room/Urgent Care.

Voice Message MUST contain ONE of the following:

- Message forwards to on-call practitioner
- Message forwards to an answering service
- Message gives the on-call practitioner’s number
- Message gives the on-call practitioner’s pager number
- Message refers patient to another office, practitioner, or on-call service

Message may not only direct patients to the Emergency Room. **The patient must be able to leave a message for an on-call doctor, speak with an on-call doctor, or be forwarded to an on-call doctor.**

3. Medicare-Medicaid Plan (MMP) Appointment and Timely Access to Care Standards

| Primary Care Appointments | |
|---|---|
| Type of Care/Appointment | Length of Wait Time |
| Preventative/Routine Care | Within five (5) weeks of request |
| Urgent/Non-Emergent (Medically Necessary) Care | Within one (1) business day of request |
| Non-Urgent/ Non-Emergent Conditions | Within three (3) weeks of request |
| Initial Prenatal w/o Problems (First Trimester) | Within two (2) weeks of request |
| Prenatal (Second Trimester) | Within one (1) week of request |
| Prenatal (Third Trimester) | Within three (3) days of request |
| Office Wait Time | Within thirty (30) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

| Behavioral Health Appointments | |
|----------------------------------|---|
| Type of Care/Appointment | Length of Wait Time |
| Life-Threatening Emergency | Within one (1) business day of request |
| Non-Life-Threatening Emergency | Within six (6) hours of request |
| Urgent Care Visit | Within forty-eight (48) hours of request |
| Initial Visit for Routine Care | Within ten (10) business days of request |
| Follow-Up Visit for Routine Care | Within twenty (20) business days of request |

| Specialty Care Appointments | |
|-----------------------------------|---|
| Type of Care/Appointment | Length of Wait Time |
| Routine Care (Adult) | Within five (5) weeks of request |
| Urgent Care Visit | Within seventy-two (72) hours of request |
| Office Wait Time | Within thirty (30) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

MMP Primary Care After-Hours Requirements

Acceptable After-Hours access mechanisms include:

- Answering service
- On-call pager/cellular connection
- Call forwarding to practitioner's home/other location
- Published after-hours telephone number and recorded voice message directing patients to a practitioner for urgent and non-life-threatening conditions.

The message should not instruct patients to obtain treatment at the Emergency Room for Non-Life-Threatening Emergencies but MUST direct patients in a medical emergency to call 911 or go to the nearest Emergency Room/Urgent Care.

Voice Message MUST contain ONE of the following:

- Message forwards to on-call practitioner
- Message forwards to an answering service
- Message gives the on-call practitioner's number
- Message gives the on-call practitioner's pager number
- Message refers patient to another office, practitioner, or on-call service

Message may not only direct patients to the Emergency Room. The patient must be able to leave a message for an on-call doctor, speak with an on-call doctor, or be forwarded to an on-call doctor.

4. Ambetter Appointment and Timely Access to Care Standards

| Primary Care Appointments | |
|--|---|
| Type of Care/Appointment | Length of Wait Time |
| Preventative/Routine Care | Within fifteen (15) calendar days of request |
| Urgent/Non-Emergent (Medically Necessary) Care | Within twenty-four (24) hours of request |
| Sick Care | Within twenty-four (24) hours of request |
| Office Wait Time | Within thirty (30) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

| Behavioral Health Appointments | |
|--------------------------------|--|
| Type of Care/Appointment | Length of Wait Time |
| Life-Threatening Emergency | Immediate admittance or referred to the Emergency Room |
| Non-Life-Threatening Emergency | Within six (6) hours of request |
| Urgent Care Visit | Within forty-eight (48) hours of request |

Ambetter Appointment and Timely Access to Care Standards (continued)

| Behavioral Health Appointments | |
|-----------------------------------|---|
| Initial Visit for Routine Care | Within ten (10) business days of request |
| Follow-Up Visit for Routine Care | Within ten (10) business days of request |
| Office Wait Time | Within thirty (30) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

| Specialty Care Appointments | |
|-----------------------------------|---|
| Type of Care/Appointment | Length of Wait Time |
| Routine Care | Within thirty (30) calendar days of request |
| Urgent Care Visit | Within forty-eight (48) hours of request |
| Office Wait Time | Within thirty (30) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

Medical coverage 24 hours a day, 7 days a week

Ambetter Primary Care After-Hours Requirements

Acceptable After-Hours access mechanisms include:

- Answering service
- On-call pager/cellular connection
- Call forwarding to practitioner's home/other location
- Published after-hours telephone number and recorded voice message directing patients to a practitioner for urgent and non-life-threatening conditions.

The message should not instruct patients to obtain treatment at the **Emergency Room for Non-Life-Threatening Emergencies** but **MUST** direct patients in a medical emergency to call 911 or go to the nearest Emergency Room/Urgent Care.

Voice Message **MUST** contain **ONE** of the following:

- Message forwards to on-call practitioner
- Message forwards to an answering service
- Message gives the on-call practitioner's number
- Message gives the on-call practitioner's pager number
- Message refers patient to another office, practitioner, or on-call service

Message may not only direct patients to the Emergency Room. The patient must be able to leave a message for an on-call doctor, speak with an on-call doctor, or be forwarded to an on-call doctor.

5. Wellcare Appointment and Timely Access to Care Standards

| Primary Care Appointments | |
|--|---|
| Type of Care/Appointment | Length of Wait Time |
| Preventative/Routine Care | Within one (1) month of request |
| Urgent/Non-Emergent (Medically Necessary) Care | Within twenty-four (24) hours of request |
| Sick Care | Within one (1) week of request |
| Non-Urgent/ Non-Emergent Conditions | Within three (3) weeks of request |
| Office Wait Time | Within fifteen (15) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

| Behavioral Health Appointments | |
|-----------------------------------|---|
| Type of Care/Appointment | Length of Wait Time |
| Life-Threatening Emergency | Immediate admittance or referred to the Emergency Room |
| Non-Life-Threatening Emergency | Within six (6) hours of request |
| Urgent Care Visit | Within forty-eight (48) hours of request |
| Initial Visit for Routine Care | Within ten (10) business days of request |
| Follow-Up Visit for Routine Care | Within thirty (30) business days of request |
| Office Wait Time | Within fifteen (15) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

| Specialty Care Appointments | |
|-----------------------------------|---|
| Type of Care/Appointment | Length of Wait Time |
| Routine Care | Within thirty (30) calendar days of request |
| Urgent Care Visit | Within twenty-four (24) hours of request |
| Office Wait Time | Within fifteen (15) minutes |
| Different Hours for Member Plans? | No, hours must be the same for all members and patients |

Medical coverage 24 hours a day, 7 days a week

Wellcare Primary Care After-Hours Requirements

Acceptable After-Hours access mechanisms include:

- Answering service
- On-call pager/cellular connection
- Call forwarding to practitioner's home/other location
- Published after-hours telephone number and recorded voice message directing patients to a practitioner for urgent and non-life-threatening conditions.

The message should not instruct patients to obtain treatment at the **Emergency Room for Non-Life-Threatening Emergencies** but **MUST** direct patients in a medical emergency to call 911 or go to the nearest Emergency Room/Urgent Care.

Voice Message MUST contain **ONE** of the following:

- Message forwards to on-call practitioner
- Message forwards to an answering service
- Message gives the on-call practitioner's number
- Message gives the on-call practitioner's pager number
- Message refers patient to another office, practitioner, or on-call service

Message may not only direct patients to the Emergency Room. The patient must be able to leave a message for an on-call doctor, speak with an on-call doctor, or be forwarded to an on-call doctor.

Caring for and Communicating with Individuals with Intellectual and Developmental Disabilities (IDD) ●●●●●

As a provider, it is important to be aware of the following health disparities individuals with intellectual and developmental disabilities may experience:

- Fewer preventive screenings than the general population
- Financial and transportation limitations
- Lack of access to providers with specialized training or experience with caring for individuals in these populations

Complete an Annual Functional Status Assessment

This assessment measures the patient's ability to perform daily tasks and helps to identify any functional decline. For Meridian patients, please indicate one of the following in the medical record:

- Notation and date that Activities of Daily Living (ADL) were assessed: Bathing, dressing, eating, transferring, using toilet, walking
- Notation and date that Instrumental Activities of Daily Living (IADL) were assessed: Shopping, driving or using public transportation, meal preparation, housework, taking medications, using the telephone

- Result of a standardized functional status assessment and the date it was performed: Assessment of Living Skills and Resources (ALSAR), Barthel ADL Index Physical Self-Maintenance (ADLS) Scale, Bayer Activities of Daily Living (B-ADL) Scale, Extended Activities of Daily Living (EADL) Scale
- Chronic conditions at a younger age
- A higher risk of obesity
- A greater incidence of mental illness
- An accelerated aging process

It is important that providers and health plans adapt and coordinate care for this population by communicating appropriately and respectfully about individuals with disabilities.

Individuals with intellectual and developmental disabilities often go through cognitive and behavioral changes. These include anxiety, depression, dementia, self-injurious behavior, and other factors. These changes may result from pain and discomfort related to other medical issues.

As a provider, it is important to be aware of the following ways to communicate and to emphasize the person first, not the disability:

- Emphasize abilities, not limitations
- Do not use language that suggests the lack of something
- Emphasize the need for accessibility, not the disability
- Do not use offensive language
- Avoid language that implies negative stereotypes
- Do not portray people with disabilities as inspirational only because of their disability

Tips on Using People-First Language

This chart provides tips on what language to use when communicating with an individual with a disability.

| Tips | Use | Do Not Use |
|---|--|--|
| Emphasize abilities, not limitations | Person who uses a wheelchair | Confined or restricted to a wheelchair, wheelchair bound |
| | Person who uses a device to speak | Can't talk, mute |
| Do not use language that suggests the lack of something | Person with a disability | Disabled, handicapped |
| | Person of short stature | Midget |
| | Person with cerebral palsy | Cerebral palsy victim |
| | Person with epilepsy or seizure disorder | Epileptic |
| | Person with multiple sclerosis | Afflicted by multiple sclerosis |

| Tips | Use | Do Not Use |
|---|--|---|
| Emphasize the need for accessibility, not the disability | Accessible parking or bathroom | Handicapped parking or bathroom |
| Do not use offensive language | Person with a physical disability | Crippled, lame, deformed, invalid, spastic |
| | Person with an intellectual, cognitive, developmental disability | Slow, simple, moronic, defective, afflicted, special person |
| | Person with an emotional or behavioral disability, a mental health impairment, or a psychiatric disability | Insane, crazy, psycho, maniac, nuts |
| Avoid language that implies negative stereotypes | Person without a disability | Normal person, healthy person |
| Do not portray people with disabilities as inspirational only because of their disability | Person who is successful, productive | Has overcome his/her disability, is courageous |

Source: <https://www.cdc.gov/ncbddd/disabilityandhealth/pdf/communicating-with-people.pdf>

Medicare-Medicaid Plan Codes

| Description | CPT Category* | CPT II Category* | HCPCS* |
|------------------------------|---------------|------------------|--------------|
| Functional Status Assessment | 99483 | 1170F | G0438, G0439 |

*Codes subject to change

Resources for Patients and Providers

Illinois Department of Healthcare and Family Services (HFS):
www.illinois.gov/hfs/MedicalClients/HCBS/Pages/support_cyadd.aspx

Illinois Department of Human Services (IDHS): 217-782-3075

For a copy of current clinical practice guidelines, visit our website at
www.ilmeridian.com and <https://mmp.ilmeridian.com/>.

Provider Resources: <https://www.ilmeridian.com/providers/resources.html>

Early Periodic Screening, Diagnosis, and Treatment (EPSDT) ●●

The Early Periodic Screening, Diagnosis, and Treatment (EPSDT) program promotes the physical, mental, social, emotional, and behavioral health of children under the age of 21 through recommended well-child screenings.

These services give children early access to preventative and comprehensive healthcare to help prevent disease and identify medical, developmental, and social-emotional concerns in their early stages — when they are more effectively treated.

Mandatory Screening Components

An EPSDT screening for Medicaid members must include:

- **Initial and interval history**, including a comprehensive health and developmental history of physical and mental development
- **An unclothed physical exam**, documented in the member's medical chart
- **Measurements**: Weight, length, head circumference, body mass index (BMI) percentile*, and blood pressure
- **Nutrition/obesity prevention**: Assess and educate, with specific documentation on nutrition and physical activity*
- **Oral health assessment*** and age-appropriate fluoride varnish application

Specific Screenings

- Caregiver and/or adolescent depression screening
- Developmental surveillance/screening
- Autism screening
- Psychosocial/behavioral assessment
- Alcohol and drug use assessment
- Sensory screenings for vision and hearing*

Immunizations and Age-Appropriate Screenings

- Review immunization history and administer immunizations at recommended ages or as needed
- Offer anticipatory guidance and health education at every visit
- Conduct age-appropriate laboratory tests, including:
 - Lipid screening
 - Hemoglobin/hematocrit
 - Lead blood testing (2)/risk screening
 - Newborn screening: blood, hearing, critical congenital heart disease
 - Sexually transmitted infections and HIV screening
 - Cervical dysplasia screening
 - TB testing
- Provide other medically necessary health care, diagnostic services, and treatment measures

* These areas are frequently non-compliant or not properly documented to show compliance during medical record reviews.

Billing Codes for New or Established Patients

| Ages | New | Established |
|-------------------------|-------|-------------|
| <1 | 99381 | 99391 |
| 1–4 | 99382 | 99392 |
| 5–11 | 99383 | 99393 |
| 12–17 | 99384 | 99394 |
| 18–21 | 99385 | 99395 |
| Fluoride Varnish: 99188 | | |

Online Resources

- American Academy of Pediatrics Recommendations for Preventive Pediatric Care (Periodicity Schedule): https://downloads.aap.org/AAP/PDF/periodicity_schedule.pdf?_ga=2.267893575.817482867.1686682266-4679424.1686682266
- Bright Futures, a national health promotion and preventive initiative led by the American Academy of Pediatrics: <https://www.aap.org/en/>
- Centers for Disease Control and Prevention (CDC) vaccination schedules: <https://www.cdc.gov/vaccines/index.html>

Supplemental Data ●●●●●

Supplemental data is data that is captured for HEDIS care gap closure, and used in rate calculation, but is not submitted through claims processing. It allows for services rendered to be captured for gap closure.

Supplemental Data Benefits

- Improve accuracy by minimizing human intervention and error that can occur through chart reviews and data entry
- Increase efficiency of data retrieval to support real-time intervention with patients for care gap closure
- Cost efficient
- Eliminate the burden on provider staff submitting high volumes of medical records
- Increase provider incentive earnings and improve provider performance
- Captures lab results and blood pressure readings, if CPT II codes are not captured on claims

Supplemental Data Implementation

If you are interested in setting up a supplemental data file, please contact our HEDIS Operations team at ILHEDISOps@mhplan.com

Please include the following information:

- Main point of contact regarding the data feed
- Tax ID Number(s)
- Product lines you plan to submit data for (Ambetter, Meridian, Wellcare, and/or YouthCare)
- List of individuals to be involved in the implementation communication
 - Please include the person responsible for generating the file and submitting the data

Adult Health



Adults' Access to Preventive/Ambulatory Health Services (AAP) ●●●

The AAP measure evaluates the percentage of patients 20 years and older who had an ambulatory or preventive care visit. Services that count include outpatient evaluation and management (E&M) visits, consultations, assisted living/home care oversight, preventive medicine, and counseling.

AAP Measure Codes

| Description | CPT* | HCPCS* | ICD-10CM* |
|-----------------------------|---|--|---|
| Ambulatory Visits | 92002, 92004, 92012, 92014, 98968, 98970-98972, 98980-98981, 99202-99205, 99211-99215, 99242-99245, 99304-99310, 99315-99316, 99421, 99341, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99421-99423, 99441-99443, 99457, 99458, 99483, 99429, 98966-98968 | G0402, G0438, G0439, G0463, G0071, G2010, G2012, G2250-G2252, S0620-S0621, T1015 | |
| Reason for Ambulatory Visit | | | Z00.00, Z00.01, Z00.121, Z00.129, Z00.3, Z00.5, Z00.8, Z02.0-Z02.6, Z02.71, Z02.79, Z02.81, Z02.84, Z02.89, Z02.9, Z76.1, Z76.2 |

*Codes subject to change

Advanced Care Planning (ACP) ●

The ACP measure evaluates percentage of adults 66 to 80 years of age with advanced illness, an indication of frailty, or who are receiving palliative care and had advanced care planning and adults 81 years of age or older who had advanced care planning during the measurement year.

A discussion or documentation about preferences for resuscitation, life-sustaining treatment, and end-of-life care.

ACP Measure Codes

| Description | Codes* |
|------------------------|--|
| Advanced Care Planning | CPT: 99483, 99497 CPT-CAT-II: 1123F, 1124F, 1157F, 1158F HCPCS: S0257 ICD-10: Z66 |

*Codes subject to change

Adult Immunization Status (AIS-E) ●●●●●👤

AIS-E is an Electronic Clinical Data Systems (ECDS) measure.

AIS-E evaluates the percentage of patients 19 years of age and older who are up to date on recommended routine vaccines for influenza, tetanus and diphtheria (Td) or tetanus, diphtheria and acellular pertussis (Tdap), zoster, pneumococcal, and hepatitis B.

Influenza:

- Patients who received an influenza vaccine on or between July 1 of the year prior to the measurement period and June 30 of the measurement period

Td/Tdap:

- Patients who received at least one Td vaccine or one Tdap vaccine between 9 years prior to the start of the measurement period and the end of the measurement period

Zoster:

- Patients who received two doses of the herpes zoster recombinant vaccine at least 28 days apart, any time on or after the patient's 50th birthday and before or during the measurement period

Pneumococcal:

- Patients who were administered at least one dose of an adult pneumococcal vaccine on or after their 19th birthday and before or during the measurement period

Hepatitis B:

- Patients who received at least two dose adult hepatitis B vaccine on or after their 19th birthday administered at least 28 days apart

AIS-E Measure Codes

| Description | Codes* |
|--|---|
| Adult Influenza Immunization | CVX: 88, 135, 140, 141, 144, 150, 153, 155, 158, 166, 168, 171, 185, 186, 197, 205 |
| Adult Influenza Vaccine Procedure | CPT: 90630, 90653, 90654, 90656, 90658, 90661, 90662, 90673, 90674, 90682, 90686, 90688, 90689, 90694, 90756 SNOMED CT: 86198006 |
| Influenza Virus LAIV Immunization | CVX: 111, 149 |
| Influenza Virus LAIV Vaccine Procedure | CPT: 90660, 90672 SNOMED CT: 787016008 |
| Members with Anaphylaxis due to Influenza Vaccine | SNOMED CT: 471361000124100 |
| Td Immunization | CVX: 09, 113, 115, 138, 139 |
| Td Vaccine Procedure | CPT: 90714 SNOMED CT: 73152006, 312869001, 395178008, 395179000, 395180002, 395181003, 414619005, 416144004, 416591003, 417211006, 417384007, 417615007, 866161006, 866184004, 866185003, 866186002, 866227002, 868266002, 868267006, 868268001, 870668008, 870669000, 870670004, 871828004, 632481000119106 |
| Tdap Vaccine Procedure | CVX: 115 CPT: 90715 SNOMED CT: 390846000, 412755006, 412756007, 412757003, 428251000124104, 571571000119105 |
| Anaphylaxis due to Diphtheria, Tetanus or Pertussis Vaccine | SNOMED CT: 428281000124107, 428291000124105 |
| Encephalitis due to Diphtheria, Tetanus or Pertussis Vaccine | SNOMED CT: 192710009, 192711008, 192712001 |
| Herpes Zoster Live Vaccine Procedure (at least 1 dose) | CVX: 121 CPT: 90736 SNOMED CT: 871898007, 871899004 |
| Herpes Zoster Recombinant Vaccine Procedure (2 doses) | CVX: 187 CPT: 90750 SNOMED CT: 722215002 |
| Anaphylaxis due to Herpes Zoster Vaccine | SNOMED CT: 471371000124107, 471381000124105 |

AIS-E Measure Codes (continued)

| Description | Codes* |
|--|---|
| Adult Hepatitis B Vaccine Procedure | CPT: 90739, 90740, 90743, 90744 90746, 90747, 90759 |
| Adult Pneumococcal Immunization | CVX: 33, 109, 133, 152, 215, 216 |
| Adult Pneumococcal Vaccine Procedure | CPT: 90670, 90671, 90677, 90732 HCPCS: G0009 SNOMED CT: 12866006, 394678003, 871833000, 1119366009, 1119367000, 1119368005, 434751000124102 |
| Members with Anaphylaxis due to the Pneumococcal Vaccine | SNOMED CT: 471141000124102 |

*Codes subject to change

Appropriate Treatment for Upper Respiratory Infection (URI) ●●●●

The URI measure evaluates the percentage of episodes for patients 3 months of age and older with a diagnosis of upper respiratory infection (URI) that did not result in an antibiotic-dispensing event.

Antibiotic Medications

| Description | Prescription |
|-------------------------------------|---|
| Aminoglycosides | <ul style="list-style-type: none"> • Amikacin • Gentamicin • Streptomycin • Tobramycin |
| Aminopenicillins | <ul style="list-style-type: none"> • Amoxicillin • Ampicillin |
| Beta-lactamase inhibitors | <ul style="list-style-type: none"> • Amoxicillin-clavulanate • Ampicillin-sulbactam • Piperacillin-tazobactam |
| First-generation cephalosporins | <ul style="list-style-type: none"> • Cefadroxil • Cefazolin • Cephalexin |
| Fourth-generation cephalosporins | <ul style="list-style-type: none"> • Cefepime |
| Lincomycin derivatives | <ul style="list-style-type: none"> • Clindamycin • Lincomycin |
| Macrolides | <ul style="list-style-type: none"> • Azithromycin • Clarithromycin • Erythromycin |
| Miscellaneous antibiotics | <ul style="list-style-type: none"> • Aztreonam • Chloramphenicol • Dalfopristin-quinupristin • Daptomycin • Linezolid • Metronidazole • Vancomycin |
| Natural penicillins | <ul style="list-style-type: none"> • Penicillin G benzathine-procaine • Penicillin G potassium • Penicillin G procaine • Penicillin G sodium • Penicillin V potassium • Penicillin G benzathine |
| Penicillinase resistant penicillins | <ul style="list-style-type: none"> • Dicloxacillin • Nafcillin • Oxacillin |
| Quinolones | <ul style="list-style-type: none"> • Ciprofloxacin • Gemifloxacin • Levofloxacin • Moxifloxacin • Ofloxacin |
| Rifamycin derivatives | <ul style="list-style-type: none"> • Rifampin |
| Second-generation cephalosporin | <ul style="list-style-type: none"> • Cefaclor • Cefotetan • Cefoxitin • Cefprozil • Cefuroxime |
| Sulfonamides | <ul style="list-style-type: none"> • Sulfadiazine • Sulfamethoxazole-trimethoprim |

Antibiotic Medications (continued)

| Description | Prescription |
|---------------------------------|---|
| Tetracyclines | <ul style="list-style-type: none"> • Doxycycline • Minocycline • Tetracycline |
| Third-generation cephalosporins | <ul style="list-style-type: none"> • Cefdinir • Cefixime • Cefotaxime • Cefpodoxime • Ceftazidime • Ceftriaxone |
| Urinary anti-infectives | <ul style="list-style-type: none"> • Fosfomycin • Nitrofurantoin • Nitrofurantoin macrocrystals-monohydrate • Trimethoprim |

Note: Comprehensive Diabetes Care (CDC) was replaced by the following three measures: Glycemic Status Assessment for Patients with Diabetes (GSD), Blood Pressure Control for Patients with Diabetes (BPD), and Eye Exam for Patients with Diabetes (EED).

Glycemic Status Assessment for Patients with Diabetes (GSD) ●●●●

The GSD measure evaluates patients 18-75 years of age with diabetes (Type 1 and 2) whose most recent glycemic status (hemoglobin A1C [HbA1c] or glucose management indicator [GMI]) was at the following levels during the measurement year.

Two rates are reported:

- Glycemic Status <8.0%
- Glycemic Status >9.0% (lower rate indicates better performance)

GSD Measure Codes

| Description | Codes* |
|---|--|
| HbA1c Lab Test (used to identify the last assessment of the measurement year, but does not close the care gap without a result) | CPT: 83036, 83037 LOINC: 4548-4, 17855-8, 17856-6, 4549-2, 96595-48 |
| HbA1c Level Greater Than 9.0 | CPT-CAT-II: 3046F |
| HbA1c Level Greater Than or Equal to 7.0 and Less Than 8.0 | CPT-CAT-II: 3051F |
| HbA1c Level Greater Than or Equal to 8.0 and Less Than or Equal to 9.0 | CPT-CAT-II: 3052F |
| HbA1c Level Less Than 7.0 | CPT-CAT-II: 3044F |
| Glucose management indicator (GMI) | LOINC: 97506-0 |

*Codes subject to change

Blood Pressure Control for Patients with Diabetes (BPD) ●●●●

The BPD measure evaluates the percentage of patients 18 to 75 years of age with diabetes (Types 1 and 2) whose last blood pressure (BP) reading of the measurement year was adequately controlled (<140/90 mm Hg).

- Consider taking two readings at each office visit. Sometimes a second blood pressure reading is lower.
- Do not round blood pressure; always use exact numbers
- Include CPT-CAT-II codes on claims to ensure the blood pressure reading is received by the health plan

BPD Measure Codes

| Description | Codes* |
|---------------------------------------|-------------------|
| Diastolic 80-89 | CPT-CAT-II: 3079F |
| Diastolic Greater Than or Equal to 90 | CPT-CAT-II: 3080F |
| Diastolic Less Than 80 | CPT-CAT-II: 3078F |
| Systolic Greater Than or Equal to 140 | CPT-CAT-II: 3077F |
| Systolic Less Than 130 | CPT-CAT-II: 3074F |
| Systolic 130-139 | CPT-CAT-II: 3075F |

*Codes subject to change

Eye Exam for Patients with Diabetes (EED) ●●●●

The EED measure evaluates percentage of patients 18 to 75 years of age with diabetes (Types 1 and 2) who had a retinal eye exam.

- Include CPT-CAT-II codes on claims to ensure the eye exam result is received by the health plan

Note: The hybrid data collection method was removed for 2025.

EED Measure Codes

| Description | Codes* |
|--|--|
| Unilateral Eye Enucleation with a Bilateral Modifier 50 or two Unilateral Eye enucleations 14 days or more apart | CPT: 65091, 65093, 65101, 65103, 65105, 65110, 65112, 65114 ICD10PCS: 08T1XZZ, 08T0XZZ |
| Automated Eye Exam | CPT: 92229 |
| Eye Exam with Retinopathy | CPT-CAT-II: 2022F, 2024F, 2026F |
| Eye Exam Without Retinopathy | CPT-CAT-II: 2023F, 2025F, 2033F |
| Diabetes Mellitus without Complications (Also requires Diabetic Retinal Screening code to close care gap) | ICD-10: E10.9, E11.9, E13.9 |
| Retinal Eye Exams | CPT: 92002, 92004, 92012, 92014, 92018, 92019, 82134, 92201, 92202, 92230, 92235, 92250, 99203, 99204, 99205, 99213-99215, 99242-99245 HCPCS: S3000, S0621, S0620 |
| Retinal imaging | CPT: 92227-92228 |
| Diabetic Retinal Screening negative in the prior year | CPT-CAT-II: 3072F |

*Codes subject to change

Kidney Health Evaluation for Patients with Diabetes (KED) ●●●●

The KED measure evaluates the percentage of patients 18 to 85 years of age with diabetes (Type 1 and Type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR), during the measurement year.

KED Measure Codes

| Description | Codes* |
|---|---|
| Estimated Glomerular Filtration Rate (eGFR) | CPT: 80047, 80048, 80050, 80053, 80069, 82565 |
| Urine Albumin-Creatinine Ratio (uACR) | CPT: 82043, 82570 |

*Codes subject to change

Diabetes Monitoring for People with Diabetes and Schizophrenia (SMD) ●

The SMD measure evaluates the percentage of patients 18 to 64 years of age with schizophrenia or schizoaffective disorder and diabetes who had both an LDL-C test and an HbA1c test.

SMD Measure Codes

| Description | Codes* |
|--|--|
| HbA1C Lab Tests | CPT: 83036, 83037 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | CPT-CAT-II: 3044F |
| Most recent hemoglobin A1c level greater than 9.0% (DM) | CPT-CAT-II: 3046F |
| Most recent hemoglobin A1c (HbA1c) level greater than or equal to 7.0% and less than 8.0% (DM) | CPT-CAT-II: 3051F |
| Most recent hemoglobin A1c (HbA1c) level greater than or equal to 8.0% and less than or equal to 9.0% (DM) | CPT-CAT-II: 3052F |
| LDL-C Lab Tests | CPT: 80061, 83700, 83701, 83704, 83721 |
| Most recent LDL-C less than 100 mg/dL (CAD) (DM) | CPT-CAT-II: 3048F |
| Most recent LDL-C 100-129 mg/dL (CAD) (DM) | CPT-CAT-II: 3049F |
| Most recent LDL-C greater than or equal to 130 mg/dL (CAD) (DM) | CPT-CAT-II: 3050F |

*Codes subject to change

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD) ●

The SSD measure evaluates the percentage of patients 18 to 64 years of age with schizophrenia, schizoaffective disorder, or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening test.

SSD Measure Codes

| Description | Codes* |
|--|---|
| HbA1C Lab Tests | CPT: 83036, 83037 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | CPT-CAT-II: 3044F |
| Most recent hemoglobin A1c level greater than 9.0% (DM) | CPT-CAT-II: 3046F |
| Most recent hemoglobin A1c (HbA1c) level greater than or equal to 7.0% and less than 8.0% (DM) | CPT-CAT-II: 3051F |
| Most recent hemoglobin A1c (HbA1c) level greater than or equal to 8.0% and less than or equal to 9.0% (DM) | CPT-CAT-II: 3052F |
| Glucose Lab Tests | CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951 |

*Codes subject to change

Cardiac Rehabilitation (CRE) ●●●

The CRE measure evaluates the percentage of patients 18 years of age and older who attended cardiac rehabilitation following a qualifying cardiac event, such as:

- Coronary artery bypass grafting
- Heart or heart/lung transplantation
- Heart valve repair/replacement
- Myocardial infarction
- Percutaneous coronary intervention

It is important patients have the following schedule of cardiac rehabilitation:

- **Initiation:** At least 2 sessions within 30 days after the event
- **Engagement:**
 - At least 12 sessions within 90 days after the event
 - At least 24 sessions within 180 days after the event
- **Achievement:**
 - At least 36 sessions within 180 days after the event
 - Encourage patients to have annual testing

CRE Measure Codes

| Description | CPT Category* | HCPCS* |
|------------------------|---------------|---------------------|
| Cardiac Rehabilitation | 93797, 93798 | G0422, G0423, S9472 |

**Codes subject to change*

Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia (SMC) ●

The SMC measure evaluates the percentage of patients 18-64 years of age with schizophrenia or schizoaffective disorder and cardiovascular disease, who had a LDL-C test during the measurement year.

SMC Measure Codes

| Description | Codes* |
|------------------------------|--|
| LDL-C Lab Test | CPT: 80061, 83700, 83701, 83704, 83721 |
| LDL-C Test Result or Finding | CPT-CAT-II: 3048F, 3049F, 3050F |

**Codes subject to change*

Colorectal Cancer Screening (COL-E)

COL-E is an Electronic Clinical Data Systems (ECDS) measure.

COL-E evaluates the percentage of patients 45 to 75 years of age who had one or more appropriate screenings for colorectal cancer.

Appropriate screenings are defined by one of the following:

- Colonoscopy during the measurement year or the nine years prior to the measurement year
- CT colonography during the measurement year or the four years prior to the measurement year
- Flexible sigmoidoscopy during the measurement year or the four years prior to the measurement year
- FIT-DNA during the measurement year or the two years prior to the measurement year
- FOBT during the measurement year

COL-E Measure Codes

| Description | Codes* |
|------------------------|---|
| Colonoscopy | CPT: 44388-44392, 44394, 44401-44408, 45378-45382, 45384-45386, 45388-45393, 45398 HCPCS: G0105, G0121 SNOMED CT: 8180007, 12350003, 25732003, 73761001, 174158000, 174185007, 235150006, 275251008, 302052009, 367535003, 443998000, 444783004, 446521004, 446745002, 447021001, 709421007, 710293001, 711307001, 789778002, 1209098000, 851000119109, 48021000087103, 4803100087101 |
| CT Colonography | CPT: 74261-74263 LOINC: 60515-4, 72531-7, 79069-1, 79071-7, 79101-2, 82688-3 SNOMED CT: 418714002 |
| sDNA FIT Lab Test | CPT: 81528 LOINC: 77353-1, 77354-9 SNOMED CT: 708699002 |
| Flexible Sigmoidoscopy | CPT: 45330-45335, 45337-45338, 45340-45342, 45346-45347, 45349-45350 HCPCS: G0104 SNOMED CT: 44441009, 396226005, 425634007, 841000119107 |

COL-E Measure Codes (continued)

| Description | Codes* |
|------------------------------|--|
| FOBT Lab Test | CPT: 82270, 82274 HCPCS: G0328 LOINC: 12503-9, 12504-7, 14563-1, 14564-9, 14565-6, 2335-8, 27396-1, 27401-9, 27925-7, 27926-5, 29771-3, 56490-6, 56491-4, 57905-2, 58453-2, 80372-6 SNOMED CT: 104435004, 441579003, 442067009, 442516004, 442554004, 442563002 |
| FOBT Test Results or Finding | SNOMED CT: 59614000, 167667006, 389076003, 71711000112103 |

*Codes subject to change

Care for Older Adults (COA) ●

The COA measure evaluates the percentage of adults 66 years of age and older who had each of the following in the measurement year:

- Medication review
 - Perform an annual medication review of the patient’s medications, including prescription medications, over-the-counter medications, and herbal or supplemental therapies.
- Functional status assessment
 - This assessment measures the patient’s ability to perform daily tasks and helps to identify any functional decline. For Medicare-Medicaid Plan patients, please indicate in the medical record:
 - Activities of Daily Living (ADL) — Note and date when activities like bathing, dressing, eating, transferring, using toilet, and walking were assessed.
 - Instrumental Activities of Daily Living (IADL) — Note and date when activities like shopping, driving or using public transportation, meal preparation, housework, taking medications, and using the telephone were assessed.
 - Standardized functional status assessments — Note results and dates of assessments like the Assessment of Living Skills and Resources (ALSAR), the Barthel Index and the Physical Self-Maintenance Scale, Bayer Activities of Daily Living (B-ADL) Scale, or Extended Activities of Daily Living (EADL) Scale.

COA Measure Codes

| Description | Codes* |
|--|---|
| Medication Review with Medication List <i>(Requires a code from both value sets)</i> | Medication List: CPT-CAT-II: 1159F HCPCS: G8427 Medication Review: CPT: 90863, 99483, 99605, 99606 CPT-CAT-II: 1160F |

COA Measure Codes (continued)

| Description | Codes* |
|--|--|
| Medication Review: Transitional Care Management Services | CPT: 99495, 99496 |
| Functional Status Assessment | CPT: 99483 CPT-CAT-II: 1170F HCPCS: G0438, G0439 |

*Codes subject to change

Controlling High Blood Pressure (CBP) ●●●●

The CBP measure evaluates the percentage of patients 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose last blood pressure (BP) reading of the measurement year was adequately controlled (<140/90 mm Hg).

- Consider taking two readings at each office visit. Sometimes a second blood pressure reading is lower.
- Do not round blood pressure; always use exact numbers
- Include CPT-CAT-II codes on claims to ensure the blood pressure reading is received by the health plan

CBP Measure Codes

| Description | Codes* |
|------------------------------------|-------------------|
| Systolic Greater Than/Equal to 140 | CPT-CAT-II: 3077F |
| Systolic 130-139 | CPT-CAT-II: 3075F |
| Systolic Less Than 130 | CPT-CAT-II: 3074F |
| Diastolic Greater Than/Equal to 90 | CPT-CAT-II: 3080F |
| Diastolic 80-89 | CPT-CAT-II: 3079F |
| Diastolic Less Than 80 | CPT-CAT-II: 3078F |

*Codes subject to change

Blood Pressure Control for Patients with Hypertension (BPC-E) ●●●●🏠

This is a first-year measure. BPC-E is an Electronic Clinical Data Systems (ECDS) measure.

BPC-E evaluates percentage of patients 18–85 years of age who had a diagnosis of hypertension (HTN) and whose most recent blood pressure (BP) was <140/90 mm Hg during the measurement period.

Note: This measure does not replace the CBP measure in MY 2025.

BPC-E Measure Codes

| Description | Codes* |
|------------------------------------|-------------------|
| Systolic Greater Than/Equal to 140 | CPT-CAT-II: 3077F |
| Systolic 130-139 | CPT-CAT-II: 3075F |
| Systolic Less Than 130 | CPT-CAT-II: 3074F |
| Diastolic Greater Than/Equal to 90 | CPT-CAT-II: 3080F |
| Diastolic 80-89 | CPT-CAT-II: 3079F |
| Diastolic Less Than 80 | CPT-CAT-II: 3078F |

Follow-Up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions (FMC) ●●

The FMC measure evaluates Emergency Department (ED) visits for patients 18 years of age and older who have multiple high-risk chronic conditions who had a follow-up service within 7 days of the ED visit on or between January 1 and December 24 of the measurement year where the patient was 18 years or older on the date of the visit.

FMC Measure Codes

| Description | Codes |
|---|--|
| BH Outpatient | CPT: 98960-98962, 99078, 99202-99205, 99211-99215, 99242-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99492-99494, 99510 HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013-H2020, T1015 |
| Case Management Encounter | CPT: 99366 HCPCS: T1016, T1017, T2022, T2023 |
| Complex Care Management Services | CPT: 99439, 99487, 99489-99491 HCPCS: G0506 |
| Electroconvulsive Therapy (Requires POS code) | CPT: 90870 ICD10 PCS: GZB0ZZZ-GZB4ZZZ |
| Substance Use Disorder Services | CPT: 99408, 99409 HCPCS: G0396, G0397, G0443, H0001, H0005, H0007, H0015, H0016, H0022, H0047, H0050, H2035, H2036, T1006, T1012 |
| Transitional Care Management Services | CPT: 99495, 99496 |
| Visit Setting Unspecified (Requires POS code) | CPT: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99252-99255 |
| Outpatient and Telehealth | CPT: 98966-98968, 98970-98972, 98980-98981, 99202-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411-99412, 99421-99423, 99429, 99441-99443, 99455-99458, 99483 HCPCS: G0071, G0402, G0438-G0439, G0463, G2010, G2012, G2250-G2252, T1015 |

FMC Measure Codes (continued)

| Description | Codes |
|---|--|
| Substance Use Counseling and Surveillance | ICD10CM: Z71.41, Z71.51 |
| Partial Hospitalization or Intensive Outpatient | HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485 |

*Codes subject to change. Refer to the Appendix for POS codes.

Persistence of Beta-Blocker Treatment After a Heart Attack (PBH) ●●●

The PBH measure evaluates the percentage of patients 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to June 30 of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for six months after discharge.

Beta-Blocker Medications

| Description | Prescription |
|----------------------------------|---|
| Noncardioselective beta-blockers | <ul style="list-style-type: none"> • Carvedilol • Pindolol • Sotalol • Labetalol • Propranolol • Nadolol • Timolol |
| Cardioselective beta-blockers | <ul style="list-style-type: none"> • Acebutolol • Atenolol • Betaxolol • Bisoprolol • Metoprolol • Nebivolol |
| Antihypertensive combinations | <ul style="list-style-type: none"> • Atenolol-chlorthalidone • Bendroflumethiazide-nadolol • Bisoprolol-hydrochlorothiazide • Hydrochlorothiazide-metoprolol • Hydrochlorothiazide-propranolol |

Pharmacotherapy Management of COPD Exacerbation (PCE) ●●●

The PCE measure evaluates the percentage of COPD exacerbations for patients 40 years of age and older who had an acute inpatient discharge or ED visit on or between January 1–November 30 and were dispensed appropriate medications.

Two rates are reported:

- Dispensed a systemic corticosteroid (or there was evidence of an active prescription) within 14 days of the event
- Dispensed a bronchodilator (or there was evidence of an active prescription) within 30 days of the event

Systemic Corticosteroid Medications

| Description | Prescription |
|-----------------|--|
| Glucocorticoids | <ul style="list-style-type: none"> • Cortisone • Dexamethasone • Prednisolone • Hydrocortisone • Methylprednisolone • Prednisone |

Bronchodilator Medications

| Description | Prescription |
|-----------------------------|--|
| Anticholinergic agents | <ul style="list-style-type: none"> • Acclidinium-bromide • Ipratropium • Tiotropium • Umeclidinium |
| Beta 2-agonists | <ul style="list-style-type: none"> • Albuterol • Arformoterol • Formoterol • Indacaterol • Levalbuterol • Metaproterenol • Olodaterol • Salmeterol |
| Bronchodilator combinations | <ul style="list-style-type: none"> • Albuterol-ipratropium • Formoterol-aclidinium • Budesonide-formoterol • Formoterol-glycopyrrolate • Formoterol-mometasone • Fluticasone furoate - umeclidinium-vilanterol • Fluticasone-salmeterol • Fluticasone-vilanterol • Indacaterol-glycopyrrolate • Olodaterol hydrochloride • Olodaterol-tiotropium • Umeclidinium-Vilanterol |

Plan All Cause Readmissions (PCR) ●●●●

The PCR measure evaluates patients 18 years of age and older who had an acute inpatient and observation stay that was followed by an unplanned acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission.

What Providers Can Do

- See the patient within seven days of discharge
- Educate the patient and family about the diagnosis and care plan
- Review medication list
- Establish care goals with the patient
- Identify barriers to health for the patient that may have contributed to the hospitalization and discuss strategies for addressing them

How Meridian Can Help

- Meridian will notify PCPs during the Transition of Care (TOC) process
- A TOC letter is faxed to the PCP within 24 hours of discharge
- Meridian's Interdisciplinary Care Team (ICT) reviews individual care plans
- Educate patients on appropriate Emergency Department utilization

Transitions of Care (TRC) ●●

The TRC measure evaluates the percentage of discharges for patients 18 years of age and older who had each of the following:

- Notification of Inpatient Admission (NIA)
- Receipt of Discharge Information (RDI)
- Patient Engagement After Inpatient Discharge (PE)
- Medication Reconciliation Post-Discharge (MRPD)

Remember to:

- Document receipt of notification of inpatient admission on the day of admission through two days after admission (for a total of 3 days)
- Record receipt of notification of discharge on the day of discharge through two days after discharge (for a total of 3 days)
- Document patient engagement within 30 days after discharge (e.g., office visits, visits to the home, telehealth)
- Document medication reconciliation on the date of discharge through 30 days after discharge (for a total of 31 days)

Patient engagement provided within 30 days after discharge. Do not include patient engagement that occurs on the date of discharge. The following meet criteria for patient engagement:

- An outpatient visit
- A telephone visit
- Transitional care management services
- An e-visit or virtual check-in

Medication reconciliation must be conducted by a prescribing practitioner, clinical pharmacist, physician assistant, or registered nurse on the date of discharge through 30 days after discharge (31 total days).

TRC Measure Codes

| Description | Codes* |
|---|--|
| Patient Engagement: Transitional Care Management Services | CPT: 99495-99496 |
| MRPD: Medication Reconciliation Encounter | CPT: 99483, 99495-99496 |
| MRPD: Medication Reconciliation Intervention | CPT-CAT-II: 1111F SNOMED CT: 430193006, 428701000124107 |

TRC Measure Codes (continued)

| Description | Codes* |
|---------------------------|--|
| Outpatient and Telehealth | <p>CPT: 98966, 98967, 98968, 98970-98972, 98980-98981, 99202-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99421-99423, 99429, 99441-99443, 99455-99458, 99483</p> <p>HCPCS: G0071, G0402, G0438, G0439, G0463, G2010, G2012, G2250, G2251, G2252, T1015</p> |

*Codes subject to change

Use of Imaging Studies for Low Back Pain (LBP) ●●●●

The LBP measure evaluates patients 18 to 75 years of age with a principal diagnosis of low back pain who did **not** have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis. *A lower rate indicates better performance.*

Numerator: An imaging study with a diagnosis of uncomplicated low back pain on the IESD or in the 28 days following the IESD

LBP Measure Codes

| Description | Codes* |
|-----------------------------|---|
| Imaging Study | <p>CPT: 72020, 72052, 72080-72084, 72100, 72110, 72040, 72050, 72070, 72072, 72074, 72100, 72110, 72114, 72120, 72125-72133, 72141, 72142, 72146-72149, 72156-72158, 72200, 72202, 72220</p> |
| Uncomplicated Low Back Pain | <p>ICD-10: M47.26-M47.28, M47.816-M47.818, M47.896-M47.898, M48.061, M48.07, M48.08, M51.16-M51.17, M51.26-M51.27, M51.36-M51.37, M51.86-M51.87, M53.2X6-M53.2X8, M53.3, M53.86-M53.88, M54.16-M54.18, M54.30-M54.32, M54.40-M54.42, M54.5, M54.50, M54.51, M54.59, M54.89, M54.9, M99.03-M99.04, M99.23, M99.33, M99.43, M99.53, M99.63, M99.73, M99.83, M99.84, S33.100A, S33.100D, S33.100S, S33.110A, S33.110D, S33.110S, S33.120A, S33.120D, S33.120S, S33.130A, S33.130D, S33.130S, S33.140A, S33.140D, S33.140S, S33.5XXA, S33.6XXA, S33.8XXA, S33.9XXA, S39.002A, S39.002D, S39.002S, S39.012A, S39.012D, S39.012S, S39.82XA, S39.82XD, S39.82XS, S39.82XA, S39.82XD, S39.82XS, S39.92XA, S39.92XD, S39.92XS</p> |

*Codes subject to change

According to the National Committee for Quality Assurance (NCQA), 75 percent of American adults will experience low back pain at some time in their lives, making it one of the most common reasons patients seek healthcare services.

Please consider imaging studies for lower back pain only if red flags are present or if there is no improvement after four weeks.

Alternative Recommendations

Meridian encourages its providers to refer to the Agency for Healthcare Research and Quality website (www.ahrq.gov) or the Meridian website (www.ILmeridian.com) for standards and guidelines in managing your patients' acute lower back pain.

Source: www.ncqa.org

Behavioral Health



Adherence to Antipsychotic Medications for People with Schizophrenia (SAA) ●●●

The SAA measure evaluates patients 18 years of age and older in the measurement year with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.

Antipsychotic Medications

| Description | |
|---------------------------------------|---|
| Antipsychotic agents – Oral | <ul style="list-style-type: none"> • Aripiprazole • Asenapine • Brexpiprazole • Cariprazine • Clozapine • Haloperidol • Iloperidone • Loxapine • Lumateperone • Lurasidone • Molindone • Molindone • Olanzapine • Paliperidone • Quetiapine • Risperidone • Ziperidone |
| Phenthiazine Antipsychotic – Oral | <ul style="list-style-type: none"> • Chlorpromazine • Fluphenazine • Perphenazine • Prochlorperazine • Thioridazine • Trifluoperazine |
| Psychotherapeutic combinations – Oral | <ul style="list-style-type: none"> • Amitriptyline-perphenazine |
| Thioxanthenes – Oral | <ul style="list-style-type: none"> • Thiothixene |
| Long-Acting Injections | <ul style="list-style-type: none"> • Risperidone • Aripiprazole • Anripiprazole lauroxil • Fluphenazine decanoate • Haloperidol decanoate • Olanzapine • Paliperidone palmitate • Risperidone |

Follow-Up After Emergency Department Visit for Mental Illness (FUM) ●●●●

The FUM measure evaluates patients 6 years of age and older with a principal diagnosis of mental illness or self-harm who had a follow-up visit for mental illness after an Emergency Department (ED) visit.

Two rates are reported:

- The percentage of ED visits where patients received follow-up within 7 days of the visit (8 total days)
- The percentage of ED visits where patients received follow-up within 30 days of the visit (31 total days)

FUM 7 & 30 Day Follow-up Measure Codes

| Description | Codes |
|--|---|
| BH Outpatient | CPT: 98960-98962, 99078, 99202-99205, 99211-99215, 99242-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99492-99494, 99510 HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013-2020, T1015 |
| Electroconvulsive Therapy (Requires POS code) | CPT: 90870 ICD-10: GZB0ZZZ-ZB4ZZZ |
| Online Assessment (e-visit or virtual check-in) | CPT: 98970-98972, 98980, 98981, 99421-99423, 99457, 99458 HCPCS: G0071, G2010, G2012, G2250-G2252 |
| Partial Hospitalization or Intensive Outpatient | HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485 |
| Telephone Visits | CPT: 98966-98968, 99441-99443 |
| Visit Setting Unspecified (Requires POS code) | CPT: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99252-99255 |
| Peer Support Services | HCPCS: G0140, G0177, H0024, H0025, H0038, H0039, H0040, H0046, H2014, H2023, S9445, T1012, T1016 |
| Psychiatric Collaborative Care Management | CPT: 99492-99494 |
| Residential Behavioral Health Treatment | HCPCS: H0017-H0019, T2048 |

FUM 7 & 30 Day Follow-up Measure Codes (continued)

| Description | Codes |
|-------------------------|---|
| Mental Health Diagnosis | <p>ICD-10-CM: F03.90, F03.911, F03.918, F03.92, F03.93, F03.94, F03.A0, F03.A11, F03.A18, F03.A2, F03.A3, F03.A4, F03.B0, F03.B11, F03.B18, F03.B2, F03.B3, F03.B4, F03.C0, F03.C11, F03.C18, F03.C2, F03.C3, F03.C4, F20.0, F20.1, F20.2, F20.3, F20.5, F20.81, F20.89, F20.9, F21, F22, F23, F24, F25.0, F25.1, F25.8, F25.9, F28, F29, F30.10, F30.11, F30.12, F30.13, F30.2, F30.3, F30.4, F30.8, F30.9, F31.0, F31.10, F31.11, F31.12, F31.13, F31.2, F31.30, F31.31, F31.32, F31.4, F31.5, F31.60, F31.61, F31.62, F31.63, F31.64, F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76, F31.77, F31.78, F31.81, F31.89, F31.9, F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.81, F32.89, F32.9, F32.A, F33.0, F33.1, F33.2, F33.3, F33.40, F33.41, F33.42, F33.8, F33.9, F34.0, F34.1, F34.81, F34.89, F34.9, F39, F40.00, F40.01, F40.02, F40.10, F40.11, F40.210, F40.218, F40.220, F40.228, F40.230, F40.231, F40.232, F40.233, F40.240, F40.241, F40.242, F40.243, F40.248, F40.290, F40.291, F40.298, F40.8, F40.9, F41.0, F41.1, F41.3, F41.8, F41.9, F42.2, F42.3, F42.4, F42.8, F42.9, F43.0, F43.10, F43.11, F43.12, F43.20, F43.21, F43.22, F43.23, F43.24, F43.25, F43.29, F43.81, F43.89, F43.9, F44.0, F44.1, F44.2, F44.4, F44.5, F44.6, F44.7, F44.81, F44.89, F44.9, F45.0, F45.1, F45.20, F45.21, F45.22, F45.29, F45.41, F45.42, F45.8, F45.9, F48.1, F48.2, F48.8, F48.9, F50.00, F50.01, F50.02, F50.2, F50.81, F50.82, F50.89, F50.9, F51.01, F51.02, F51.03, F51.04, F51.05, F51.09, F51.11, F51.12, F51.13, F51.19, F51.3, F51.4, F51.5, F51.8, F51.9, F52.0, F52.1, F52.21, F52.22, F52.31, F52.32, F52.4, F52.5, F52.6, F52.8, F52.9, F53.0, F53.1, F59, F60.0, F60.1, F60.2, F60.3, F60.4, F60.5, F60.6, F60.7, F60.81, F60.89, F60.9, F63.0, F63.1, F63.2, F63.3, F63.81, F63.89, F63.9, F64.0, F64.1, F64.2, F64.8, F64.9, F65.0, F65.1, F65.2, F65.3, F65.4, F65.50, F65.51, F65.52, F65.81, F65.89, F65.9, F66, F68.10, F68.11, F68.12, F68.13, F68.8, F68.A, F69, F80.0,</p> |

FUM 7 & 30 Day Follow-up Measure Codes (continued)

| Description | Codes |
|-------------------------------------|--|
| Mental Health Diagnosis (continued) | F80.1, F80.2, F80.4, F80.81, F80.82, F80.89, F80.9, F81.0, F81.2, F81.81, F81.89, F81.9, F82, F84.0, F84.2, F84.3, F84.5, F84.8, F84.9, F88, F89, F90.0, F90.1, F90.2, F90.8, F90.9, F91.0, F91.1, F91.2, F91.3, F91.8, F91.9, F93.0, F93.8, F93.9, F94.0, F94.1, F94.2, F94.8, F94.9, F95.0, F95.1, F95.2, F95.8, F95.9, F98.0, F98.1, F98.21, F98.29, F98.3, F98.4, F98.5, F98.8, F98.9, F99 |

*Codes subject to change. Refer to the Appendix for POS codes.

Follow-Up After Emergency Department Visit for Substance Use (FUA) ●●●●

The percentage of Emergency Department (ED) visits among patients aged 13 years and older with a principal diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose, for which there was follow-up.

Two rates are reported:

- The percentage of ED visits where patients received follow-up within 30 days of the visit (31 total days)
- The percentage of ED visits where patients received follow-up within 7 days of the visit (8 total days)

FUA 7 & 30 Day Follow-up Measure Codes

| Description | Codes |
|---|---|
| Behavioral Health Assessment | CPT: 99408, 99409 HCPCS: G0211, G0396, G0397, G0442, G2011, H0001, H0002, H0031, H0049 |
| Online Assessments | CPT: 98970-98972, 98980-98981, 99421-99423, 99457, 99458 HCPCS: G0071, G2010, G2012, G2250-G2252 |
| ODU Weekly Drug Treatment Service | HCPCS: G2067-G2070, G2072, G2073 |
| ODU Weekly Non-Drug Service | HCPCS: G2071, G2074-G2077, G2080 |
| Partial Hospitalization or Intensive Outpatient | HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485 |
| Peer Support Services | HCPCS: G0177, H0024, H0025, H0038-H0040, H0046, H2014, H2023, S9445, T1012, T1016 |

FUA 7 & 30 Day Follow-up Measure Codes (continued)

| Description | Codes |
|---|---|
| Substance Use Disorder Services | CPT: 99408, 99409 HCPCS: G0396, G0397, G0443, H0001, H0005, H0007, H0015, H0016, H0022, H0047, H0050, H2035, H2036, T1006, T1012 |
| Substance Use Services | HCPCS: H0006, H0028 |
| Visit Setting Unspecified <i>(Requires POS code)</i> | CPT: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99252-99255 POS: 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 52, 53, 57, 71, 72 |
| ODU Monthly Office Based Treatment | HCPCS: G2086-G2087 |
| Substance Abuse Counseling and Surveillance | ICD10CM: Z71.41, Z71.51 |
| BH Outpatient | CPT: 98960-98962, 99078, 99202-99205, 99211-99215, 99242-99245, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411-99412, 99483, 99492-99494, 99510 HCPCS: G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0034, H0036, H0037, H0039, H0040, H2000, H2011, H2013-H2020, T1015 |
| Telephone Visits | CPT: 98966, 98967, 98968, 99441, 99442, 99443 |
| AOD Medication Treatment | HCPCS: G2069, G2070, G2072, G2073, H0020, H0033, J0570, J0571, J0572, J0573, J0574, J0575, J2315, Q9991, Q9992, S0109 |

FUA 7 & 30 Day Follow-up Measure Codes (continued)

| Description | Codes |
|--------------------------|--|
| AOD Abuse and Dependence | ICD 10 CM: F10.10, F10.120, F10.121, F10.129, F10.130, F10.131, F10.132, F10.139, F10.14, F10.150, F10.151, F10.159, F10.180, F10.181, F10.182, F10.188, F10.19, F10.20, F10.220, F10.221, F10.229, F10.230, F10.231, F10.232, F10.239, F10.24, F10.250, F10.251, F10.259, F10.26, F10.27, F10.280, F10.281, F10.282, F10.288, F10.29, F11.10, F11.120, F11.121, F11.122, F11.129, F11.13, F11.14, F11.150, F11.151, F11.159, F11.181, F11.182, F11.188, F11.19, F11.20, F11.220, F11.221, F11.222, F11.229, F11.23, F11.24, F11.250, F11.251, F11.259, F11.281, F11.282, F11.288, F11.29, F12.10, F12.120, F12.121, F12.122, F12.129, F12.13, F12.150, F12.151, F12.159, F12.180, F12.188, F12.19, F12.20, F12.220, F12.221, F12.222, F12.229, F12.23, F12.250, F12.251, F12.259., F12.280, F12.288, F12.29, F13.10, F13.120, F13.121, F13.129, F13.130, F13.131, F13.132, F13.139, F13.14, F13.150, F13.151, F13.159, F13.180, F13.181, F13.182, F13.188, F13.19, F13.20, F13.220, F13.221, F13.229, F13.230, F13.231, F13.232, F13.239, F13.24, F13.250, F13.251, F13.259, F13.26, F13.27, F13.280, F13.281, F13.282, F13.288, F13.29, F14.10, F14.120, F14.121, F14.122, F14.129, F14.13, F14.14, F14.150, F14.151, F14.159, F14.180, F14.181, F14.182, F14.188, F14.19, F14.20, F14.220, F14.221, F14.222, F14.229, F14.23, F14.24, F14.250, F14.251, F14.259, F14.280, F14.281, F14.282, F14.288, F14.29, F15.10, F15.120, F15.121, F15.122, F15.129, F15.13, F15.14, F15.150, F15.151, F15.159, F15.180, F15.181, F15.182, F15.188, F15.19, F15.20, F15.220, F15.221, F15.222, F15.229, F15.23, F15.24, F15.250, F15.251, F15.259, F15.280, F15.281, F15.282, F15.288, F15.29, F16.10, F16.120, F16.121, F16.122, F16.129, F16.14, F16.150, F16.151, F16.159, F16.180, F16.183, F16.188, F16.19, F16.20, F16.220, F16.221, F16.229, F18.20, F18.220, F18.221, F18.229, F18.24, F18.250, F18.251, F18.259, F18.27, F18.280, F18.288, F18.29, F19.10, F19.120, F19.121, |

FUA 7 & 30 Day Follow-up Measure Codes (continued)

| Description | Codes |
|---|---|
| <p>AOD Abuse and Dependence (continued)</p> | <p>F19.122, F19.129, F19.130, F19.131, F19.132, F19.139, F19.14, F19.150, F19.151, F19.159, F19.16, F19.17, F19.180, F19.181, F19.182, F19.188, F19.19, F19.20, F19.220, F19.221, F19.222, F19.229, F19.230, F19.231, F19.232, F19.239, F19.24, F19.250, F19.251, F19.259, F19.26, F19.27, F19.280, F19.281, F19.282, F19.288, F19.29</p> |
| <p>Substance Induced Disorders</p> | <p>ICD 10 CM: F10.90, F10.920, F10.921, F10.929, F10.930, F10.931, F10.932, F10.939, F10.94, F10.950, F10.951, F10.959, F10.96, F10.97, F10.980, F10.981, F10.982, F10.988, F10.99, F11.90, F11.920, F11.921, F11.922, F11.929, F11.93, F11.94, F11.950, F11.951, F11.959, F11.981, F11.982, F11.988, F11.99, F12.90, F12.920, F12.921, F12.922, F12.929, F12.93, F12.950, F12.951, F12.959, F12.980, F12.988, F12.99, F13.90, F13.920, F13.921, F13.929, F13.930, F13.931, F13.932, F13.939, F13.94, F13.950, F13.951, F13.959, F13.96, F13.97, F13.980, F13.981, F13.982, F13.988, F13.99, F14.90, F14.920, F14.921, F14.922, F14.929, F14.93, F14.94, F14.950, F14.951, F14.959, F14.980, F14.981, F14.982, F14.988, F14.99, F15.90, F15.920, F15.921, F15.922, F15.929, F15.93, F15.94, F15.950, F15.951, F15.959, F15.980, F15.981, F15.982, F15.988, F15.99, F16.90, F16.920, F16.921, F16.929, F16.94, F16.950, F16.951, F16.959, F16.980, F16.983, F16.988, F16.99, F18.90, F18.920, F18.921, F18.929, F18.94, F18.950, F18.951, F18.959, F18.97, F18.980, F18.988, F18.99, F19.90, F19.920, F19.921, F19.922, F19.929, F19.930, F19.931, F19.932, F19.939, F19.94, F19.950, F19.951, F19.959, F19.96, F19.97, F19.980, F19.981, F19.982, F19.988, F19.99</p> |

FUA 7 & 30 Day Follow-up Measure Codes (continued)

| Description | Codes |
|-----------------------------|--|
| Unintentional Drug Overdose | ICD 10 CM: T40.0X1A, T40.0X1D, T40.0X1S, T40.0X4A, T40.0X4D, T40.0X4S, T40.1X1A, T40.1X1D, T40.1X1S, T40.1X4A, T40.1X4D, T40.1X4S, T40.2X1A, T40.2X1D, T40.2X1S, T40.2X4A, T40.2X4D, T40.2X4S, T40.3X1A, T40.3X1D, T40.3X1S, T40.3X4A, T40.3X4D, T40.3X4S, T40.411A, T40.411D, T40.411S, T40.414A, T40.414D, T40.414S, T40.421A, T40.421D, T40.421S, T40.424A, T40.424D, T40.424S, T40.491A, T40.491D, T40.491S, T40.494A, T40.494D, T40.494S, T40.5X1A, T40.5X1D, T40.5X1S, T40.5X4A, T40.5X4D, T40.5X4S, T40.601A, T40.601D, T40.601S, T40.604A, T40.604D, T40.604S, T40.691A, T40.691D, T40.691S, T40.694A, T40.694D, T40.694S, T40.711A, T40.711D, T40.711S, T40.714A, T40.714D, T40.714S, T40.721A, T40.721D, T40.721S, T40.724A, T40.724D, T40.724S, T40.8X1A, T40.8X1D, T40.8X1S, T40.8X4A, T40.8X4D, T40.8X4S, T40.901A, T40.901D, T40.901S, T40.904A, T40.904D, T40.904S, T40.991A, T40.991D, T40.991S, T40.994A, T40.994D, T40.994S, T41.0X1A, T41.0X1D, T41.0X1S, T41.0X4A, T41.0X4D, T41.0X4S, T41.1X1A, T41.1X1D, T41.1X1S, T41.1X4A, T41.1X4D, T41.1X4S, T41.201A, T41.201D, T41.201S, T41.204A, T41.204D, T41.204S, T41.291A, T41.291D, T41.291S, T41.294A, T41.294D, T41.294S, T41.3X1A, T41.3X1D, T41.3X1S, T41.3X4A, T41.3X4D, T41.3X4S, T41.41XA, T41.41XD, T41.41XS, T41.44XA, T41.44XD, T41.44XS, T41.5X1A, T41.5X1D, T41.5X1S, T41.5X4A, T41.5X4D, T41.5X4S, T42.3X1A, T42.3X1D, T42.3X1S, T42.3X4A, T42.3X4D, T42.3X4S, T42.4X1A, T42.4X1D, T42.4X1S, T42.4X4A, T42.4X4D, T42.4X4S, T43.601A, T43.601D, T43.601S, T43.604A, T43.604D, T43.604S, T43.621A, T43.621D, T43.621S, T43.624A, T43.624D, T43.624S, T43.631A, T43.631D, T43.631S, T43.634A, T43.634D, T43.634S, T43.641A, T43.641D, T43.641S, T43.644A, T43.644D, T43.644S, T43.651A, T43.651D, T43.651S, T43.654A, T43.654D, T43.654S, |

FUA 7 & 30 Day Follow-up Measure Codes (continued)

| Description | Codes |
|---|--|
| Unintentional Drug Overdose (continued) | T43.691A, T43.691D, T43.691S, T43.694A, T43.694D, T43.694S, T51.0X1A, T51.0X1D, T51.0X1S, T51.0X4A, T51.0X4D, T51.0X4S |
| AOD Medication Treatment | HCPCS: G2069, G2070, G2072, G2073, H0020, H0033, J0570, J0571, J0572, J0573, J0574, J0575, J2315, Q9991, Q9992, S0109 |
| AOD Abuse and Dependence | ICD-10-CM: F10.10, F10.120, F10.121, F10.129, F10.130, F10.131, F10.132, F10.139, F10.14, F10.150, F10.151, F10.159, F10.180, F10.181, F10.182, F10.188, F10.19, F10.20, F10.220, F10.221, F10.229, F10.230, F10.231, F10.232, F10.239, F10.24, F10.250, F10.251, F10.259, F10.26, F10.27, F10.280, F10.281, F10.282, F10.288, F10.29, F11.10, F11.120, F11.121, F11.122, F11.129, F11.13, F11.14, F11.150, F11.151, F11.159, F11.181, F11.182, F11.188, F11.19, F11.20, F11.220, F11.221, F11.222, F11.229, F11.23, F11.24, F11.250, F11.251, F11.259, F11.281, F11.282, F11.288, F11.29, F12.10, F12.120, F12.121, F12.122, F12.129, F12.13, F12.150, F12.151, F12.159, F12.180, F12.188, F12.19, F12.20, F12.220, F12.221, F12.222, F12.229, F12.23, F12.250, F12.251, F12.259, F12.280, F12.288, F12.29, F13.10, F13.120, F13.121, F13.129, F13.130, F13.131, F13.132, F13.139, F13.14, F13.150, F13.151, F13.159, F13.180, F13.181, F13.182, F13.188, F13.19, F13.20, F13.220, F13.221, F13.229, F13.230, F13.231, F13.232, F13.239, F13.24, F13.250, F13.251, F13.259, F13.26, F13.27, F13.280, F13.281, F13.282, F13.288, F13.29, F14.10, F14.120, F14.121, F14.122, F14.129, F14.13, F14.14, F14.150, F14.151, F14.159, F14.180, F14.181, F14.182, F14.188, F14.19, F14.20, F14.220, F14.221, F14.222, F14.229, F14.23, F14.24, F14.250, F14.251, F14.259, F14.280, F14.281, F14.282, F14.288, F14.29, F15.10, F15.120, F15.121, F15.122, F15.129, F15.13, F15.14, F15.150, F15.151, F15.159, F15.180, F15.181, F15.182, F15.188, F15.19, F15.20, F15.220, F15.221, F15.222, F15.229, F15.23, F15.24, F15.250, F15.251, F15.259, F15.280, F15.281, |

FUA 7 & 30 Day Follow-up Measure Codes (continued)

| Description | Codes |
|--------------------------------------|---|
| AOD Abuse and Dependence (continued) | F15.282, F15.288, F15.29, F16.10, F16.120, F16.121, F16.122, F16.129, F16.14, F16.150, F16.151, F16.159, F16.180, F16.183, F16.188, F16.19, F16.20, F16.220, F16.221, F16.229, F16.24, F16.250, F16.251, F16.259, F16.280, F16.283, F16.288, F16.29, F18.10, F18.120, F18.121, F18.129, F18.14, F18.150, F18.151, F18.159, F18.17, F18.180, F18.188, F18.19, F18.20, F18.220, F18.221, F18.229, F18.24, F18.250, F18.251, F18.259, F18.27, F18.280, F18.288, F18.29, F19.10, F19.120, F19.121, F19.122, F19.129, F19.130, F19.131, F19.132, F19.139, F19.14, F19.150, F19.151, F19.159, F19.16, F19.17, F19.180, F19.181, F19.182, F19.188, F19.19, F19.20, F19.220, F19.221, F19.222, F19.229, F19.230, F19.231, F19.232, F19.239, F19.24, F19.250, F19.251, F19.259, F19.26, F19.27, F19.280, F19.281, F19.282, F19.288, F19.29 |

*Codes subject to change. Refer to the Appendix for POS codes.

Follow-Up After High Intensity Care for Substance Disorder (FUI) ●●●

The FUI measure evaluates the percentage of acute inpatient hospitalizations, residential treatment, or detoxification visits for a diagnosis of substance use disorder among patients 13 years of age and older that result in a follow-up visit or service for substance use disorder.

FUI measure reports two rates:

- The percentage of visits or discharges for which the member received follow-up for substance use disorder within the 30 days after the visit or discharge
- The percentage of visits or discharges for which the member received follow-up for substance use disorder within the 7 days after the visit or discharge.

FUI Measure Codes

| Description | Codes |
|---|---|
| BH Outpatient | CPT: 98960-98962, 99078, 99202-99205, 99211-99215, 99242-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99510, 99483, 99492-99494, 99510 HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013-H2020, T1015 |
| Online Assessment | CPT: 98970-98972, 98980-98981, 99421-99423, 99457, 99458 HCPCS: G0071, G2010, G2012, G2250-G2252 |
| Visit Setting Unspecified <i>(Requires POS code)</i> | CPT: 90791, 90792, 90832, 90833, 90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99252-99255 |
| Partial Hospitalization or Intensive Outpatient | HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485 |
| Residential Behavioral Health Treatment | HCPCS: H0017-H0019, T2048 |
| Substance Use Disorder Services | CPT: 99408, 99409 HCPCS: G0396, G0397, G0443, H0001, H0005, H0007, H0015, H0016, H0022, H0047, H0050, H2035, H2036, T1006, T1012 |
| Telephone Visits | CPT: 98966-98968, 99441-99443 |
| ODU Monthly Office Based Treatment | HCPCS: G2086-G2087 |

FUI Measure Codes (continued)

| Description | Codes |
|--|--|
| <p> OUD Weekly Drug Treatment Service </p> | <p> HCPCS: G2067-G2070, G2072-G2073 </p> |
| <p> OUD Weekly Non-Drug Service </p> | <p> HCPCS: G2071, G2074-G2077, G2080 </p> |
| <p> Substance Use Counseling and Surveillance </p> | <p> ICD-10-CM: Z71.41, Z71.51 </p> |
| <p> AOD Abuse and Dependence </p> | <p> ICD-10: F10.10, F10.120, F10.121, F10.129, F10.130, F10.131, F10.132, F10.139, F10.14, F10.150, F10.151, F10.159, F10.180, F10.181, F10.182, F10.188, F10.19, F10.20, F10.220, F10.221, F10.229, F10.230, F10.231, F10.232, F10.239, F10.24, F10.250, F10.251, F10.259, F10.26, F10.27, F10.280, F10.281, F10.282, F10.288, F10.29, F11.10, F11.120, F11.121, F11.122, F11.129, F11.13, F11.14, F11.150, F11.151, F11.159, F11.181, F11.182, F11.188, F11.19, F11.20, F11.220, F11.221, F11.222, F11.229, F11.23, F11.24, F11.250, F11.251, F11.259, F11.281, F11.282, F11.288, F11.29, F12.10, F12.120, F12.121, F12.122, F12.129, F12.13, F12.150, F12.151, F12.159, F12.180, F12.188, F12.19, F12.20, F12.220, F12.221, F12.222, F12.229, F12.23, F12.250, F12.251, F12.259, F12.280, F12.288, F12.29, F13.10, F13.120, F13.121, F13.129, F13.130, F13.131, F13.132, F13.139, F13.14, F13.150, F13.151, F13.159, F13.180, F13.181, F13.182, F13.188, F13.19, F13.20, F13.220, F13.221, F13.229, F13.230, F13.231, F13.232, F13.239, F13.24, F13.250, F13.251, F13.259, F13.26, F13.27, F13.280, F13.281, F13.282, F13.288, F13.29, F14.10, F14.120, F14.121, F14.122, F14.129, F14.13, F14.14, F14.150, F14.151, F14.159, F14.180, F14.181, F14.182, F14.188, F14.19, F14.20, F14.220, F14.221, F14.222, F14.229, F14.23, F14.24, F14.250, F14.251, F14.259, F14.280, F14.281, F14.282, F14.288, F14.29, F15.10, F15.120, F15.121, F15.122, F15.129, F15.13, F15.14, F15.150, F15.151, F15.159, F15.180, F15.181, F15.182, F15.188, F15.19, F15.20, F15.220, F15.221, F15.222, F15.229, F15.23, F15.24, F15.250, F15.251, F15.259, F15.280, F15.281, F15.282, F15.288, F15.29, F16.10, F16.120, F16.121, F16.122, F16.129, F16.14, F16.150, F16.151, F16.159, F16.180, F16.183, F16.188, F16.19, F16.20, F16.220, F16.221, </p> |

FUI Measure Codes (continued)

| Description | Codes |
|--------------------------------------|---|
| AOD Abuse and Dependence (continued) | F16.229, F16.24, F16.250, F16.251, F16.259, F16.280, F16.283, F16.288, F16.29, F18.10, F18.120, F18.121, F18.129, F18.14, F18.150, F18.151, F18.159, F18.17, F18.180, F18.188, F18.19, F18.20, F18.220, F18.221, F18.229, F18.24, F18.250, F18.251, F18.259, F18.27, F18.280, F18.288, F18.29, F19.10, F19.120, F19.121, F19.122, F19.129, F19.130, F19.131, F19.132, F19.139, F19.14, F19.150, F19.151, F19.159, F19.16, F19.17, F19.180, F19.181, F19.182, F19.188, F19.19, F19.20, F19.220, F19.221, F19.222, F19.229, F19.230, F19.231, F19.232, F19.239, F19.24, F19.250, F19.251, F19.259, F19.26, F19.27, F19.280, F19.281, F19.282, F19.288, F19.29 |

*Codes subject to change. Refer to the Appendix for POS codes.

Follow-Up After Hospitalization for Mental Illness (FUH) ●●●●●

The FUH measure evaluates the percentage of discharges for patients 6 years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit **with a mental health provider**.

Two rates are reported:

- Discharges for which the member received **follow-up within 7 days after discharge**
- Discharges for which the member received **follow-up within 30 days after discharge**

The following providers can perform the FUH: psychologist, psychiatrist, clinical social worker, mental health occupational therapist, psychiatric/mental health nurse practitioner/clinical nurse specialist, neuropsychologist, psychoanalyst, professional counselor, marriage and family therapist.

FUH Measure Codes

| Description | Codes* |
|--|--|
| Visit Setting Unspecified (Requires POS code) | CPT: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99252-99255 |

FUH Measure Codes (continued)

| Description | Codes* |
|---|--|
| BH Outpatient Visit | <p>CPT: 98960-98962, 99202-99205, 99078, 99211-99215, 99242-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99492-99494, 99510</p> <p>HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013-H2020, T1015</p> |
| Partial Hospitalization/ Intensive Outpatient | <p>HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485</p> |
| Residential Behavioral Health Treatment | <p>HCPCS: H0017-H0019, T2048</p> |
| Electroconvulsive Therapy with Ambulatory Surgical Center POS/Community Mental Health Center POS | <p>CPT: 90870</p> <p>ICD-10: GZB0ZZZ-GZB4ZZZ</p> |
| Transitional Care | <p>CPT: 99495, 99496</p> |
| Telephone Visit with Telehealth POS | <p>CPT: 98966-98968, 99441-99443</p> |
| Psychiatric Collaborative Care Management | <p>CPT: 99492-99494</p> <p>HCPCS: G0512</p> |
| Peer Support Services | <p>CPT: G0140, G0177, H0024, H0025, H0038, H0039, H0040, H0046, H2014, H2023, S9445, T1012, T1016</p> |
| Mental Health Diagnosis | <p>ICD-10-CM: F03.90, F03.911, F03.918, F03.92, F03.93, F03.94, F03.A0, F03.A11, F03.A18, F03.A2, F03.A3, F03.A4, F03.B0, F03.B11, F03.B18, F03.B2, F03.B3, F03.B4, F03.C0, F03.C11, F03.C18, F03.C2, F03.C3, F03.C4, F20.0, F20.1, F20.2, F20.3, F20.5, F20.81, F20.89, F20.9, F21, F22, F23, F24, F25.0, F25.1, F25.8, F25.9, F28, F29, F30.10, F30.11, F30.12, F30.13, F30.2, F30.3, F30.4, F30.8, F30.9, F31.0, F31.10, F31.11, F31.12, F31.13, F31.2, F31.30, F31.31, F31.32, F31.4, F31.5, F31.60, F31.61, F31.62, F31.63, F31.64, F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76, F31.77, F31.78,</p> |

FUH Measure Codes (continued)

| Description | Codes* |
|--|--|
| Mental Health Diagnosis (continued) | F31.81, F31.89, F31.9, F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.81, F32.89, F32.9, F32.A, F33.0, F33.1, F33.2, F33.3, F33.40, F33.41, F33.42, F33.8, F33.9, F34.0, F34.1, F34.81, F34.89, F34.9, F39, F40.00, F40.01, F40.02, F40.10, F40.11, F40.210, F40.218, F40.220, F40.228, F40.230, F40.231, F40.232, F40.233, F40.240, F40.241, F40.242, F40.243, F40.248, F40.290, F40.291, F40.298, F40.8, F40.9, F41.0, F41.1, F41.3, F41.8, F41.9, F42.2, F42.3, F42.4, F42.8, F42.9, F43.0, F43.10, F43.11, F43.12, F43.20, F43.21, F43.22, F43.23, F43.24, F43.25, F43.29, F43.81, F43.89, F43.9, F44.0, F44.1, F44.2, F44.4, F44.5, F44.6, F44.7, F44.81, F44.89, F44.9, F45.0, F45.1, F45.20, F45.21, F45.22, F45.29, F45.41, F45.42, F45.8, F45.9, F48.1, F48.2, F48.8, F48.9, F50.00, F50.01, F50.02, F50.2, F50.81, F50.82, F50.89, F50.9, F51.01, F51.02, F51.03, F51.04, F51.05, F51.09, F51.11, F51.12, F51.13, F51.19, F51.3, F51.4, F51.5, F51.8, F51.9, F52.0, F52.1, F52.21, F52.22, F52.31, F52.32, F52.4, F52.5, F52.6, F52.8, F52.9, F53.0, F53.1, F59, F60.0, F60.1, F60.2, F60.3, F60.4, F60.5, F60.6, F60.7, F60.81, F60.89, F60.9, F63.0, F63.1, F63.2, F63.3, F63.81, F63.89, F63.9, F64.0, F64.1, F64.2, F64.8, F64.9, F65.0, F65.1, F65.2, F65.3, F65.4, F65.50, F65.51, F65.52, F65.81, F65.89, F65.9, F66, F68.10, F68.11, F68.12, F68.13, F68.8, F68.A, F69, F80.0, F80.1, F80.2, F80.4, F80.81, F80.82, F80.89, F80.9, F81.0, F81.2, F81.81, F81.89, F81.9, F82, F84.0, F84.2, F84.3, F84.5, F84.8, F84.9, F88, F89, F90.0, F90.1, F90.2, F90.8, F90.9, F91.0, F91.1, F91.2, F91.3, F91.8, F91.9, F93.0, F93.8, F93.9, F94.0, F94.1, F94.2, F94.8, F94.9, F95.0, F95.1, F95.2, F95.8, F95.9, F98.0, F98.1, F98.21, F98.29, F98.3, F98.4, F98.5, F98.8, F98.9, F99 |

*Codes subject to change. Refer to the Appendix for POS codes.

Initiation and Engagement of Substance Use Disorder (IET) ●●●●●

The IET measure evaluates the percentage of patients 13 years of age and older with a new episode of substance use disorder that resulted in treatment initiation and engagement who received the following:

- Initiation of substance use disorder treatment: Percentage of patients who initiate treatment through an inpatient new SUD episodes that result in treatment initiation through an inpatient SUD admission, outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth, or medication treatment within 14 days
- Engagement of substance use disorder treatment: Percentage of patients who had new SUD episodes that have evidence of treatment engagement within 34 days of the initiation

Alcohol Use Disorder Treatment Medications

| Description | Prescription |
|----------------------------------|--|
| Aldehyde dehydrogenase inhibitor | Disulfiram (oral) |
| Antagonist | Naltrexone (oral and injectable) |
| Other | Acamprosate (oral; delayed-release tablet) |

Opioid Use Disorder Treatment Medications

| Description | Prescription | Medication Lists |
|-----------------|--|---|
| Antagonist | Naltrexone (oral) | Naltrexone Oral Medication List |
| Antagonist | Naltrexone (injectable) | Naltrexone Injection Medication List |
| Partial Agonist | Buprenorphine (sublingual tablet) | Buprenorphine Oral Medication List |
| Partial Agonist | Buprenorphine (injection) | Buprenorphine Injection Medication List |
| Partial Agonist | Buprenorphine (implant) | Buprenorphine Implant Medication List |
| Partial Agonist | Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film) | Buprenorphine Naloxone Medication List |

IET Medications

| Description | Codes* |
|-------------------------|----------------------------|
| Buprenorphine Implant | HCPCS: G2070, G2072, J0570 |
| Buprenorphine Injection | HCPCS: G2069, Q9991, Q9992 |
| Buprenorphine Naloxone | HCPCS: J0572-J0575 |
| Buprenorphine Oral | HCPCS: H0033, J0571 |

IET Medications (continued)

| Description | Codes* |
|---------------------------|----------------------------------|
| Buprenorphine Oral Weekly | HCPCS: G2068, F2079 |
| Detoxification | HCPCS: H0008, H0009, H0010-H0014 |
| Methadone Oral | HCPCS: H0020, S0109 |
| Methadone Oral Weekly | HCPCS: G2067, G2078 |
| Naltrexone Injection | HCPCS: G2073, J2315 |

*Codes subject to change

IET OP Measure Codes

| Description | Codes* |
|--|---|
| BH Outpatient | CPT: 98960-98962, 99078, 99202-99205, 99211-99215, 99242-99245, 99341-99345, 99347-99349, 99350, 99381-99383, 99384-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99492-99494, 99510 HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013-H2020, T1015 Note: Include ICD-10 code for Alcohol abuse and other drug dependence diagnosis |
| Online Assessments | CPT: 98970-98972, 98980, 98981, 99421-99523, 99444, 99457, 99458 HCPCS: G0071, G2010, G2012, G2250-G2251 |
| Visit Setting Unspecified (Requires POS code) | CPT: 90791, 90792, 90832-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99252-99255 |
| Partial Hospitalization or Intensive Outpatient | HCPCS: H0035, H2001, H2012, G0410, G0411 |
| Substance Use Disorder Services | CPT: 99408, 99409 HCPCS: G0396, G0397, G0443, H0001, H0005, H0007, H0015, H0016, H0022, H0047, H0050, H2035, H2036, T1006, T1012 |
| ODU Monthly Office Based Treatment | HCPCS: G2086, G2087 |
| Telephone Visits | CPT: 98966-98968, 99441-99443 |
| ODU Weekly Drug Treatment Services | HCPCS: G2067, G2070, G2072, G2073 |
| ODU Weekly Non-Drug Service | HCPCS: G2071, G2074-G2077, G2080 |

IET OP Measure Codes (continued)

| Description | Codes* |
|---|--|
| Substance Abuse Counseling & Surveillance | ICD 10 CM: Z71.41, Z71.51 |
| Alcohol Abuse and Dependence | ICD 10 CM: F10.10, F10.120, F10.121, F10.129, F10.130, F10.131, F10.132, F10.139, F10.14, F10.150, F10.151, F10.159, F10.180, F10.181, F10.182, F10.188, F10.19, F10.20, F10.220, F10.221, F10.229, F10.230, F10.231, F10.232, F10.239, F10.24, F10.250, F10.251, F10.259, F10.26, F10.27, F10.280, F10.281, F10.282, F10.288, F10.29 |
| Opioid Abuse and Dependence | ICD 10 CM: F11.10, F11.120, F11.121, F11.122, F11.129, F11.13, F11.14, F11.150, F11.151, F11.159, F11.181, F11.182, F11.188, F11.19, F11.20, F11.220, F11.221, F11.222, F11.229, F11.23, F11.24, F11.250, F11.251, F11.259, F11.281, F11.282, F11.288, F11.29 |
| Other Drug Abuse and Dependence | ICD 10 CM: F12.10, F12.120, F12.121, F12.122, F12.129, F12.13, F12.150, F12.151, F12.159, F12.180, F12.188, F12.19, F12.20, F12.220, F12.221, F12.222, F12.229, F12.23, F12.250, F12.251, F12.259, F12.280, F12.288, F12.29, F13.10, F13.120, F13.121, F13.129, F13.130, F13.131, F13.132, F13.139, F13.14, F13.150, F13.151, F13.159, F13.180, F13.181, F13.182, F13.188, F13.19, F13.20, F13.220, F13.221, F13.229, F13.230, F13.231, F13.232, F13.239, F13.24, F13.250, F13.251, F13.259, F13.26, F13.27, F13.280, F13.281, F13.282, F13.288, F13.29, F14.10, F14.120, F14.121, F14.122, F14.129, F14.13, F14.14, F14.150, F14.151, F14.159, F14.180, F14.181, F14.182, F14.188, F14.19, F14.20, F14.220, F14.221, F14.222, F14.229, F14.23, F14.24, F14.250, F14.251, F14.259, F14.280, F14.281, F14.282, F14.288, F14.29, F15.10, F15.120, F15.121, F15.122, F15.129, F15.13, F15.14, F15.150, F15.151, F15.159, F15.180, F15.181, F15.182, F15.188, F15.19, F15.20, F15.220, F15.221, F15.222, F15.229, F15.23, F15.24, F15.250, F15.251, F15.259, F15.280, F15.281, F15.282, F15.288, F15.29, F16.10, F16.120, F16.121, F16.122, F16.129, F16.14, F16.150, F16.151, F16.159, F16.180, F16.183, F16.188, F16.19, F16.20, F16.220, F16.221, F16.229, F16.24, F16.250, F16.251, F16.259, F16.280, F16.283, F16.288, F16.29, F18.10, F18.120, F18.121, F18.129, F18.14, F18.150, F18.151, F18.159, F18.17, F18.180, F18.188, F18.19, F18.20, F18.220, F18.221, F18.229, F18.24, F18.250, F18.251, |

IET OP Measure Codes (continued)

| Description | Codes* |
|---|---|
| Other Drug Abuse and Dependence (continued) | F18.259, F18.27, F18.280, F18.288, F18.29, F19.10, F19.120, F19.121, F19.122, F19.129, F19.130, F19.131, F19.132, F19.139, F19.14, F19.150, F19.151, F19.159, F19.16, F19.17, F19.180, F19.181, F19.182, F19.188, F19.19, F19.20, F19.220, F19.221, F19.222, F19.229, F19.230, F19.231, F19.232, F19.239, F19.24, F19.250, F19.251, F19.259, F19.26, F19.27, F19.280, F19.281, F19.282, F19.288, F19.29 |

For the follow-up treatments, include an ICD-10 diagnosis for Alcohol or Other Drug Dependence from the Mental, Behavioral and Neurodevelopmental Disorder Section of ICD-10 along with a procedure code for the preventive service, evaluation, and management consultation or counseling service.

** Codes listed are subject to change. Meridian recognizes that the circumstances around the services provided may not always directly support/match the codes. It is crucial that the medical record documentation describes the services rendered in order to support the medical necessity and use of these codes. Refer to the Appendix for POS codes.*

Pharmacotherapy for Opioid Use Disorder (POD) ●●●●

The POD measure evaluates patients 16 years of age and older with a diagnosis of Opioid Use Disorder (OUD) and a new OUD pharmacotherapy that lasted at least 180 days.

The treatment period of 180+ days begins on the new OUD pharmacotherapy event date through 179 days without a gap in treatment of 8 or more consecutive days.

Opioid Use Disorder Treatment Medications

| Description | Prescription | Medication Lists |
|-----------------|---|--|
| Antagonist | • Naltrexone (oral) | • Naltrexone Oral Medications List |
| Antagonist | • Naltrexone (injectable) | • Naltrexone Injection Medications List |
| Partial agonist | • Buprenorphine (sublingual tablet) | • Buprenorphine Oral Medications List |
| Partial agonist | • Buprenorphine (injection) | • Buprenorphine Injection Medications List |
| Partial agonist | • Buprenorphine (implant) | • Buprenorphine Implant Medications List |
| Partial agonist | • Buprenorphine/ naloxone (sublingual tablet, buccal film, sublingual film) | • Buprenorphine Naloxone Medications List |
| Agonist | • Methadone (oral) | • NA (refer to Note below) |

Methadone is not included on the medication lists for this measure. Methadone for OUD administered or dispensed by federally certified opioid treatment programs (OTP) is billed on a medical claim. A pharmacy claim for methadone would be indicative of treatment for pain rather than OUD.

Unhealthy Alcohol Use Screening and Follow-Up (ASF-E) ●●●●🏠

ASF-E is an Electronic Clinical Data Systems (ECDS) measure.

ASF-E evaluates the percentage of patients 18 years of age and older who were screened for unhealthy alcohol use using a standardized instrument and, if screened positive, received appropriate follow-up care within 2 months (61 days total).

Eligible standard assessment instruments that have been normalized and validated for the adult patient population with thresholds for positive findings include:

| Screening Instrument | Total Score LOINC Codes* | Positive Finding |
|---|--------------------------|--|
| Alcohol Use Disorders Identification Test (AUDIT) screening instrument | 75624-7 | Total score ≥ 8 |
| Alcohol Use Disorders Identification Test Consumption (AUDIT-C) screening instrument | 75626-2 | Total score ≥ 4 for men Total score ≥ 3 for women |
| Single-question screen (for men): "How many times in the past year have you had 5 or more drinks in a day?" | 88037-7 | Response ≥ 1 |
| Single-question screen (for women and all adults older than 65 years): "How many times in the past year have you had 4 or more drinks in a day?" | 75889-6 | Response ≥ 1 |

*Codes subject to change

| Description | Codes* |
|--|---|
| Alcohol Counseling or Other Follow-Up Care | ICD-10-CM: Z71.41 CPT: 99408, 99409 HCPCS: G0396, G0397, G0443, G2011, H0005, H0007, H0015, H0016, H0022, H0050, H2035, H2036, T1006, T1012 SNOMED CT: 20093000, 23915005, 24165007, 64297001, 386449006, 408945004, 408947007, 408948002, 413473000, 707166002, 429291000124102 |

*Codes subject to change

Screening for Depression and Follow-Up Plan (CDF-AD) ●

This is a CMS core set measure. For more information, visit [cms.gov](https://www.cms.gov).

The CDF-AD measure evaluates patients aged 18 and older screened for depression who have never had a diagnosis of depression or bipolar disorder on the date of the encounter or 14 days prior to the date of the encounter using an age-appropriate standardized depression screening tool. If positive, a follow-up plan is documented on the date of the eligible encounter.

CDF-B Codes to Document Depression Screen

| Code | Description |
|-------|---|
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented |
| G8510 | Screening for depression is documented as negative; a follow-up plan is not required |

**Codes subject to change*

Screening for Depression and Follow-Up Plan (CDF-CH) ●

This is a CMS core set measure. For more information, visit [cms.gov](https://www.cms.gov).

The CDF-CH Measure evaluates members aged 12 to 17 years screened for depression who have never had a diagnosis of depression or bipolar disorder on the date of the encounter or 14 days prior to the date of the encounter using an age-appropriate standardized depression screening tool. If positive, a follow-up plan is documented on the date of the eligible encounter.

CDF-B Codes to Document Depression Screen

| Code | Description |
|-------|---|
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented |
| G8510 | Screening for depression is documented as negative; a follow-up plan is not required |

**Codes subject to change*

Depression Screening and Follow-Up for Adolescents and Adults (DSF-E) ●●●●👤

DSF-E is an Electronic Clinical Data Systems (ECDS) measure.

DSF-E evaluates the percentage of patients 12 years of age and older who were screened for clinical depression between January 1 and December 1 of the measurement year, using a standardized instrument and, if screened positive, received follow-up care within 30 days.

** Refer to the Appendix for a list of Approved Depression Screening Instruments, Codes, and Positive Findings*

Depression Remission or Response for Adolescents and Adults (DRR-E) ●●●●👤

DRR-E is an Electronic Clinical Data Systems (ECDS) measure.

DRR-E evaluates the percentage of patients 12 years of age and older with a diagnosis of depression and an elevated PHQ-9 score, who had evidence of response or remission within 120–240 days (4 to 8 months) of the elevated score.

- **Follow-Up PHQ-9:** The percentage of members who have a follow-up PHQ-9 score documented within 120–240 days (4 to 8 months) after the initial elevated PHQ-9 score.
- **Depression Remission:** The percentage of patients who achieved remission of depression symptoms, as demonstrated by the most recent PHQ-9 total score of <5 during the depression follow-up period (within 120–240 days [4–8 months] after the initial elevated PHQ-9 score).
- **Depression Response:** The percentage of patients who showed response to treatment for depression, as demonstrated by the most recent PHQ-9 total score of at least 50% lower than the PHQ-9 score associated with the diagnosis, documented during the depression follow-up period (within 120–240 days [4–8 months] after the initial elevated PHQ-9 score).

DRR-E Codes

| Depression / PHQ-9 Follow-Up, Remission, and Response | LOINC Codes* |
|---|--------------------|
| Members 12 years of age and older | 44261-6, 89204-2** |

**Codes subject to change*

***For adolescents ages 12–17 assessed with Patient Health Questionnaire Modified for Teens (PHQ-9M)[®]*

Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)



DMS-E is an Electronic Clinical Data Systems (ECDS) measure.

DMS-E evaluates the percentage of patients 12 years of age and older with a diagnosis of major depression or dysthymia who had an outpatient encounter with a PHQ-9 score present in their record in the same assessment period as the encounter.

The measurement period is divided into three assessment periods with specific dates of service:

- Assessment period 1: January 1–April 30
- Assessment period 2: May 1–August 31
- Assessment period 3: September 1–December 31

DMS-E Codes

| Utilization of PHQ-9 | LOINC Codes* |
|-----------------------------------|--------------------|
| Members 12 years of age and older | 44261-6, 89204-2** |

**Codes subject to change*

***For adolescents ages 12-17 assessed with Patient Health Questionnaire Modified for Teens (PHQ-9M)[®]*

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) ●●

The APP measure evaluates patients 1 to 17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment.

Antipsychotic Medications

| Miscellaneous Antipsychotic Agents | | |
|------------------------------------|--------------------------|-------------------|
| • Aripiprazone | • Iloperidone | • Pimozide |
| • Asenapine | • Loxapine | • Quetiapine |
| • Brexpiprazole | • Lurasidone | • Risperidone |
| • Cariprazine | • Molindone | • Ziprasidone |
| • Clozapine | • Olanzapine | |
| • Haloperidol | • Paliperidone | |
| Phenothiazine Antipsychotics | | |
| • Chlorpromazine | • Perphenazine | • Trifluoperazine |
| • Fluphenazine | • Thioridazine | |
| Thioxanthenes | | |
| • Thiothixene | | |
| Long-Acting Injections | | |
| • Arripiprazole | • Haloperidol decanoate | • Risperidone |
| • Arripiprazole lauroxil | • Olanzapine | |
| • Fluphenazine decanoate | • Paliperidone palmitate | |

Antipsychotic Combination Medications

| Psychotherapeutic Combinations |
|--------------------------------|
| • Fluoxetine-olanzapine |
| • Perphenazine-amitriptyline |

APP Measure Codes

| Description | CPT* | HCPCS* |
|---|--|---|
| Psychosocial Care | 90832-90834, 90836-90840, 90845-90847, 90849, 90853, 90875, 90876, 90880 | G0176, G0177, G0409, G0410, G0411, H0004, H0035-H0040, H2000, H2001, H2011-H2014, H2017-H2020, S0201, S9480, S9484, S9485 |
| Residential Behavioral Health Treatment | | H0017, H0018, H0019, T2048 |

*Codes subject to change

General Health



Appropriate Testing for Pharyngitis (CWP) ●●●●

The CWP measure evaluates the percentage of episodes for patients aged 3 years and older where the patient was diagnosed with pharyngitis, dispensed an antibiotic, and received a group A streptococcus (strep) test for the episode.

CWP Measure Codes

| Description | ICD-10-CM Diagnosis* |
|---------------------------|----------------------|
| Acute pharyngitis | J02.9 |
| Acute tonsillitis | J03.90 |
| Streptococcal sore throat | J02.0 |

*Codes subject to change

Group A Strep Test Codes

| CPT* |
|--|
| 87070, 87071, 87081, 87430, 87650-87652, 87880 |

*Codes subject to change

Asthma Medication Ratio (AMR) ●●

The AMR measure evaluates the percentage of patients 5 to 64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medication of 0.50 or greater.

Oral medication dispensing event: One prescription of an amount lasting 30 days or less. Multiple prescriptions for different medications dispensed on the same day are counted as separate dispensing events.

Inhaler dispensing event: All inhalers of the same medication dispensed on the same day count as one dispensing event. Different inhaler medications dispensed on the same day are counted as different dispensing events.

Injection dispensing event: Each injection counts as one dispensing event. Multiple dispensed injections of the same or different medications count as separate dispensing events.

Step 1: For each member, count the units of asthma controller medications (Asthma Controller Medications List) dispensed during the measurement year.

Step 2: For each member, count the units of asthma reliever medications (Asthma Reliever Medications List) dispensed during the measurement year.

- For each member, sum the units calculated in Step 1 and Step 2 to determine units of total asthma medications.

- For each member, calculate ratio using the below:

- Units of Controller Medications/Units of Total Asthma Medications

Asthma Controller Medications

| Description | Prescriptions | Medication Lists | Route |
|------------------------------|--------------------------|---|------------|
| Antibody inhibitors | • Omalizumab | Omalizumab Medications List | Injection |
| Anti-interleukin-4 | • Dupilumab | Dupilumab Medications List | Injection |
| Anti-interleukin-5 | • Benralizumab | Benralizumab Medications List | Injection |
| Anti-interleukin-5 | • Mepolizumab | Mepolizumab Medications List | Injection |
| Anti-interleukin-5 | • Reslizumab | Reslizumab Medications List | Injection |
| Inhaled steroid combinations | • Budesonide-formoterol | Budesonide Formoterol Medications List | Inhalation |
| Inhaled steroid combinations | • Fluticasone-salmeterol | Fluticasone Salmeterol Medications List | Inhalation |
| Inhaled steroid combinations | • Fluticasone-vilanterol | Fluticasone Vilanterol Medications List | Inhalation |
| Inhaled steroid combinations | • Formoterol-mometasone | Formoterol Mometasone Medications List | Inhalation |
| Inhaled corticosteroids | • Beclomethasone | Beclomethasone Medications List | Inhalation |
| Inhaled corticosteroids | • Budesonide | Budesonide Medications List | Inhalation |

Asthma Controller Medications (continued)

| Description | Prescriptions | Medication Lists | Route |
|-------------------------|----------------|-------------------------------|------------|
| Inhaled corticosteroids | • Ciclesonide | Ciclesonide Medications List | Inhalation |
| Inhaled corticosteroids | • Flunisolide | Flunisolide Medications List | Inhalation |
| Inhaled corticosteroids | • Fluticasone | Fluticasone Medications List | Inhalation |
| Inhaled corticosteroids | • Mometasone | Mometasone Medications List | Inhalation |
| Leukotriene modifiers | • Montelukast | Montelukast Medications List | Oral |
| Leukotriene modifiers | • Zafirlukast | Zafirlukast Medications List | Oral |
| Leukotriene modifiers | • Zileuton | Zileuton Medications List | Oral |
| Methylxanthines | • Theophylline | Theophylline Medications List | Oral |

Asthma Reliever Medications

| Description | Prescriptions | Medication Lists | Route |
|--|----------------------|---------------------------------------|------------|
| Short-acting, inhaled beta-2 agonists | Albuterol | Albuterol Medications List | Inhalation |
| Short-acting, inhaled beta-2 agonists | Levalbuterol | Levalbuterol Medications List | Inhalation |
| Beta-2 adrenergic agonist-corticosteroid combination | Albuterol-Budesonide | Albuterol-Budesonide Medications List | Inhalation |

Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB) ●●●●

The AAB measure evaluates patients 3 months of age and older who had a diagnosis of acute bronchitis/bronchiolitis that did not result in an antibiotic dispensing event. *A lower rate indicates better performance.*

Treating Uncomplicated Acute Bronchitis

- Avoid prescribing antibiotics
- Treat presented symptoms only
- Prescribe antitussive agents for short-term relief of coughing

AAB Antibiotic Medications Table

| Description | Prescriptions |
|----------------------------------|---|
| Aminoglycosides | <ul style="list-style-type: none"> • Amikacin • Gentamicin • Streptomycin • Tobramycin |
| Aminopenicillins | <ul style="list-style-type: none"> • Amoxicillin Ampicillin |
| Beta-lactamase inhibitors | <ul style="list-style-type: none"> • Amoxicillin-clavulanate • Ampicillin-sulbactam • Piperacillin-tazobactam |
| First-generation cephalosporins | <ul style="list-style-type: none"> • Cefadroxil • Cefazolin • Cephalexin |
| Fourth-generation cephalosporins | <ul style="list-style-type: none"> • Cefepime |
| Lincomycin derivatives | <ul style="list-style-type: none"> • Clindamycin • Lincomycin |
| Macrolides | <ul style="list-style-type: none"> • Azithromycin • Clarithromycin • Erythromycin |
| Miscellaneous antibiotics | <ul style="list-style-type: none"> • Aztreonam • Chloramphenicol • Dalfopristin-quinupristin • Daptomycin • Linezolid • Metronidazole • Vancomycin |

AAB Antibiotic Medications Table (continued)

| Description | Prescriptions |
|-------------------------------------|---|
| Natural penicillins | <ul style="list-style-type: none"> • Penicillin G benzathine-procaine • Penicillin G potassium • Penicillin G procaine • Penicillin G sodium • Penicillin V potassium • Penicillin G benzathine |
| Penicillinase resistant penicillins | <ul style="list-style-type: none"> • Dicloxacillin • Nafcillin • Oxacillin |
| Quinolones | <ul style="list-style-type: none"> • Ciprofloxacin • Gemifloxacin • Levofloxacin • Moxifloxacin • Ofloxacin |
| Rifamycin derivatives | <ul style="list-style-type: none"> • Rifampin |
| Second-generation cephalosporin | <ul style="list-style-type: none"> • Cefaclor • Cefotetan • Cefoxitin • Cefprozil • Cefuroxime |
| Sulfonamides | <ul style="list-style-type: none"> • Sulfadiazine • Sulfamethoxazole-trimethoprim |
| Tetracyclines | <ul style="list-style-type: none"> • Doxycycline • Minocycline • Tetracycline |
| Third-generation cephalosporins | <ul style="list-style-type: none"> • Cefdinir • Cefixime • Cefotaxime • Cefpodoxime • Ceftazidime • Ceftriaxone |
| Urinary anti-infectives | <ul style="list-style-type: none"> • Fosfomycin • Nitrofurantoin • Nitrofurantoin macrocrystals-monohydrate • Trimethoprim |

Social Need Screening and Intervention (SNS-E) ●●●🏠

SNS-E is an Electronic Clinical Data Systems (ECDS) measure.

SNS-E evaluates the percentage of patients who were screened, using prespecified instruments, at least once during the measurement period for unmet food, housing, and transportation needs, and received a corresponding intervention within one month if they screened positive.

Food Screening: Patients with a documented result for food insecurity screening performed between January 1 and December 1 of the measurement period

Eligible screening instruments with thresholds for positive findings include:

| Food Insecurity Instruments | Screening Item LOINC Codes | Positive Finding LOINC Codes |
|---|----------------------------|------------------------------|
| Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool | 88122-7 | LA28397-0 LA6729-3 |
| | 88123-5 | LA28397-0 LA6729-3 |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool | 88122-7 | LA28397-0 LA6729-3 |
| | 88123-5 | LA28397-0 LA6729-3 |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool—short form | 88122-7 | LA28397-0 LA6729-3 |
| | 88123-5 | LA28397-0 LA6729-3 |
| Health Leads Screening Panel ^① | 95251-5 | LA33-6 |
| Hunger Vital Sign ^{TM1} (HVS) | 88124-3 | LA19952-3 |
| Protocol for Responding to and Assessing Patients' Assets, Risks and Experiences [PRAPARE] ^① | 93031-3 | LA30125-1 |
| Safe Environment for Every Kid (SEEK) ^① | 95400-8 | LA33-6 |
| | 95399-2 | LA33-6 |
| U.S. Household Food Security Survey [U.S. FSS] | 95264-8 | LA30985-8 LA30986-6 |
| U.S. Adult Food Security Survey [U.S. FSS] | 95264-8 | LA30985-8 LA30986-6 |
| U.S. Child Food Security Survey [U.S. FSS] | 95264-8 | LA30985-8 LA30986-6 |
| U.S. Household Food Security Survey—Six-Item Short Form [U.S. FSS] | 95264-8 | LA30985-8 LA30986-6 |

| Food Insecurity Instruments | Screening Item LOINC Codes | Positive Finding LOINC Codes |
|-----------------------------|----------------------------|------------------------------|
| We Care Survey | 96434-6 | LA32-8 |
| WellRx Questionnaire | 93668-2 | LA33-6 |

¹ Proprietary; may be cost or licensing requirement associated with use.

*Codes subject to change

Food Intervention: Patients who received a food insecurity intervention on or up to 30 days after the date of the first positive food insecurity screen (31 days total)

| Food Insecurity Procedures Codes* |
|---|
| CPT: 96156, 96160, 96161, 97802, 97803, 97804 |
| HCPCS: S5170, S9470 |
| SNOMED CT: 1759002, 61310001, 103699006, 308440001, 385767005, 710824005, 710925007, 711069006, 713109004, 1002223009, 1002224003, 1002225002, 1004109000, 1004110005, 1148446004, 1162436000, 1230338004, 441041000124100, 441201000124108, 441231000124100, 441241000124105, 441251000124107, 441261000124109, 441271000124102, 441281000124104, 441291000124101, 441301000124100, 441311000124102, 441321000124105, 441331000124108, 441341000124103, 441351000124101, 445291000124103, 445301000124102, 445641000124105, 461481000124109, 462481000124102, 462491000124104, 464001000124109, 464011000124107, 464021000124104, 464031000124101, 464041000124106, 464051000124108, 464061000124105, 464071000124103, 464081000124100, 464091000124102, 464101000124108, 464111000124106, 464121000124103, 464131000124100, 464141000124105, 464151000124107, 464161000124109, 464171000124102, 464181000124104, 464191000124101, 464201000124103, 464211000124100, 464221000124108, 464231000124106, 464241000124101, 464251000124104, 464261000124102, 464271000124109, 464281000124107, 464291000124105, 464301000124106, 464311000124109, 464321000124101, 464331000124103, 464341000124108, 464351000124105, 464361000124107, 464371000124100, 464381000124102, 464401000124102, 464411000124104, 464421000124107, 464431000124105, 464611000124102, 464621000124105, 464631000124108, 464641000124103, 464651000124101, 464661000124104, 464671000124106, 464681000124109, 464691000124107, 464701000124107, 464721000124102, 467591000124102, 467601000124105, 467611000124108, 467621000124100, 467631000124102, 467641000124107, 467651000124109, 467661000124106, 467671000124104, 467681000124101, 467691000124103, 467711000124100, 467721000124108, 467731000124106, 467741000124101, 467751000124104, 467761000124102, 467771000124109, 467781000124107, 467791000124105, 467801000124106, 467811000124109, 467821000124101, 468401000124109, 470231000124107, 470241000124102, 470261000124103, 470281000124108, |

Food Insecurity Procedures Codes*

470291000124106, 470301000124107, 470311000124105, 470321000124102, 470591000124109, 470601000124101, 470611000124103, 471111000124101, 471121000124109, 471131000124107, 472151000124109, 472331000124100, 551101000124107

*Codes subject to change

Housing Screening: Patients with a documented result for housing instability, homelessness or housing inadequacy screening performed between January 1 and December 1 of the measurement period

Eligible screening instruments with thresholds for positive findings include:

| Housing Instability and Homelessness Instruments | Screening Item LOINC Codes | Positive Finding LOINC Codes |
|--|----------------------------|------------------------------|
| Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool | 71802-3 | LA31994-9 LA31995-6 |
| | 99550-6 | LA33-6 |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool—short form | 71802-3 | LA31994-9 LA31995-6 |
| | 98976-4 | LA33-6 |
| Children’s Health Watch Housing Stability Vital Signs™ ¹ | 98977-2 | ≥3 |
| | 98978-0 | LA33-6 |
| Health Leads Screening Panel® ¹ | 99550-6 | LA33-6 |
| Protocol for Responding to and Assessing Patients’ Assets, Risks and Experiences [PRAPARE]® ¹ | 93033-9 | LA33-6 |
| | 71802-3 | LA30190-5 |
| We Care Survey | 96441-1 | LA33-6 |
| WellRx Questionnaire | 93669-0 | LA33-6 |

*Codes subject to change

| Housing Inadequacy Instruments | Screening Item LOINC Codes | Positive Finding LOINC Codes |
|--|----------------------------|---|
| Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool | 96778-6 | LA28580-1 LA31996-4 LA31997-2 LA31998-0 LA31999-8 LA32000-4 LA32001-2 |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool | 96778-6 | LA28580-1 LA32693-6 LA32694-4 LA32695-1 LA32696-9 LA32001-2 LA32691-0 |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool—short form | 96778-6 | LA28580-1 LA31996-4 LA31997-2 LA31998-0 LA31999-8 LA32000-4 LA32001-2 LA33-6 |
| Norwalk Community Health Center Screening Tool [NCHC] | 99134-9 | LA33-6 |
| | 99135-6 | LA28580-1 LA31996-4 LA31997-2 LA31998-0 LA31999-8 LA32000-4 LA32001-2 |

¹ Proprietary; may be cost or licensing requirement associated with use.

*Codes subject to change

Housing Intervention: Patients who received an intervention corresponding to the type of housing need identified on or up to 30 days after the date of the first positive housing screen (31 days total)

Inadequate Housing Procedures Codes*

CPT: 96156, 96160, 96161

SNOMED CT: 49919000, 308440001, 710824005, 711069006, 1148446004, 1148813002, 1148815009, 1148823006, 1162436000, 1230338004, 461481000124109, 462481000124102, 462491000124104, 464001000124109, 464011000124107, 464021000124104, 464131000124100, 464161000124109, 464291000124105, 464301000124106, 464311000124109, 464611000124102, 470231000124107, 470431000124106, 470441000124101, 470451000124104, 470461000124102, 470591000124109, 470601000124101, 470611000124103, 471111000124101, 471121000124109, 471131000124107, 472151000124109, 472201000124100, 472211000124102, 472231000124108, 472251000124101, 472331000124100, 472371000124102, 480881000124103, 480891000124100, 480911000124103, 480951000124102, 551041000124105, 551051000124107, 551061000124109, 551071000124102, 551081000124104, 551101000124107

*Codes subject to change

Transportation Screening: Patients with a documented result for transportation insecurity screening performed between January 1 and December 1 of the measurement period.

Eligible screening instruments with thresholds for positive findings include:

| Transportation Insecurity Instruments | Screening Item LOINC Codes | Positive Finding LOINC Codes |
|--|----------------------------|-------------------------------------|
| Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool | 93030-5 | LA33-6 |
| | 99594-4 | LA33-6 |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool—short form | 99594-4 | LA30134-3 LA33093-8 |
| Comprehensive Universal Behavior Screen (CUBS) | 89569-8 | LA29232-8 LA29233-6 LA29234-4 |
| Health Leads Screening Panel®1 | 99553-0 | LA33-6 |
| Inpatient Rehabilitation Facility - Patient Assessment Instrument (IRF-PAI)—version 4.0 [CMS Assessment] | 93030-5 | LA30133-5 LA30134-3 |
| Outcome and assessment information set (OASIS) form—version E—Discharge from Agency [CMS Assessment] | 93030-5 | LA30133-5 LA30134-3 |
| Outcome and assessment information set (OASIS) form—version E—Resumption of Care [CMS Assessment] | 93030-5 | LA30133-5 LA30134-3 |

| Transportation Insecurity Instruments | Screening Item LOINC Codes | Positive Finding LOINC Codes |
|---|----------------------------|-------------------------------------|
| Outcome and assessment information set (OASIS) form—version E—Start of Care [CMS Assessment] | 93030-5 | LA30133-5 LA30134-3 |
| Protocol for Responding to and Assessing Patients' Assets, Risks and Experiences [PRAPARE] ^① | 93030-5 | LA30133-5 LA30134-3 |
| PROMIS ^① | 92358-1 | LA30024-6 LA30026-1 LA30027-9 |
| WellRx Questionnaire | 93671-6 | LA33-6 |

^① Proprietary; may be cost or licensing requirement associated with use.

*Codes subject to change

Transportation Intervention: Patients who received a transportation insecurity intervention on or up to 30 days after the date of the first positive transportation screen (31 days total)

| Transportation Insecurity Procedures Codes* |
|--|
| <p>CPT: 96156, 96160, 96161</p> <p>SNOMED CT: 308440001, 710824005, 711069006, 1148446004, 1162436000, 1230338004, 461481000124109, 462481000124102, 462491000124104, 464001000124109, 464011000124107, 464021000124104, 464131000124100, 464161000124109, 464291000124105, 464301000124106, 464311000124109, 464611000124102, 470231000124107, 470591000124109, 470601000124101, 470611000124103, 471111000124101, 471121000124109, 471131000124107, 472151000124109, 472331000124100, 551101000124107, 551111000124105, 551121000124102, 551141000124109, 551161000124108, 551191000124100, 551201000124102, 551211000124104, 551221000124107, 551231000124105, 551241000124100, 551251000124103, 551261000124101, 551271000124108, 551281000124106, 551291000124109, 551301000124105, 551311000124108, 551321000124100, 551331000124102, 551341000124107, 551351000124109, 551361000124106, 551371000124104, 551381000124101, 551401000124101, 551421000124106, 551431000124109, 610961000124100, 610971000124107, 610981000124105, 610991000124108, 611001000124109, 611011000124107, 611021000124104, 611031000124101, 611041000124106, 611051000124108, 611061000124105, 611071000124103, 611081000124100, 611101000124108, 611121000124103, 611281000124107, 611291000124105, 611301000124106, 611311000124109, 611321000124101, 611331000124103, 611341000124108, 611351000124105, 611361000124107, 611371000124100, 611381000124102, 611391000124104, 611401000124102, 611411000124104, 611421000124107, 611431000124105, 611441000124100</p> |

*Codes subject to change

Pediatric Health



Childhood Immunization Status (CIS-E) ●●●📶

Beginning in MY 2025, this measure transitioned to the Electronic Clinical Data Systems (ECDS) reporting method only.

CIS-E evaluates the percentage of children 2 years of age during the measurement year who completed the following immunizations on or before child's second birthday.

| Immunization | Required Doses |
|---|---|
| DTaP (Diphtheria, Tetanus, Acellular Pertussis) | 4 doses |
| PCV (Pneumococcal Conjugate) | 4 doses |
| HiB (Haemophiles Influenza Type B) | 3 doses |
| Hep B (Hepatitis B) | 3 doses |
| IPV (Polio; Inactivated Polio Virus) | 3 doses |
| Flu (Influenza) | 2 doses |
| RV (Rotavirus) | 2 or 3 dose series |
| Hep A (Hepatitis A) | 1 dose on or between the 1st and 2nd birthday |
| MMR (Measles, Mumps, Rubella) | 1 dose on or between the 1st and 2nd birthday |
| VZV (Chicken Pox; Varicella zoster) | 1 dose on or between the 1st and 2nd birthday |

CIS-E Measure Codes

| Description | Codes* |
|--|---|
| DTaP Immunization | CVX: 20, 50, 106, 107, 110, 120, 146 |
| DTaP Vaccine Procedure | CPT: 90697, 90698, 90700, 90723 SNOMED CT: 310306005, 310307001, 310308006, 312870000, 313383003, 390846000, 390865008, 399014008, 412755006, 412756007, 412757003, 412762002, 412763007, 412764001, 414001002, 414259000, 414620004, 415507003, 415712004, 770608009, 770616000, 770617009, 770618004, 787436003, 866158005, 866159002, 866226006, 868273007, 868274001, 868276004, 868277008, 1162640003, 428251000124104, 571571000119105, 572561000119108, 16290681000119103 |
| Anaphylaxis due to Diphtheria, Tetanus or Pertussis Vaccine | SNOMED CT: 428281000124107, 428291000124105 |
| Encephalitis due to Diphtheria, Tetanus or Pertussis Vaccine | SNOMED CT: 192710009, 192711008, 192712001 |
| HiB Immunization | CVX: 17, 46, 47, 48, 49, 50, 51, 120, 146, 148 |
| HiB Vaccine Procedure | CPT: 90644, 90647, 90648, 90697, 90698, 90748 SNOMED CT: 127787002, 170343007, 170344001, 170345000, 170346004, 310306005, 310307001, 310308006, 312869001, 312870000, 313383003, 414001002, 414259000, 415507003, 415712004, 428975001, 712833000, 712834006, 770608009, 770616000, 770617009, 770618004, 786846001, 787436003, 1119364007, 1162640003, 16292241000119109 |
| Anaphylaxis due to the HiB Vaccine | SNOMED CT: 433621000124101 |
| Hepatitis B Immunization | CVX: 08, 44, 45, 51, 110, 146 |
| Hepatitis B Vaccine Procedure | CPT: 90697, 90723, 90740, 90744, 90747, 90748 HCPCS: G0010 SNOMED CT: 16584000, 170370000, 170371001, 170372008, 170373003, 170374009, 170375005, 170434002, 170435001, 170436000, 170437009, 312868009, 396456003, 416923003, 770608009, 770616000, 770617009, 770618004, 786846001, 1162640003, 572561000119108 |

CIS-E Measure Codes (continued)

| Description | Codes* |
|--|--|
| History of Hepatitis B Illness | ICD10CM: B16.0, B16.1, B16.2, B16.9, B17.0, B18.0, B18.1, B19.10, B19.11 SNOMED CT: 1116000, 13265006, 26206000, 38662009, 50167007, 53425008, 60498001, 61977001, 66071002, 76795007, 111891008, 165806002, 186624004, 186626002, 186639003, 235864009, 235865005, 235869004, 235871004, 271511000, 313234004, 406117000, 424099008, 424340000, 442134007, 442374005, 446698005, 838380002, 1230342001, 153091000119109, 551621000124109 |
| Anaphylaxis due to the Hepatitis B Vaccine | SNOMED CT: 428321000124101 |
| IPV Immunization | CVX: 10, 89, 110, 120, 146 |
| IPV Procedure | CPT: 90697, 90698, 90713, 90723 SNOMED CT: 310306005, 310307001, 310308006, 312869001, 312870000, 313383003, 390865008, 396456003, 412762002, 412763007, 412764001, 414001002, 414259000, 414619005, 414620004, 415507003, 415712004, 416144004, 416591003, 417211006, 417384007, 417615007, 866186002, 866227002, 868266002, 868267006, 868268001, 868273007, 868274001, 868276004, 868277008, 870670004, 572561000119108, 16290681000119103 |
| Anaphylaxis due to IPV Vaccine | SNOMED CT: 471321000124106 |
| MMR Immunization | CVX: 03, 94 |
| MMR Vaccine Procedure | CPT: 90707, 90710 SNOMED CT: 38598009, 170431005, 170432003, 170433008, 432636005, 433733003, 871909005, 571591000119106, 572511000119105 |
| History of Measles Illness | ICD10CM: B05.0, B05.1, B05.2, B05.3, B05.4, B05.81, B05.89, B05.9 SNOMED CT: 14189004, 28463004, 38921001, 60013002, 74918002, 111873003, 161419000, 186561002, 186562009, 195900001, 240483006, 240484000, 359686005, 371111005, 406592004, 417145006, 424306000, 105841000119101 |

CIS-E Measure Codes (continued)

| Description | Codes* |
|--|---|
| History of Mumps Illness | ICD10CM: B26.0, B26.1, B26.2, B26.3, B26.81, B26.82, B26.83, B26.84, B26.85, B26.89, B26.9 SNOMED CT: 10665004, 17121006, 31524007, 31646008, 36989005, 40099009, 44201003, 63462008, 72071001, 74717002, 75548002, 78580004, 89231008, 89764009, 111870000, 161420006, 235123001, 236771002, 237443002, 240526004, 240527008, 240529006, 371112003, 1163539003, 105821000119107 |
| History of Rubella Illness | ICD10CM: B06.00, B06.01, B06.02, B06.09, B06.81, B06.82, B06.89, B06.9 SNOMED CT: 10082001, 13225007, 19431000, 36653000, 51490003, 64190005, 79303006, 128191000, 161421005, 165792000, 186567003, 186570004, 192689006, 231985001, 232312000, 240485004, 253227001, 406112006, 406113001, 1092361000119109, 10759761000119100 |
| Anaphylaxis due to the MMR Vaccine | SNOMED CT: 471331000124109 |
| Pneumococcal Conjugate Immunization | CVX: 109, 133, 152, 215 |
| Pneumococcal Conjugate Vaccine Procedure | CPT: 90670, 90671 HCPCS: G0009 SNOMED CT: 1119368005, 434751000124102 |
| Anaphylaxis due to Pneumococcal Vaccine | SNOMED CT: 471141000124102 |
| Varicella Zoster (VZV) Immunization | CVX: 21, 94 |
| Varicella Zoster (VZV) Vaccine Procedure | CPT: 90710, 90716 SNOMED CT: 425897001, 428502009, 432636005, 433733003, 737081007, 871898007, 871899004, 871909005, 572511000119105 |

CIS-E Measure Codes (continued)

| Description | Codes* |
|--|--|
| <p>History of Varicella Zoster (Chicken Pox) Illness</p> | <p>ICD10CM: B01.0, B01.11, B01.12, B01.2, B01.81, B01.89, B01.9, B02.0, B02.1, B02.21, B02.22, B02.23, B02.24, B02.29, B02.30, B02.31, B02.32, B02.33, B02.34, B02.39, B02.7, B02.8, B02.9 SNOMED CT: 4740000, 10698009, 21954000, 23737006, 24059009, 36292003, 38907003, 42448002, 49183009, 55560002, 87513003, 111859007, 111861003, 161423008, 186524006, 195911009, 230176008, 230198004, 230262004, 230536009, 232400003, 235059009, 240468001, 240470005, 240471009, 240472002, 240473007, 240474001, 309465005, 371113008, 397573005, 400020001, 402897003, 402898008, 402899000, 410500004, 410509003, 421029004, 422127002, 422446008, 422471006, 422666006, 423333008, 423628002, 424353002, 424435009, 424801004, 424941009, 425356002, 426570007, 428633000, 713250002, 713733003, 713964006, 715223009, 723109003, 838357005, 1163465001, 1163483009, 1179456002, 12551000132107, 12561000132105, 12571000132104, 98541000119101, 331071000119101, 681221000119108, 1087131000119102, 15678761000119105, 15678801000119102, 15678841000119100, 15680201000119106, 15680241000119108, 15680281000119103, 15681321000119100, 15681401000119101, 15685081000119102, 15685121000119100, 15685201000119100, 15685281000119108, 15936581000119108, 15936621000119108, 15989271000119107, 15989311000119107, 15989351000119108, 15991711000119108, 15991751000119109, 15991791000119104, 15992351000119104, 16000751000119105, 16000791000119100, 16000831000119106</p> |
| <p>Anaphylaxis due to the VZV Vaccine</p> | <p>SNOMED CT: 471341000124104</p> |
| <p>Hep A Immunization</p> | <p>CVX: 31, 83, 85</p> |

CIS-E Measure Codes (continued)

| Description | Codes* |
|--|---|
| Hepatitis A Vaccine Procedure | CPT: 90633 SNOMED CT: 170378007, 170379004, 170380001, 170381002, 170434002, 170435001, 170436000, 170437009, 243789007, 312868009, 314177003, 314178008, 314179000, 394691002, 871752004, 871753009, 871754003, 571511000119102 |
| History of Hepatitis A illness | ICD10CM: B15.0, B15.9 SNOMED CT: 16060001, 18917003, 25102003, 40468003, 43634002, 79031007, 111879004, 165997004, 206373002, 278971009, 310875001, 424758008, 428030001, 105801000119103 |
| Anaphylaxis due to hepatitis A vaccine | SNOMED CT: 471311000124103 |
| Influenza Immunization | CVX: 88, 140, 141, 150, 153, 155, 158, 161, 171, 186 |
| Influenza Vaccine Procedure | CPT: 90655, 90657, 90661, 90673, 90674, 90685, 90686, 90687, 90688, 90689, 90756 HCPCS: G0080 SNOMED CT: 86198006 |
| Influenza Virus LAIV Immunization (Recommended for children 2 years of age and older. When administered on the child's second birthday, meets the criteria for one of two required doses for Flu immunization.) | CVX: 111, 149 |
| Influenza Virus LAIV Vaccine Procedure | CPT: 90660, 90672 SNOMED CT: 787016008 |
| Anaphylaxis due to the Influenza Vaccine | SNOMED CT: 471361000124100 |
| Combination 3 | DTaP, IPV, MMR, HiB, hepatitis B, VZV, and pneumococcal indicators |
| Combination 7 | DTaP, IPV, MMR, HiB, hepatitis B, VZV, pneumococcal, hepatitis A, and rotavirus indicators |
| Combination 10 | DTaP, IPV, MMR, HiB, hepatitis B, VZV, pneumococcal, hepatitis A, rotavirus and influenza indicators |

CIS-E Measure Codes (continued)

| Description | Codes* |
|---|--|
| Rotavirus Immunization (2 dose schedule) | CPT: 90681 CVX: 119 SNOMED CT: 434741000124104 |
| Rotavirus Immunization (3 dose schedule) | CVX: 116, 122 |
| Rotavirus Procedure (3 dose schedule) | CPT: 90680 SNOMED CT: 434731000124109 |
| Anaphylaxis due to the Rotavirus Vaccine | SNOMED CT: 428331000124103 |

*Codes subject to change

NOTE: Rotavirus is either 2 dose OR 3 dose for compliance

Follow-Up Care for Children Prescribed ADHD Medication (ADD-E) ●●👤

ADD-E is an Electronic Clinical Data Systems (ECDS) measure.

The ADD-E measure evaluates the percentage of children newly prescribed attention deficit hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed.

Two rates are reported:

- **Initiation Phase:** Percentage of patients 6 to 12 years of age with a prescription dispensed for ADHD medication, who had one follow-up visit with a practitioner with prescribing authority during the 30-day Initiation Phase
- **Continuation and Maintenance (C&M) Phase:** Percentage of patients 6 to 12 years of age with a prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.

ADD-E Measure Codes

| Description | Codes* |
|--|--|
| Outpatient POS | POS: 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 71, 72 |
| BH Outpatient Visit | CPT: 98960-98962, 99078, 99202-99205, 99211-99215, 99242-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99510, 99483, 99492-99494 HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013, H2014, H2015, H2016, H2017, H2018, H2019, H2020, T1015 |
| Health and Behavior Assessment/Intervention | CPT: 96156, 96158, 96159, 96164, 96165, 96167, 96168, 96170, 96171 |
| Online Assessments | CPT: 98970-98972, 98980, 98981, 99421-99423, 99457, 99458 HCPC: G0071, G2010, G2012, G2250-G2252 |
| Partial Hospitalization/ Intensive Outpatient | HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485 SNOMED CT: 7133001, 305345009, 305346005, 305347001, 391038005, 391042008, 391043003, 391046006, 391047002, 391048007, 391054008, 391055009, 391056005, 391133003, 391150001, 391151002, 391152009, 391153004, 391170007, 391185001, 391186000, 391187009, 391188004, 391191004, 391192006, 391194007, 391195008, 391207001, 391208006, 391209003, 391210008, 391211007, 391228005, 391229002, 391232004, 391252003, 391254002, 391255001, 391256000 |
| Telehealth POS | POS: 02, 10 |
| Telephone Visits | CPT: 98966-98968, 99441-99443 SNOMED CT: 185317003, 314849005, 386472008, 386473003, 401267002 |
| Visit Setting Unspecified Value Set | CPT: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99252-99255 POS: 52, 53 |

*Codes subject to change

CNS Stimulants

| | |
|---|---|
| <ul style="list-style-type: none"> • Dexmethylphenidate • Dextroamphetamine • Lisdexamfetamine | <ul style="list-style-type: none"> • Methamphetamine • Methylphenidate • Serdexmethylphenidate • Viloxazine |
|---|---|

Immunizations for Adolescents (IMA-E) ●●●👤

Beginning in MY 2025, this measure transitioned to the Electronic Clinical Data Systems (ECDS) reporting method only.

IMA-E evaluates the percentage of adolescents 13 years of age in the measurement year who completed the following immunizations on or before the member's 13th birthday.

| Immunization | Required Doses |
|--|---|
| Meningococcal | 1 dose between the 11th and 13th birthdays |
| Tdap (Tetanus, Diphtheria Toxoids and Acellular Pertussis) | 1 dose between the 10th and 13th birthdays |
| HPV (Human Papillomavirus) | 2 or 3 doses between the 9th and 13th birthdays |

Note: HPV is either two doses with 146 days between the first and second dose OR three doses on different dates of service for compliancy

IMA-E Measure Codes

| Description | Codes* |
|---|---|
| Meningococcal-serogroup A,C,W, and Y Immunization | CVX: 32, 108, 114, 136, 147, 167, 203 |
| Meningococcal Vaccine Procedure | CPT: 90619, 90733, 90734 SNOMED CT: 871874000, 428271000124109, 16298691000119102 |
| Anaphylaxis due to the Meningococcal Vaccine | SNOMED CT: 428301000124106 |
| Tdap Immunization | CVX: 115 |
| Tdap Vaccine Procedure | CPT: 90715 SNOMED CT: 390846000, 412755006, 412756007, 412757003, 428251000124104, 571571000119105 |
| Anaphylaxis due to the Tetanus, Diphtheria, or Pertussis Vaccine | SNOMED CT: 428281000124107, 428291000124105 |
| Encephalitis due to the Tetanus, Diphtheria, or Pertussis Vaccine | SNOMED CT: 192710009, 192711008, 192712001 |

IMA-E Measure Codes (continued)

| Description | Codes* |
|------------------------------------|---|
| HPV Immunization | CVX: 62, 118, 137, 165 |
| HPV Vaccine Procedure | CPT: 90649, 90650, 90651 SNOMED CT: 428741008, 428931000, 429396009, 717953009, 724332002, 734152003, 761841000, 1209198003 |
| Anaphylaxis due to the HPV Vaccine | SNOMED CT: 428241000124101 |

*Codes subject to change

Lead Screening in Children (LSC) ●

The LSC measure evaluates the percentage of children 2 years of age in the measurement year who had one or more capillary or venous lead blood test for lead poisoning on or before patient's second birthday.

Lead Test

| |
|--|
| CPT: 83655 SNOMED: 8655006, 3583309 LOINC: 10368-9, 10912-4, 14807-2, 17052-2, 25459-9, 27129-6, 32325-3, 5674-7, 77307-7 |
|--|

*Codes subject to change

In order to ensure that children receive appropriate public health follow-up services, physicians and other health providers have an obligation to report blood lead results greater than or equal to 10mg/dL within 48 hours to the Illinois Department of Public Health (IDPH) Childhood Lead Poisoning Reporting System. Providers using the IDPH laboratory are not required to report blood lead results.

Illinois Department of Public Health
Illinois Lead Program
535 W. Jefferson Street
Springfield, IL 62761
P: 217-782-3517
www.idph.state.il.us

The Illinois Department of Healthcare and Family Services (HFS) encourages providers to send all blood lead specimens to the IDPH laboratory for analysis. Providers who utilize the state laboratory for blood lead analysis can order supplies for blood lead specimen collection free of charge by calling the IDPH Laboratory Shipping Section at 217-524-6222, or by downloading the Clinical Supplies Requisition Form from the HFS website: <https://www.dph.illinois.gov/>.

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E) ●●👤

APM-E is an Electronic Clinical Data Systems (ECDS) measure.

The APM-E measure evaluates the percentage of children and adolescents one to 17 years of age who had two or more antipsychotic prescriptions and had metabolic testing.

Three rates are reported:

- Percentage of children and adolescents on antipsychotics who received blood glucose testing
- Percentage of children and adolescents on antipsychotics who received cholesterol testing
- Percentage of children and adolescents on antipsychotics who received blood glucose and cholesterol testing

APM-E Measure Codes

| Description | Codes* |
|--|---|
| HbA1c Lab Tests | CPT: 83036, 83037 LOINC: 17855-8, 17856-6, 4548-4, 4549-2, 96595-4 SNOMED CT: 43396009, 313835008 |
| HbA1c Level Greater Than 9.0 | CPT-CAT-II: 3046F |
| HbA1c Level Greater Than or Equal To 7.0 and Less Than 8.0 | CPT-CAT-II: 3051F |
| HbA1c Level Greater Than or Equal To 8.0 and Less Than or Equal To 9.0 | CPT-CAT-II: 3052F |
| HbA1c Level Less Than 7.0 | CPT-CAT-II: 3044F |
| HbA1c Test Result or Finding | CPT-CAT-II: 3044F, 3046F, 3051F, 3052F SNOMED CT: 165679005, 451061000124104 |

APM-E Measure Codes (continued)

| Description | Codes* |
|--|---|
| Glucose Lab Tests | <p>CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951</p> <p>LOINC: 10450-5, 1492-8, 1494-4, 1496-9, 1499-3, 1501-6, 1504-0, 1507-3, 1514-9, 1518-0, 1530-5, 1533-9, 1554-5, 1557-8, 1558-6, 17865-7, 20436-2, 20437-0, 20438-8, 20440-4, 2345-7, 26554-6, 41024-1, 49134-0, 6749-6, 9375-7</p> <p>SNOMED CT: 22569008, 33747003, 52302001, 72191006, 73128004, 88856000, 104686004, 167086002, 167087006, 167088001, 167095005, 167096006, 167097002, 250417005, 271061004, 271062006, 271063001, 271064007, 271065008, 275810004, 302788006, 302789003, 308113006, 313474007, 313545000, 313546004, 313624000, 313626003, 313627007, 313628002, 313630000, 313631001, 313697000, 313698005, 313810002, 412928005, 440576000, 443780009, 444008003, 444127006</p> |
| Glucose Test Results or Finding | <p>SNOMED CT: 166890005, 166891009, 166892002, 166914001, 166915000, 166916004, 166917008, 166918003, 166919006, 166921001, 166922008, 166923003, 442545002, 444780001, 1179458001</p> |
| LDL-C Lab Tests | <p>CPT: 80061, 83700, 83701, 83704, 83721</p> <p>LOINC: 12773-8, 13457-7, 18261-8, 18262-6, 2089-1, 49132-4, 55440-2, 96259-7</p> <p>SNOMED CT: 113079009, 166833005, 166840006, 166841005, 167074000, 167075004, 314036004</p> |
| LDL-C Test Result or Finding | <p>CPT-CAT-II: 3048F, 3049F, 3050F</p> |
| Most recent LDL-C less than 100 mg/dL (CAD) (DM) | <p>CPT-CAT-II: 3048F</p> |
| Most recent LDL-C 100-129 mg/dL (CAD) (DM) | <p>CPT-CAT-II: 3049F</p> |

APM-E Measure Codes (continued)

| Description | Codes* |
|---|--|
| Most recent LDL-C greater than or equal to 130 mg/dL (CAD) (DM) | CPT-CAT-II: 3050F |
| Cholesterol Lab Tests | CPT: 82465, 83718, 83722, 84478 LOINC: 2085-9, 2093-3, 2571-8, 3043-7, 9830-1 SNOMED CT: 14740000, 28036006, 77068002, 104583003, 104584009, 104586006, 104784006, 104990004, 104991000, 121868005, 166832000, 166838001, 166839009, 166849007, 166850007, 167072001, 167073006, 167082000, 167083005, 167084004, 271245006, 275972003, 314035000, 315017003, 390956002, 412808005, 412827004, 443915001 |
| Cholesterol Test Result or Finding | SNOMED CT: 166830008, 166848004, 259557002, 365793008, 365794002, 365795001, 365796000, 439953004, 707122004, 707123009, 1162800007, 1172655006, 1172656007, 67991000119104 |

*Codes subject to change

Oral Evaluation, Dental Services (OED) ●●●

The OED measure evaluates the percentage of patients under 21 years of age who received a comprehensive or periodic oral evaluation with a dental provider during the measurement year.

OED Measure Codes

| Description | Codes* |
|-----------------|--------------------------|
| Oral Evaluation | CDT: D0120, D0145, D0150 |

*Codes subject to change

Topical Fluoride for Children (TFC) ●●

The TFC measure evaluates the percentage of patients 1 to 4 years of age who received at least two fluoride varnish applications during the measurement year.

TFC Measure Codes

| Description | Codes* |
|---------------------------------|---|
| Application of Fluoride Varnish | CPT: 99188 CDT: D1206 SNOMED: 313042009 |

*Codes subject to change

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) ●●●

The WCC measure evaluates the percentage of patients 3 to 17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of each of the following during the measurement year:

- BMI Percentile
- Counseling for Nutrition
- Counseling for Physical Activity

WCC Measure Codes

| Description | Codes* |
|------------------------------|--|
| BMI Percentile | ICD-10: Z68.51, Z68.52, Z68.53, Z68.54 LOINC: 59574-4, 59575-1, 59576-9 |
| Nutrition Counseling | CPT: 97802-97804 ICD-10: Z71.3 HCPCS: G0270, G0271, G0447, S9449, S9452, S9470 |
| Physical Activity Counseling | HCPCS: G0447, S9451, G0447 ICD-10: Z02.5, Z71.82 |

*Codes subject to change

Well-Child and Adolescent Well-Care Visits (W30 ●●/WCV ●●●)

The W30/WCV measure evaluates the percentage of patients within designated ages who had comprehensive well-care visit(s) as defined in each measure, with a PCP or an OB/GYN practitioner during the measurement year.

Well-Child Visits in the First 30 Months of Life (W30)

Months of Life: The percentage of patients who had the following number of well-child visits with a PCP during the last 15 months

Two rates are reported:

- Well-Child Visits in the First 15 Months
 - Children who turned 15 months old during the measurement year:
 - Six or more well-child visits
- Well-Child Visits for Age 15 Months–30 Months
 - Children who turned 30 months old during the measurement year:
 - Two or more well-child visits

W30 Measure Codes

| CPT* | HCPCS* | ICD-10* |
|---------------------------------|--|---|
| 99381-99385, 99391-99395, 99461 | G0438, G0439, S0302, S0610, S0612, S0613 | Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.2, Z00.3, Z01.411, Z01.419, Z02.5, Z76.1, Z76.2 |

**Codes subject to change*

(WCV) Child and Adolescent Well-Care Visits: Patients 3 to 21 years of age who had a least one comprehensive well-care visit with a PCP or an OB/GYN

WCV Measure Codes

| CPT* | HCPCS* | ICD-10* |
|---------------------------------|--|---|
| 99381-99385, 99391-99395, 99461 | G0438, G0439, S0302, S0610, S0612, S0613 | Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.2, Z00.3, Z01.411, Z01.419, Z02.5, Z76.1, Z76.2 |

**Codes subject to change*

Pharmacy Measures



Adherence to Cholesterol Medications (STAT) ●

The STAT measure evaluates the percentage of members 18 years of age and older with the CHOL medication with a Proportion of Days Covered (PDC) \geq 80%.

PDC is calculated utilizing total days supplied of CHOL pharmacy claims/date of first RASA fill to the end of the reporting period.

Each medication claim must be submitted to the health plan (cash payment/samples/filled at out-of-network pharmacy do not count).

CHOL Medications

- | | |
|---------------------------|----------------------------|
| • Atorvastatin (Lipitor®) | • Pravastatin (Pravachol®) |
| • Fluvastatin (Lescol®) | • Rosuvastatin (Crestor®) |
| • Lovastatin (Mevacor®) | • Simvastatin (Zocor®) |

Adherence to Diabetes Medications (DIAB) ●

The DIAB measure evaluates the percentage of members 18 years of age and older with a diabetes medication with a Proportion of Days Covered (PDC) \geq 80%.

PDC is calculated utilizing total days supplied of diabetes pharmacy claims/ date of first diabetes fill to the end of the reporting period.

Each medication claim must be submitted to the health plan (cash payment/ samples/filled at out-of-network pharmacy do not count).

Diabetes Medications:

| Category | Medication |
|---|---|
| Sulfonylureas | Glipizide and glyburide |
| Biguanides | Metaform |
| Thiazolidinediones | Actos (pioglitazone) |
| Alpha-glucosidase inhibitors | Precose (acarbose) |
| Glucagon-like peptide 1 (GLP-1) agonists | Adlyxin (lixisenatide), Byetta, Bydureon (exenatide), Ozempic (semaglutide), Tanzeum (albiglutide), Trulicity (dulaglutide) and Victoza (liraglutide) |
| Sodium-glucose cotransporter 2 (SGLT2) inhibitors | Farxiga (dapagliflozin), Invokana (canagliflozin) and Jardiance (empagliflozin) |

Adherence to Hypertensive Medications (RASA) ●

The RASA measure evaluates the percentage of members 18 years of age and older with a RASA medication with a Proportion of Days Covered (PDC) \geq 80%.

PDC calculated utilizing total days supplied of hypertensive pharmacy claims/ date of first RASA fill to the end of the reporting period.

Each medication claim must be submitted to the health plan (cash payment/ samples/filled at out-of-network pharmacy do not count).

RASA Medications

| Description | Prescription |
|----------------------------------|--|
| Direct Renin Inhibitor | <ul style="list-style-type: none"> aliskiren (+/- hydrochlorothiazide) |
| ARB Medications and Combinations | <ul style="list-style-type: none"> Azilsartan (+/- chlorthalidone) candesartan (+/- hydrochlorothiazide) eprosartan (+/- hydrochlorothiazide) Irbesartan (+/- hydrochlorothiazide) losartan (+/- hydrochlorothiazide) olmesartan (+/- amlodipine, hydrochlorothiazide) Telmisartan (+/- amlodipine hydrochlorothiazide) valsartan (+/- amlodipine, hydrochlorothiazide nebivolol) |
| ACE Inhibitor Medications | <ul style="list-style-type: none"> benazepril (+/- amlodipine, hydrochlorothiazide) captopril (+/- hydrochlorothiazide) enalapril (+/- hydrochlorothiazide) fosinopril (+/- hydrochlorothiazide) lisinopril (+/- hydrochlorothiazide) moexipril (+/- hydrochlorothiazide) perindopril (+/- amlodipine) quinapril (+/- hydrochlorothiazide) ramipril trandolapril (+/- verapamil) |

Statin Therapy for Patients with Cardiovascular Disease (SPC) ●●●●

The SPC measure evaluates males 21 to 75 years of age and females 40 to 75 years of age who were identified as having Clinical Atherosclerotic Cardiovascular Disease (ASCVD).

Two rates are reported:

- **Received Statin Therapy:** Members who were dispensed at least one high-intensity or moderate-intensity statin medication during the measurement year
- **Statin Adherence:** Members who remained on a high-intensity or moderate-intensity statin medication for at least 80% of the treatment period

SPC Medications

| Description | Prescription |
|-----------------------------------|------------------------------------|
| High-intensity statin therapy | • Atorvastatin 40-80 mg |
| High-intensity statin therapy | • Amlodipine-atorvastatin 40-80 mg |
| High-intensity statin therapy | • Rosuvastatin 20-40 mg |
| High-intensity statin therapy | • Simvastatin 80 mg |
| High-intensity statin therapy | • Ezetimibe-simvastatin 80 mg |
| Moderate-intensity statin therapy | • Atorvastatin 10-20 mg |
| Moderate-intensity statin therapy | • Amlodipine-atorvastatin 10-20 mg |
| Moderate-intensity statin therapy | • Rosuvastatin 5-10 mg |
| Moderate-intensity statin therapy | • Simvastatin 20-40 mg |
| Moderate-intensity statin therapy | • Ezetimibe-simvastatin 20-40 mg |
| Moderate-intensity statin therapy | • Pravastatin 40-80 mg |
| Moderate-intensity statin therapy | • Lovastatin 40 mg |
| Moderate-intensity statin therapy | • Fluvastatin 40-80 mg |
| Moderate-intensity statin therapy | • Pitavastatin 1-4 mg |

Statin Therapy for Patients with Diabetes (SPD) ●●●●

The SPD measure evaluates patients 40 to 75 years of age with diabetes (Types 1 and 2) who do not have clinical atherosclerotic cardiovascular disease (ASCVD).

Two rates are reported:

- **Received Statin Therapy:** Members who were dispensed at least one statin medication of any intensity during the measurement year
- **Statin Adherence 80%:** Members who remained on a statin medication of any intensity for at least 80% of the treatment period

SPD Medications

| Description | Prescription |
|------------------------------|--|
| Alpha-glucosidase inhibitors | <ul style="list-style-type: none"> • Acarbose • Miglitol |
| Amylin analogs | <ul style="list-style-type: none"> • Pramlintide |
| Antidiabetic combinations | <ul style="list-style-type: none"> • Alogliptin-metformin • Alogliptin-pioglitazone • Canagliflozin-metformin • Dapagliflozin-metformin • Dapagliflozin-saxagliptin • Empagliflozin-linagliptin • Empagliflozin-linagliptin-metformin • Empagliflozin-metformin • Ertugliflozin-metformin • Ertugliflozin-sitagliptin • Glimepiride-pioglitazone • Glipizide-metformin • Glyburide-metformin • Linagliptin-metformin • Metformin-pioglitazone • Metformin-repaglinide • Metformin-rosiglitazone • Metformin-saxagliptin • Metformin-sitagliptin |

SPD Medications (continued)

| Description | Prescription |
|--|---|
| Insulin | <ul style="list-style-type: none"> • Insulin aspart • Insulin aspart-insulin aspart protamine • Insulin degludec • Insulin degludec-liraglutide • Insulin detemir • Insulin glargine • Insulin glargine-lixisenatide • Insulin glulisine • Insulin isophane human • Insulin isophane-insulin regular • Insulin lispro • Insulin lispro-insulin lispro protamine • Insulin regular human • Insulin human inhaled |
| Meglitinides | <ul style="list-style-type: none"> • Nateglinide • Repaglinide |
| Biguanides | <ul style="list-style-type: none"> • Metformin |
| Glucagon-like peptide-1 (GLP1) agonists | <ul style="list-style-type: none"> • Albiglutide • Dulaglutide • Exenatide • Liraglutide • Lixisenatide • Semaglutide |
| Sodium glucose cotransporter 2 (SGLT2) inhibitor | <ul style="list-style-type: none"> • Canagliflozin • Dapagliflozin • Empagliflozin • Ertugliflozin |
| Sulfonylureas | <ul style="list-style-type: none"> • Chlorpropamide • Glimepiride • Glipizide • Glyburide • Tolazamide • Tolbutamide |
| Thiazolidinediones | <ul style="list-style-type: none"> • Pioglitazone • Rosiglitazone |
| Dipeptidyl peptidase-4 (DDP-4) inhibitors | <ul style="list-style-type: none"> • Alogliptin • Linagliptin • Saxagliptin • Sitagliptin |

Women's Health



Breast Cancer Screening (BCS-E) ●●●●●

BCS-E is an Electronic Clinical Data Systems (ECDS) measure.

The BCS-E measure evaluates the percentage of patients 50 to 74 years of age who were recommended for routine breast cancer screening and had a mammogram any time on or between October 1 two years prior to the measurement period and the end of the measurement period.

Patients recommended for routine breast cancer screening include:

- Administrative Gender of Female at any time in the patient's history
- Sex Assigned at Birth of Female at any time in the patient's history
- Sex Parameter for Clinical Use of Female during the measurement period

BCS-E Measure Codes

| Description | Codes* |
|-------------|--|
| Mammogram | LOINC: 24604-1, 24605-8, 24606-6, 24610-8, 26175-0, 26176-8, 26177-6, 26287-3, 26289-9, 26291-5, 26346-7, 26347-5, 26348-3, 26349-1, 26350-9, 26351-7, 36319-2, 36625-2, 36626-0, 36627-8, 36642-7, 36962-9, 37005-6, 37006-4, 37016-3, 37017-1, 37028-8, 37029-6, 37030-4, 37037-9, 37038-7, 37052-8, 37053-6, 37539-4, 37542-8, 37543-6, 37551-9, 37552-7, 37553-5, 37554-3, 37768-9, 37769-7, 37770-5, 37771-3, 37772-1, 37773-9, 37774-7, 37775-4, 38070-9, 38071-7, 38072-5, 38090-7, 38091-5, 38807-4, 38820-7, 38854-6, 38855-3, 39150-8, 39152-4, 39153-2, 39154-0, 42168-5, 42169-3, 42174-3, 42415-0, 42416-8, 46335-6, 46336-4, 46337-2, 46338-0, 46339-8, 46342-2, 46350-5, 46351-3, 46354-7, 46355-4, 46356-2, 46380-2, 48475-8, 48492-3, 69150-1, 69251-7, 69259-0, 72137-3, 72138-1, 72139-9, 72140-7, 72141-5, 72142-3, 86462-9, 86463-7, 91517-3, 91518-1, 91519-9, 91520-7, 91521-5, 91522-3 |

BCS-E Measure Codes (continued)

| Description | Codes* |
|-----------------------|---|
| Mammogram (continued) | CPT: 77061-77063, 77065-77067 SNOMED CT: 12389009, 24623002, 43204002, 71651007, 241055006, 241057003, 241058008, 258172002, 439324009, 450566007, 709657006, 723778004, 723779007, 723780005, 726551006, 833310007, 866234000, 866235004, 866236003, 866237007, 384151000119104, 392521000119107, 392531000119105, 566571000119105, 572701000119102 |

*Codes subject to change

Documented Assessment After Mammogram (DBM-E) ●●●●👤

This is a first-year measure in MY 2025. DBM-E is an Electronic Clinical Data Systems (ECDS) measure.

DBM-E evaluates the percentage of episodes of mammograms in the form of a BI-RADS assessment within 14 days of the mammogram for patients 40-74 years of age.

DBM-E Measure Codes

| Description | Codes* |
|-------------------|---|
| BI-RADS Assesment | SNOMED CT: 397138000, 397140005, 397141009, 397143007, 397144001, 397145000, 6111000179101, 6121000179106, 6131000179108, 6141000179100 |

Follow-Up After Abnormal Mammogram Assessment (FMA-E) ●●●●👤

This is a first-year measure in MY 2025. FMA-E is an Electronic Clinical Data Systems (ECDS) measure.

FMA-E evaluates the percentage of episodes for patients age 40-74 years of age with inconclusive or high-risk BI-RADS assessments that received appropriate follow-up within 90 days of the assessment.

FMA-E Measure Codes

| Description | Codes* |
|---------------|---|
| Breast Biopsy | CPT: 19081, 19083, 19085, 19100, 19101 SNOMED CT: 10940003, 116219004, 116220005, 116334007, 1179705005, 1179707002, 1179705005, 117970700, 1179708007, 12131000087109, 1220570007, 1220571006, 1220572004, 122601001, 122737001, 122738006, 122739003, 1264555004, 1264556003, 1264555004, 1264556003, 1268323005, 1268996004, 16214691000119105, 16214971000119103, 172086006, 2131000087106, 2141000087100, 237372000, 237375003, 237376002, 237377006, 237378001, 237379009, 265253005, 274331003, 2841000087108, 287553003, 28768007, 303689004, 305011000000108, 306381000000106, 306641000000107, 307298009, 307971000000105, 307981000000107, 309058007, 309061008, 373101006, 373102004, 373103009, 387736007, 42125001, 432109009, 432157003, 432337008, 432550005, 433008009, 433685008, 433805008, 442963006, 445171002, 445437001, 44578009, 448336005, 448689003, 4541000087104, 4551000087101, 5181000087103, 709628007, 711508007, 723990008, 725936002, 736615002, 770568001, 770569009, 770570005, 771086002, 771625002, 785800009, 786883001, 866232001 |

Cervical Cancer Screening (CCS-E) ●●🏠

Beginning in MY 2025, this measure transitioned to the Electronic Clinical Data Systems (ECDS) reporting method only.

The CCS-E measure evaluates the percentage of patients 21 to 64 years of age who were recommended for routine cervical cancer screening and screened for cervical cancer using either of the following criteria:

- Patients 21 to 64 years of age who had cervical cytology performed within the last 3 years
- Patients 30 to 64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years
- Patients 30 to 64 years of age who had cervical cytology/high risk human papillomavirus (hrHPV) co-testing within the last 5 years

CCS Measure Codes

| Description | Codes* |
|-------------------------------------|---|
| Cervical Cytology Lab Test (20-64) | <p>CPT: 88141-88143, 88147, 88148, 88150, 88152-88153, 88164-88167, 88174, 88175</p> <p>HCPCS: G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091</p> <p>LOINC: 10524-7, 18500-9, 19762-4, 19764-0, 19765-7, 19766-5, 19774-9, 33717-0, 47527-7, 47528-5</p> <p>SNOMED CT: 171149006, 416107004, 417036008, 440623000, 448651000124104</p> |
| Cervical Cytology Result or Finding | <p>SNOMED CT: 168406009, 168407000, 168408005, 168410007, 168414003, 168415002, 168416001, 168424006, 250538001, 269957009, 269958004, 269959007, 269960002, 269961003, 269963000, 275805003, 281101005, 309081009, 310841002, 310842009, 416030007, 416032004, 416033009, 439074000, 439776006, 439888000, 441087007, 441088002, 441094005, 441219009, 441667007, 700399008, 700400001, 1155766001, 62051000119105, 62061000119107, 98791000119102</p> |

CCS-E Measure Codes (continued)

| Description | Codes* |
|---------------------------------|---|
| High-Risk HPV Lab Tests (30-64) | CPT: 87624, 87625 HCPCS: G0476 LOINC: 21440-3, 30167-1, 38372-9, 59263-4, 59264-2, 59420-0, 69002-4, 71431-1, 75694-0, 77379-6, 77399-4, 77400-0, 82354-2, 82456-5, 82675-0, 95539-3 SNOMED CT: 35904009, 448651000124104, 718591004 |

*Codes subject to change

Chlamydia Screening in Women (CHL) ●●

The CHL measure evaluates the percentage of women 16 to 24 years of age who were identified as sexually active and who had at least one test for chlamydia.

Meridian covers all types of chlamydia screenings. This includes traditional methods, as well as urine screening (bill with CPT code 87110) for men and women. The advantage to urine screening is that it is simple, quick to administer, and has a higher accuracy rate than other methods.

CHL Measure Codes

| CPT* |
|---|
| 87110, 87270, 87320, 87490-87492, 87810 |

*Codes subject to change

Osteoporosis Management in Women Who Had a Fracture (OMW) ●●

The OMW measure evaluates the percentage of women 67 to 85 years of age who suffered a fracture and had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

OMW Measure Codes

| Description | Codes* |
|--|---|
| Bone Mineral Density Tests | CPT: 76977, 77078, 77080, 77081, 77085, 77086 ICD10PSC: BP48ZZ1, BP49ZZ1, BP4GZZ1, BP4HZZ1, BP4LZZ1, BP4MZZ1, BP4NZZ1, BP4PZZ1, BQ00ZZ1, BQ01ZZ1, BQ03ZZ1, BQ04ZZ1, BR00ZZ1, BR07ZZ1, BR09ZZ1, BR0GZZ1 |
| Osteoporosis Medications Therapy | HCPCS: J0897, J1740, J3110, J3111, J3489 |
| Long-Acting Osteoporosis Medications during Inpatient Stay | HCPCS: J0897, J1740, J3489 |

*Codes subject to change

Osteoporosis Medications

| Description | Prescription |
|-----------------|---|
| Bisphosphonates | <ul style="list-style-type: none"> • Alendronate • Alendronate-cholecalciferol • Ibandronate • Risedronate • Zoledronic acid |
| Other agents | <ul style="list-style-type: none"> • Abaloparatide • Denosumab • Raloxifene • Romosozumab • Teriparatide |

Osteoporosis Screening in Older Women (OSW) ●●

The OSW measure evaluates the percentage of women 65 to 75 years of age who received osteoporosis screening.

OSW Measure Codes

| Description | Codes* |
|------------------------------|--|
| Osteoporosis Screening Tests | CPT: 76977, 77078, 77080, 77081, 77085 |

*Codes subject to change

Prenatal and Postpartum Care (PPC) ●●

The PPC measure evaluates the percentage of deliveries of live births on or between October 8 of the year prior to the measurement year and October 7 of the measurement year. For these patients, the measure assesses the following facets of prenatal and postpartum care.

Timeliness of Prenatal Care: Percentage of deliveries that received a prenatal care visit in the first trimester, on or before the enrollment start date, or within 42 days of enrollment in the organization

Postpartum Care: Percentage of deliveries that had a postpartum visit on or between 7 and 84 days after delivery

PPC Measure Codes

Prenatal:

| Description | Codes* |
|--|--|
| Prenatal Visits with Pregnancy diagnosis (Visit must be performed in the first trimester [13 weeks], on or before the enrollment start date, or within 42 days of enrollment if already pregnant at the time of enrollment with Meridian) | CPT: 98966-98968, 98970-98972, 98980-98981, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245, 99421-99423, 99441-99443, 99457, 99458, 99483 HCPCS: G0463, T1015, G0071, G2010, G2012, G2250, G2251, G2252 |
| Stand-Alone Prenatal Visits | CPT: 99500 CPT-CAT-II: 0500F, 0501F, 0502F HCPCS: H1000, H1001, H1002, H1003, H1004 |
| Prenatal Bundled Services | CPT: 59400, 59425, 59426, 59510, 59610, 59618 HCPCS: H1005 |

PPC Postpartum Measure Codes (continued)

Postpartum:

| Description | Codes* |
|---|---|
| Cervical Cytology Lab Test | CPT: 88141-88143, 88147, 88148, 88150, 88152-88153, 88164-88167, 88174, 88175 HCPCS: G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091 |
| Encounter for Postpartum Care (must be on or between 7 days and 84 days after delivery) | ICD-10: Z01.411, Z01.419, Z01.42, Z30.430, Z39.1, Z39.2 |
| Postpartum Bundled Services | CPT: 59400, 59410, 59510, 59515, 59610, 59614, 59618, 59622 |
| Postpartum Care | CPT: 57170, 58300, 59430, 99501 CPT-CAT II: 0503F HCPCS: G0101 |

*Codes subject to change

NOTE: When using the Prenatal Visit codes, remember to also include a Pregnancy Diagnosis code.

For information about Global Maternity Billing, please refer to the HFS website (<http://www.hfs.illinois.gov>) for more information.

Prenatal Immunization Status (PRS-E)

PRS-E is an Electronic Clinical Data Systems (ECDS) measure.

PRS-E evaluates the percentage of deliveries in the measurement period in which members had received influenza and tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccinations.

Influenza:

- Patients who received an adult influenza vaccine on or between July 1 of the year prior to the measurement period and the delivery date

Tdap:

- Patients who received at least one Tdap vaccine during the pregnancy (including on the delivery date)

PRS-E Codes

| Description | Codes* |
|--|---|
| Adult Influenza Immunization | CVX: 88, 135, 140, 141, 144, 150, 153, 155, 158, 166, 168, 171, 185, 186, 197, 205 |
| Adult Influenza Vaccine Procedure | CPT: 90630, 90653, 90654, 90656, 90658, 90661, 90662, 90673, 90674, 90682, 90686, 90688, 90689, 90694, 90756 SNOMED CT: 86198006 |
| Deliveries where members had anaphylaxis due to the influenza vaccine on or before the delivery date | SNOMED CT: 471361000124100 |
| Tdap Vaccine Procedure | CVX: 115 CPT: 90715 SNOMED CT: 390846000, 412755006, 412756007, 412757003, 428251000124104, 571571000119105 |
| Anaphylaxis due to Diphtheria, Tetanus, or Pertussis Vaccine | SNOMED CT: 428281000124107, 428291000124105 |
| Encephalitis due to Diphtheria, Tetanus or Pertussis Vaccine | SNOMED CT: 192710009, 192711008, 192712001 |

*Codes subject to change

Advisory Committee on Immunization Practices (ACIP) clinical guidelines recommend that all women who are pregnant or who might be pregnant in the upcoming influenza season receive inactivated influenza vaccines. ACIP also recommends that pregnant women receive one dose of Tdap during each pregnancy, preferably during the early part of gestational weeks 27–36, regardless of prior history of receiving Tdap.

Prenatal Depression Screening and Follow-Up (PND-E) ● 🏠

PND-E is an Electronic Clinical Data Systems (ECDS) measure.

PND-E evaluates the percentage of deliveries in which patients were screened for clinical depression while pregnant using a standardized instrument and, if screened positive, received follow-up care within 30 days.

- **Deliveries between January 1 and December 1 of the measurement period:** Screening should be performed between the pregnancy start date and the delivery date (including on the delivery date).
- **Deliveries between December 2 and December 31 of the measurement period:** Screening should be performed between the pregnancy start date and December 1 of the measurement period.

** Refer to the Appendix for a list of Approved Depression Screening Instruments, Codes, and Positive Findings*

***Refer to the Appendix for a list of follow-up visit codes*

Postpartum Depression Screening and Follow-Up (PDS-E) ● 🏠

PDS-E is an Electronic Clinical Data Systems (ECDS) measure.

PDS-E evaluates the percentage of deliveries in which patients were screened for clinical depression during the postpartum period (7 to 84 days following delivery), using a standardized instrument and, if screened positive, received follow-up care within 30 days.

** Refer to the Appendix for a list of Approved Depression Screening Instruments, Codes, and Positive Findings*

***Refer to the Appendix for a list of follow-up visit codes*

Appendix

Antidepressant Medication List ●●●●

| Description | Prescription |
|----------------------------------|---|
| Miscellaneous antidepressants | <ul style="list-style-type: none"> • Bupropion • Vortioxetine • Vilazodone |
| Monoamine oxidase inhibitors | <ul style="list-style-type: none"> • Isocarboxazid • Phenelzine • Selegiline • Tranylcypromine |
| Phenylpiperazine antidepressants | <ul style="list-style-type: none"> • Nefazodone • Trazodone |
| Psychotherapeutic combinations | <ul style="list-style-type: none"> • Amitriptyline-chlordiazepoxide • Amitriptyline-perphenazine • Fluoxetine-olanzapine |
| SNRI antidepressants | <ul style="list-style-type: none"> • Desvenlafaxine • Duloxetine • Levomilnacipran • Venlafaxine |
| SSRI antidepressants | <ul style="list-style-type: none"> • Citalopram • Escitalopram • Fluoxetine • Fluvoxamine • Paroxetine • Sertraline |
| Tetracyclic antidepressants | <ul style="list-style-type: none"> • Maprotiline • Mirtazapine |
| Tricyclic antidepressants | <ul style="list-style-type: none"> • Amitriptyline • Amoxapine • Clomipramine • Desipramine • Doxepin (>6 mg) • Imipramine • Nortriptyline • Protriptyline • Trimipramine |

Approved Depression Screening Instruments, Codes, and Positive Findings ●●●●

A standard assessment instrument that has been normalized and validated for the appropriate patient population. Eligible screening instruments with thresholds for positive findings include:

| Instruments for Adolescents (≤17 years) | Total Score LOINC Codes* | Positive Finding |
|--|--------------------------|---------------------------|
| Patient Health Questionnaire (PHQ-9) [®] | 44261-6 | Total score ≥10 |
| Patient Health Questionnaire Modified for Teens (PHQ- 9M) [®] | 89204-2 | Total score ≥10 |
| Patient Health Questionnaire-2 (PHQ-2) ^{®1} | 55758-7 | Total score ≥3 |
| Beck Depression Inventory— Fast Screen (BDI-FS) ^{®1,2} | 89208-3 | Total score ≥8 |
| Center for Epidemiologic Studies Depression Scale—Revised (CESD-R) | 89205-9 | Total score ≥17 |
| Edinburgh Postnatal Depression Scale (EPDS) | 71354-5 | Total score ≥10 |
| PROMIS Depression | 71965-8 | Total score (T Score) ≥60 |

¹ Brief screening instrument. All other instruments are full-length.

² Proprietary; may be cost or licensing requirement associated with use.

*Codes subject to change

| Instruments for Adults (18+ years) | Total Score LOINC Codes* | Positive Finding |
|--|--------------------------|------------------|
| Patient Health Questionnaire (PHQ-9) [®] | 44261-6 | Total score ≥10 |
| Patient Health Questionnaire-2 (PHQ-2) ^{®1} | 55758-7 | Total score ≥3 |
| Beck Depression Inventory—Fast Screen (BDI-FS) ^{®1,2} | 89208-3 | Total score ≥8 |
| Beck Depression Inventory (BDI-II) | 89209-1 | Total score ≥20 |
| Center for Epidemiologic Studies Depression Scale—Revised (CESD-R) | 89205-9 | Total score ≥17 |
| Duke Anxiety-Depression Scale (DUKE-AD) ^{®2} | 90853-3 | Total score ≥30 |
| Edinburgh Postnatal Depression Scale (EPDS) | 71354-5 | Total score ≥10 |
| My Mood Monitor (M-3) [®] | 71777-7 | Total score ≥5 |

| Instruments for Adults (18+ years) | Total Score LOINC Codes* | Positive Finding |
|--|--------------------------|---------------------------------|
| PROMIS Depression | 71965-8 | Total score (T Score) ≥ 60 |
| Clinically Useful Depression Outcome Scale (CUDOS) | 90221-3 | Total score ≥ 31 |

¹ Brief screening instrument. All other instruments are full-length.

² Proprietary; may be cost or licensing requirement associated with use.

*Codes subject to change

Follow-Up Visit ●●●●

| Description | Codes* |
|---|--|
| An outpatient, telephone, e-visit, or virtual check-in follow-up visit with a diagnosis of depression or other behavioral health condition. | <p>CPT: 98960-98962, 98966-98968, 98970-98972, 98980, 98981, 99078, 99202-99205, 99211-99215, 99242-99245, 99341, 99342, 99344, 99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99421-99423, 99441-99443, 99457, 99458, 99483</p> <p>HCPCS: G0071, G0463, G2010, G2012, G2250-G2252 T1015</p> <p>SNOMED CT: 42137004, 50357006, 86013001, 90526000, 108220007, 108221006, 185317003, 185389009, 281036007, 314849005, 386472008, 386473003, 390906007, 401267002, 406547006, 870191006</p> |
| Depression Case Management Encounter | <p>CPT: 99366, 99492-99494</p> <p>HCPCS: T1016, T1017, T2022, T2023</p> <p>SNOMED CT: 182832007, 225333008, 385828006, 386230005, 409022004, 410216003, 410219005, 410328009, 410335001, 410346003, 410347007, 410351009, 410352002, 410353007, 410354001, 410356004, 410360001, 410363004, 410364005, 410366007, 416341003, 416584001, 424490002, 425604002, 737850002, 621561000124106, 661051000124109, 662081000124106, 662541000124107</p> |

| Description | Codes* |
|--|---|
| Behavioral Health Encounter | <p>CPT: 90791, 90792, 90832-90834, 90836-90839, 90845-90847, 90849, 90853, 90865, 90867-90870, 90875, 90876, 90880, 90887, 99484, 99492, 99493</p> <p>HCPCS: G0155, G0176, G0177, G0409-G0411, G0511, G0512, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, S0201, S9480, S9484, S9485</p> <p>SNOMED CT: 5694008, 10197000, 10997001, 38756009, 45392008, 79094001, 88848003, 90407005, 91310009, 165171009, 165190001, 225337009, 370803007, 372067001, 385721005, 385724002, 385725001, 385726000, 385727009, 385887004, 385889001, 385890005, 401277000, 410223002, 410224008, 410225009, 410226005, 410227001, 410228006, 410229003, 410230008, 410231007, 410232000, 410233005, 410234004, 439141002</p> <p>ICD10-CM: Z71.82</p> |
| <p>A dispensed antidepressant medication</p> <p>Antidepressant Medications List</p> | See Antidepressant Medications List . |
| Documentation of additional depression screening on a full-length instrument indicating either no depression or no symptoms that require follow-up (i.e., a negative screen) on the same day as a positive screen on a brief screening instrument. *** | |

*Codes subject to change

Depression or Other Behavioral Health Condition ●●●●

| Depression or Other Behavioral Health Condition Codes* |
|---|
| ICD10CM: F01.51, F01.511, F01.518, F06.4, F10.180, F10.280, F10.980, F11.188, F11.288, F11.988, F12.180, F12.280, F12.980, F13.180, F13.280, F13.980, F14.180, F14.280, F14.980, F15.180, F15.280, F15.980, F16.180, F16.280, F16.980, F18.180, F18.280, F18.980, F19.180, F19.280, F19.980, F20.0, F20.1, F20.2, F20.3, F20.5, F20.81, F20.89, F20.9, F21, F22, F23, F24, F25.0, F25.1, F25.8, F25.9, F28, F29, F30.10, F30.11, F30.12, F30.13, F30.2, F30.3, F30.4, F30.8, F30.9, F31.0, F31.10, F31.11, F31.12, F31.13, F31.2, F31.30, F31.31, F31.32, F31.4, F31.5, F31.60, F31.61, F31.62, F31.63, F31.64, F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76, F31.77, F31.78, F31.81, F31.89, F31.9, F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.8, F32.81, F32.89, F32.9, F32.A, F33.0, F33.1, F33.2, F33.3, F33.40, F33.41, F33.42, F33.8, F33.9, F34.0, F34.1, F34.8, F34.81, F34.89, F34.9, F39, F40.00, F40.01, F40.02, F40.10, F40.11, F40.210, F40.218, F40.220, F40.228, F40.230, F40.231, F40.232, F40.233, F40.240, F40.241, F40.242, F40.243, F40.248, F40.290, F40.291, F40.298, F40.8, F40.9, F41.0, F41.1, F41.3, F41.8, F41.9, F42, F42.2, F42.3, F42.4, F42.8, F42.9, F43.0, F43.10, F43.11, F43.12, F43.20, F43.21, F43.22, F43.23, F43.24, F43.25, F43.29, F43.8, F43.81, F43.89, F43.9, F44.89, F45.21, F51.5, F53, F53.0, F53.1, F60.0, F60.1, F60.2, F60.3, F60.4, F60.5, F60.6, F60.7, F60.81, F60.89, F60.9, F63.0, F63.1, F63.2, F63.3, F63.81, F63.89, F63.9, F68.10, F68.11, F68.12, F68.13, F68.8, F68.A, F84.0, F84.2, F84.3, F84.5, F84.8, F84.9, F90.0, F90.1, F90.2, F90.8, F90.9, F91.0, F91.1, F91.2, F91.3, F91.8, F91.9, F93.0, F93.8, F93.9, F94.0, F94.1, F94.2, F94.8, F94.9, O90.6, O99.340, O99.341, O99.342, O99.343, O99.344, O99.345 |

Depression or Other Behavioral Health Condition Codes*

SNOMED CT: 109006, 162004, 281004, 600009, 832007, 899001, 1145003, 1196001, 1376001, 1380006, 1383008, 1499003, 1686006, 1816003, 1855002, 1973000, 2312009, 2403008, 2506003, 2618002, 2815001, 3109008, 3158007, 3530005, 3914008, 4306003, 4441000, 4926007, 4932002, 4997005, 5095008, 5158005, 5444000, 5464005, 5507002, 5509004, 5510009, 5703000, 6348008, 7025000, 7052005, 7200002, 7291006, 7397008, 7461003, 7794004, 8185002, 8635005, 8837000, 9167000, 9340000, 9674006, 9760005, 10278007, 10327003, 10586006, 10875004, 10981006, 11806006, 11941006, 12939007, 12969000, 13127006, 13313007, 13438001, 13581000, 13601005, 13670005, 13746004, 14070001, 14077003, 14144000, 14183003, 14291003, 14495005, 14784000, 15193003, 15277004, 15639000, 15945005, 15977008, 16295005, 16506000, 16805009, 16966009, 16990005, 17155009, 17226007, 17262008, 17496003, 17782008, 17961008, 18003009, 18085000, 18260003, 18478005, 18573003, 18653004, 18689007, 18818009, 18941000, 19300006, 19445006, 19527009, 19694002, 19766004, 20010003, 20250007, 20385005, 20876004, 20960007, 21586000, 21634003, 21897009, 21900002, 22121000, 22230001, 22407005, 22419002, 23148009, 23560001, 23645006, 24121004, 24125008, 24315006, 24781009, 25501002, 25766007, 25922000, 26025008, 26203008, 26453000, 26472000, 26516009, 26530004, 26665006, 26714005, 27387000, 27544004, 27956007, 28357009, 28368009, 28475009, 28663008, 28676002, 28864000, 28884001, 29212009, 29599000, 29733004, 29929003, 30059008, 30310000, 30336007, 30491001, 30509009, 30520009, 30605009, 30687003, 30935000, 31027006, 31177006, 31358003, 31373002, 31446002, 31611000, 31648009, 31658008, 31715000, 31781004, 32009006, 32174002, 32358001, 32388005, 32552001, 32721004, 32875003, 32880007, 33078009, 33135002, 33323008, 33380008, 33449004, 33736005, 33871004, 34116005, 34315001, 34938008, 35218008, 35252006, 35253001, 35481005, 35489007, 35607004, 35722002, 35827000, 35846004, 35919005, 36170009, 36217008, 36474008, 36583000, 36622002, 36923009, 37331004, 37739004, 37746008, 37868008, 37872007, 37941009, 38295006, 38328002, 38368003, 38451003, 38547003, 38694004, 39003006, 39465007, 39610001, 39807006, 39809009, 39951001, 40379007, 40568001, 40571009, 40673001, 40926005, 40987004, 41021005, 41083005, 41526007, 41552001, 41832009, 41836007, 42344001, 42594001, 42810003, 42868002, 42925002, 43150009, 43497001, 43568002, 43614003, 43769008, 44031002, 44124003, 44376007, 44966003, 45479006, 45677003, 45912004, 46206005, 46229002, 46244001, 46721000, 46975003, 47372000, 47447001, 47505003, 47664006, 47916000, 48500005, 48589009, 48826008, 48937005, 49271002, 49468007, 49481000, 49512000, 49564006, 50026000, 50320000, 50705009, 50722006, 50933003, 50983008, 51133006, 51443000, 51493001, 51637008, 51771007, 52702003, 52824009,

Depression or Other Behavioral Health Condition Codes*

52866005, 52910006, 52954000, 53049002, 53050002, 53467004, 53607008, 53936005, 53956006, 54319003, 54417002, 54502004, 54587008, 54761006, 55009008, 55341008, 55516002, 55668003, 55967005, 56576003, 56627002, 56641006, 56882008, 57194009, 57588009, 57715001, 58214004, 58329000, 58535001, 58647003, 58703003, 59216005, 59617007, 59645001, 59651006, 59923000, 60099002, 60123008, 61104008, 61144001, 61157009, 61180001, 61212007, 61403008, 61569007, 61831009, 61901004, 62351001, 63181006, 63204009, 63249007, 63393005, 63395003, 63412003, 63649001, 63701002, 63778009, 63909006, 63983005, 64060000, 64165008, 64731001, 64905009, 65042007, 65064003, 65179007, 66307007, 66344007, 66347000, 66381006, 66590003, 66631006, 66936004, 67002003, 67123006, 67195008, 67711008, 68019004, 68569003, 68618008, 68890003, 68963006, 68995007, 69322001, 69361009, 69392006, 69479009, 69482004, 70328006, 70546001, 70691001, 70747007, 70814008, 70932007, 71103003, 71294008, 71328000, 71336009, 71787009, 71959007, 71961003, 71984005, 72366004, 72861004, 73097000, 73462009, 73471000, 73867007, 74010007, 74266001, 74686005, 74732009, 74850006, 74934004, 75084000, 75122001, 75360000, 75752004, 75837004, 76105009, 76129002, 76236006, 76441001, 76566000, 76812003, 76868007, 77355000, 77475008, 77486005, 77675002, 77815007, 77911002, 78004001, 78269000, 78358001, 78640000, 78667006, 79204003, 79298009, 79524000, 79584002, 79842004, 79866005, 80711002, 80868005, 81319007, 81463002, 82218004, 82339009, 82415003, 82494000, 82738004, 82998009, 83176005, 83225003, 83253003, 83367009, 83458005, 83501007, 83631006, 83746006, 83890006, 84466009, 84760002, 84788008, 84984002, 85061001, 85080004, 85248005, 85561006, 85821003, 85861002, 86058007, 87132004, 87203005, 87414006, 87512008, 87798009, 87842000, 87950005, 87991007, 88740003, 88845000, 88939009, 88975006, 89415002, 89451009, 89618007, 89948007, 90755006, 90790003, 93461009, 95637005, 106015009, 109805003, 111475002, 111477005, 111479008, 111480006, 111482003, 111483008, 111484002, 111485001, 111487009, 111490003, 111491004, 126943008, 128293007, 129104009, 129604005, 129606007, 162218007, 162313000, 187921002, 191447007, 191455000, 191457008, 191458003, 191459006, 191466007, 191471000, 191475009, 191476005, 191478006, 191480000, 191483003, 191485005, 191486006, 191492000, 191493005, 191494004, 191495003, 191496002, 191499009, 191501001, 191508007, 191526005, 191527001, 191531007, 191542003, 191547009, 191548004, 191554003, 191555002, 191559008, 191561004, 191562006, 191563001, 191564007, 191565008, 191567000, 191569002, 191570001, 191571002, 191572009, 191574005, 191577003, 191583000, 191584006, 191586008, 191588009, 191590005, 191592002, 191593007, 191595000, 191597008, 191604000, 191610000, 191611001, 191613003, 191616006, 191618007, 191620005,

*Codes subject to change

Depression or Other Behavioral Health Condition Codes*

191621009, 191623007, 191625000, 191627008, 191629006, 191630001, 191634005, 191636007, 191638008, 191639000, 191641004, 191643001, 191659001, 191667009, 191668004, 191670008, 191672000, 191676002, 191678001, 191680007, 191687005, 191689008, 191690004, 191692007, 191693002, 191696005, 191697001, 191714002, 191722009, 191724005, 191725006, 191726007, 191736004, 191737008, 191738003, 191753006, 191765005, 191766006, 191772006, 191773001, 191774007, 191787001, 191811004, 191812006, 191813001, 191966002, 192014006, 192037000, 192038005, 192039002, 192041001, 192042008, 192044009, 192046006, 192049004, 192051000, 192052007, 192054008, 192056005, 192057001, 192058006, 192061007, 192063005, 192064004, 192065003, 192069009, 192072002, 192073007, 192079006, 192080009, 192082001, 192092009, 192097003, 192099000, 192100008, 192108001, 192110004, 192119003, 192127007, 192131001, 192132008, 192147004, 192362008, 192527004, 192562009, 192611004, 192616009, 192631000, 197480006, 199257008, 199259006, 199260001, 199261002, 199262009, 229623002, 229699006, 229700007, 229701006, 229715008, 229740001, 229744005, 229745006, 230334008, 230455006, 231437006, 231438001, 231442003, 231443008, 231444002, 231445001, 231446000, 231449007, 231452004, 231453009, 231454003, 231455002, 231456001, 231467000, 231485007, 231487004, 231489001, 231494001, 231496004, 231500002, 231504006, 231516000, 231520001, 231521002, 231522009, 231523004, 231524005, 231525006, 231526007, 231527003, 231528008, 231530005, 231536004, 231537008, 231538003, 231539006, 231540008, 231541007, 231542000, 231864002, 233690008, 235004005, 237351003, 237352005, 238961003, 238966008, 238967004, 238972008, 238973003, 238974009, 238976006, 238977002, 238978007, 238979004, 247803002, 247804008, 267320004, 268612007, 268617001, 268619003, 268621008, 268622001, 268624000, 268633003, 268634009, 268658008, 268661009, 268662002, 268664001, 268666004, 268667008, 268668003, 268669006, 268673009, 268734000, 270901009, 270902002, 270905000, 271428004, 271952001, 274948002, 274952002, 274953007, 275446004, 275473003, 275474009, 276296007, 276297003, 278506006, 278508007, 278852008, 278853003, 279611005, 280032002, 280943007, 280949006, 280994000, 286933003, 300706003, 300979000, 307417003, 310495003, 310496002, 310497006, 311173003, 312098001, 312936002, 313182004, 313915006, 317816007, 318784009, 319768000, 320751009, 357705009, 370143000, 371024007, 371026009, 371596008, 371599001, 371600003, 371604007, 371631005, 373618009, 386701004, 386810004, 386820009, 386821008, 386822001, 386823006, 386824000, 386825004, 402732001, 402733006, 402735004, 402736003, 403578003, 403579006, 403590001, 403593004, 403594005, 403595006, 404906000, 406506008, 408856003, 408857007, 416340002, 417143004, 417294004, 420774007, 425914008, 425919003, 426174008, 426881004, 427469003, 427975003, 428687006, 428703001, 429672007, 430744005, 430751001, 430852001, 430909002, 432091002, 439960005, 441704009, 441711008,

Depression or Other Behavioral Health Condition Codes*

441716003, 441833000, 442057004, 442245003, 442314000, 442351006, 443919007, 446175003, 446180007, 450714000, 473452003, 473456000, 473457009, 609225004, 698689005, 698690001, 698692009, 698693004, 698696007, 698697003, 698699000, 698700004, 698701000, 698946008, 698947004, 698951002, 699241002, 702356009, 702450004, 702732007, 702815001, 708037001, 712823008, 712824002, 712850003, 712884004, 713491003, 713583005, 713862009, 714829008, 715737004, 715924009, 716096005, 716199000, 716578009, 718393002, 719592004, 719600006, 720451004, 720452006, 720453001, 720454007, 720455008, 722287002, 723332005, 723899008, 723900003, 723901004, 723903001, 723905008, 723913009, 724673008, 724674002, 724675001, 724693000, 724706006, 724718002, 724719005, 724730008, 724733005, 724734004, 724735003, 724736002, 724737006, 724738001, 724739009, 724740006, 724741005, 724742003, 726772006, 733623005, 735549008, 735550008, 737225007, 762327001, 762332000, 762347009, 762509000, 762516004, 765176007, 766824003, 767631007, 767632000, 767633005, 767635003, 767636002, 770790004, 771448004, 771512003, 782501005, 783089006, 789061003, 789399002, 870260008, 870261007, 870262000, 870263005, 870264004, 870265003, 870266002, 870267006, 870268001, 870269009, 870270005, 870280009, 870282001, 870303005, 870304004, 870305003, 870306002, 870307006, 870308001, 1153575004, 1204417003, 1220650006, 1254652005, 251000119105, 261000119107, 271000119101, 281000119103, 7031000119100, 18491000119109, 21071000119101, 21831000119109, 22641000119109, 22981000119106, 23601000119102, 23741000119105, 31081000119101, 39951000119105, 60401000119104, 62211000119103, 62231000119108, 89381000119107, 89501000119108, 92501000119101, 94631000119100, 97571000119109, 104851000119103, 130121000119104, 133091000119105, 133121000119109, 153071000119108, 270291000119109, 288271000119103, 288421000119100, 288511000119108, 288751000119101, 288851000119106, 288861000119108, 368361000119108, 1740001000004102, 10811121000119102, 10811161000119107, 16238741000119105, 16264621000119109, 16264821000119108, 16264901000119109, 16265061000119105, 16265301000119106, 16265951000119109, 16266831000119100, 16266991000119108

*Codes subject to change

Exclusions ● ● ● ● ●

| Exclusions | Applicable Measures | Codes* |
|---|--|---|
| Hospice | All Measures | CPT: 99377, 99378 HCPCS: G9473, G9474, G9475, G9476, G9477, G9478, G9479, Q5003, Q5004, Q5005, Q5006, Q5007, Q5008, Q5010, S9126, T2042, T2043, T2044, T2045, T2046, G0182 |
| Palliative Care | BCS-E, BPD, CBP, CCS, COL-E, CRE, EED, GSD, KED, LBP, OMW, OSW, SPC, SPD | HCPCS: G9054, M1017 ICD-10: Z51.5 |
| Colorectal Cancer | COL-E | ICD-10: C18.0-C18.9, C19, C20, C21.2, C21.8, C78.5, Z85.038, Z85.048 |
| Total Colectomy | COL-E | CPT: 44150-44153, 44155-44158, 44210-44212 |
| Bilateral Mastectomy | BCS-E | ICD-10: 0HTV0ZZ |
| Unilateral Mastectomy with Bilateral Modifier | BCS-E | CPT: 19180, 19200, 19220, 19240, 19303-19307 |
| Bilateral Procedure/ Bilateral Modifier | BCS-E | Modifier: 50 – Used for bilateral procedure |
| History of Bilateral Mastectomy | BCS-E | ICD-10: Z90.13 |
| Complete Hysterectomy with No Residual Cervix and Absence of Cervix Diagnosis | CCS | CPT: 57530, 57531, 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200, 58210, 58240, 58260, 58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290-58294, 58548, 58550, 58552-58554, 58570-58573, 58575, 58951, 58953, 58954, 58956, 59135 ICD-10: Q51.5, Z90.710, Z90.712 |
| ESRD Diagnosis | CBP, KED, SPC, SPD | ICD-10: N18.5-N18.6, Z99.2 |

| Exclusions | Applicable Measures | Codes* |
|---------------------|---------------------|--|
| Kidney Transplant | CBP | CPT: 50360, 50365, 50380 HCPCS: S2065 ICD-10: OTY00Z0, OTY00Z1, OTY00Z2, OTY10Z0, OTY10Z1, OTY10Z2 |
| Partial Nephrectomy | CBP | CPT: 50240 ICD-10: OTB00ZZ, OTB04ZZ, OTB07ZZ, OTB08ZZ, OTB10ZZ, OTB13ZZ, OTB14ZZ, OTB17ZZ, OTB18ZZ |
| Total Nephrectomy | CBP | CPT: 50220, 50225, 50230, 50234, 50236, 50340, 50370, 50543, 50545, 50546, 50548 ICD-10: OTT00ZZ, OTT04ZZ, OTT10ZZ, OTT14ZZ, OTT20ZZ, OTT24ZZ |
| Non-Live Births | PPC | ICD-10: Z37.1, Z37.4, Z37.7 |

| Exclusions | Applicable Measures | Codes* |
|---------------------|--|---|
| Pregnancy Diagnosis | WCC, CHL* <i>*With a prescription of isotretinoin or an X-Ray within 6 days after pregnancy test, CBP, SPC, & SPD</i> | ICD-10: O09.00-O09.03, O09.10-O09.13, O09.211-O09.213, O09.219, O09.291-O09.293, O09.299, O09.30-O09.33, O09.40-O09.43, O09.511-O09.513, O09.519, O09.521-O09.523, O09.529, O09.611-O09.613, O09.621-O09.623, O09.629, O09.70-O09.73, O09.811-O09.813, O09.819, O09.821-O09.823, O09.829, O09.891-O09.893, O09.899, O09.90-O09.93, O09.A0-O09.A3, O10.011-O10.013, O10.019, O10.111-O10.113, O10.119, O10.211-O10.213, O10.219, O10.311-O10.313, O10.319, O10.411-O10.413, O10.419, O10.911-O10.913, O10.919, O11.1, O11.2, O11.3, O11.9, O12.00-O12.03, O12.10-O12.13, O12.20-O12.23, O13.1-O13.3, O13.9, O14.00, O14.02-O14.03, O14.10, O14.12-O14.13, O14.20, O14.22-O14.23, O14.90, O14.92-O14.93, O15.00, O15.02-O15.03, O15.1, O15.9, O16.1-O16.3, O16.9, O20.0, O20.8, O20.9, O21.0-O21.2, O21.8-O21.9, O22.00-O22.03, O22.20-O22.23, O22.30-O22.33, O22.40-O22.43, O22.50-O22.53, O22.8X1-O22.8X3, O22.8X9, O22.90-O22.93, O23.00-O23.03, O23.10-O23.13, O23.20-O23.23, O23.30-O23.33, O23.40-O23.43, O23.511-O23513, O23.519, O23.521-O23.523, O23.529, O23.591-O23.593. O23.599, O23.90-O23.93, O24.011-O24.013, O24.019, O24.111-O24.113, O24.119, O24.311-O24.313, O24.319, O24.410, O24.414-O24.415, O24.419, O24.811-O24.813, O24.819, O24.911-O24.913, O24.919, O25.10-O25.13, O26.00-O26.03, |

| Exclusions | Applicable Measures | Codes* |
|---------------------------------|---------------------|--|
| Pregnancy Diagnosis (continued) | | O26.11-O26.13, O26.20-O26.23, O26.30-O26.33, O26.40-O26.43, O26.50-O26.53, O26.611-O26613, O26.619, O26.711-O26.713, O26.719, O26.811-O26.813, O26.819, O26.821-O26.823, O26.829, O26.831-O26.833, O26.839, O26.841-O26.843, O26.849, O26.851-O26.853, O26.859, O26.86, O26.872-O26.873, O26.879, O26.891-O26.893, O26.899, O26.90-O26.93, O28.0-O285, O28.8-O28.9, O29.011-O29.013, O29.019, O29.021-O29.23, O29.029, O29.091-O29.093, O29.099, O229.111-O29.113, O29.119, O29.121-O29.123, O29.129, O29.191-O29.193, O29.199, O29.211-O29.213, O29.219, O29.291-O29.293, O29.299, O29.3X1- O29.3X3, O29.3X9, O29.40-O29.43, O29.5X1-O29.5X3, O29.5X9, O29.60-O29.63, O29.8X1-O29.8X3, O29.8X9, O29.90-O29.93, O30.001-O30.003, O30.009, O30.011-O30.013, O30.019, O30.021-O30.023, O30.029, O30.031-O30.033, O30.039, O30.041-O30.043, O30.049, O30.091-O30-093, O30.099, O30.101-O30.103, O30.109, O30.111-O30.113, O30.119, O30.121-O30.123, O30.129, O30.131-O30.133, O30.139, O30.191-O30.193, O30.199, O30.201-O30.203, O30.209, O30.211-O30.213, O30.219, O30.221-O30.223, O30.229, O30.231-O30.233, O30.239, O30.291-O30.293, O30.299, O30.801-O30.803, O30.809, O30.811-O30.813, O30.819, O30.821-O30.823, O30.829, O30.831-O30.833, O30.839, |

| Exclusions | Applicable Measures | Codes* |
|---------------------------------|---------------------|---|
| Pregnancy Diagnosis (continued) | | O30.891-O30.893, O30.899, O30.90-O30.93, O31.00X0-O30.00X5, O31.00X9, O31.01X0-O31.01X5, O31.01X9, O31.02X0-O31.02X5, O31.02X9, O31.03X0-O31.03X5, O31.03X9, O31.10X0-O31.10X5, O31.10X9, O31.11X0-O31.11X5, O31.11X9, O31.12X0-O31.12X5, O31.12X9, O31.13X0-O31.13X5, O31.13X9, O31.20X0-O31.20X5, O31.20X9, O31.21X0-O31.21X5, O31.21X9, O31.22X0-O31.22X5, O31.22X9, O31.23X0-O31.23X5, O31.23X9, O31.30X0-O31.30X5, O31.30X9, O31.31X0-O31.31X5, O31.31X9, O31X0-O31.32X5, O31.32X9, O33X0-O31.33X5, O31.33X9, O31.8X10-O32.8X15, O31.8X19, O31.8X20-O31.8X25, O31.8X29, O31.8X30-O31.8X35, O31.8X39, O31.8X90-O31.8X95, O31.8X99, O32.0XX0-O32.0XX5, O32.0XX9, O32.1XX0-O32.1XX5, O32.1XX9, O32.2XX0-O32.2XX5, O32.2XX9, O32.3XX0-O32.3XX5, O32.3XX9, O32.4XX0-O32.4XX5, O32.4XX9, O32.6XX0-O32.6XX5, O32.6XX9, O32.8XX0-O32.8XX5, O32.8XX9, O32.9XX0-O32.9XX5, O32.9XX9, O33.0-O33.2, O33.3XX0- O33.3XX5, O33.3XX9, O33.4XX0- O33.4XX5, O33.4XX9, O33.5XX0- O33.5XX5, O33.5XX9, O33.6XX0-O33.6XX5, O33.6XX9, O33.7, O33.7XX0-O33.7XX5, O33.7XX9, O33.8, O33.9, 34.00-O34.030, O34.10-O34.13, O34.21, O34.211-O34.212, O34.218-O34.219, O34.22, O34.29-O34.33, O34.40-O34.43, O34.511-O34.513, O34.519, O34.521-O34.523, O34.529, O34.531-O34.533, O34.539, O34.591-O34.593, O34.599, O34.60-O34.63, O34.70-O34.73, |

| Exclusions | Applicable Measures | Codes* |
|---------------------------------|---------------------|--|
| Pregnancy Diagnosis (continued) | | O34.80-O34.83, O34.90-O34.93, O35.0XX0-O35.0XX5, O35.0XX9, O35.1XX0-O35.1XX5, O35.1XX9, O35.2XX0-O35.2XX5, O35.2XX9, O35.3XX0-O35.3XX5, O35.3XX9, O35.4XX0-O35.4XX5, O35.4XX9, O35.5XX0-O35.5XX5, O35.5XX9, O35.6XX0-O35.6XX5, O35.6XX9, O35.7XX0-O35.7XX5, O35.7XX9, O35.8XX0-O35.8XX5, O35.8XX9, O35.9XX0-O35.9XX5, O35.9XX9, O36.0110-O36.0115, O36.0119, O36.0120-O36.0125, O36.0129, O36.0130-O36.0135, O36.0139, O36.0190-O36.0195, O36.0199, O36.0910-O36.0915, O36.0919, O36.0920-O36.0925, O36.0929, O36.0930-O36.0935, O36.0939, O36.0990-O36.0995, O36.0999, O36.1110-O36.1115, O36.1119, O36.1120-O36.1125, O36.1129, O36.1130-O36.1135, O36.1139, O36.1190-O36.1195, O36.1199, O36.1910-O36.1915, O36.1919, O36.1920-O36.1925, O36.1929, O36.1930-O36.1935, O36.1939, O36.1990-O36.1995, O36.1999, O36.20X0-O36.20X5, O36.20X9, O36.21X0-O36.21X5, O36.21X9, O36.22X0-O36.22X5, O36.22X9, O36.23X0-O36.23X5, O36.23X9, O36.4XX0-O36.4XX5, O36.4XX9, O36.5110-O36.5115, O36.5119-O36.5125, O36.5129-O36.5135, O36.5139, O36.5190-O36.5195, O36.5199, O36.5910-O36.5915, O36.5919-O36.5925, O36.5929-O36.5935, O36.5939, O36.5990-O36.5995, O36.5999, O36.60X0-O36.60X5, O36.60X9, O36.61X0-O36.61X5, O36.61X9, O36.62X0-O36.621X5, O36.62X9, O36.63X0-O36.63X5, O36.63X9, |

| Exclusions | Applicable Measures | Codes* |
|---------------------------------|---------------------|---|
| Pregnancy Diagnosis (continued) | | O36.70X0-O36.70X5, O36.70X9, O36.71X0-O36.71X5, O36.71X9, O36.72X0-O36.72X5, O36.72X9, O36.73X0-O36.73X5, O36.73X9, O36.80X0-O36.80X5, O36.80X9, O36.8120-O36.8125, O36.8129, O36.8130-O36.8135, O36.8139, O36.8190-O36.8195, O36.8199, O36.8210-O36.8215, O36.8219, O36.8220-O36.8225, O36.8229, O36.8230-O36.8235, O36.8239, O36.8290-O36.8295, O36.8299, O36.8310-O36.8315, O36.8319, O36.8320-O36.8325, O36.8329-O36.8335, O36.8339, O36.8390-O36.8395, O36.8399, O36.8910-O36.8915, O36.8919, O36.8920-O36.8925, O36.8929, O36.8930-O36.8935, O36.8939, O36.8990-O36.8995, O36.8999, O36.90X0-O36.90X5, O36.90X9, O36.91X0-O36.91X5, O36.91X9, O36.92X0-O36.92X5, O36.92X9, O36.93X0-O36.93X5, O36.93X9, O40.1XX0-O40.1XX5, O40.1XX9, O40.2XX0-O40.2XX5, O40.2XX9, O4.31XX0-O40.3XX5, O40.3XX9, O40.9XX0-O40.9XX5, O40.9XX9, O41.00X0-O41.00X5, O41.00X9, O41.01X0-O41.01X5, O41.01X9, O41.02X0-O41.02X5, O41.02X9, O41.03X0-O41.03X5, O41.03X9, O41.1010-O41.1015, O41.1019-O41.1025, O41.1029-O41.1035, O41.1039, O41.1090-O41.1095, O41.1099, O41.1210-O41.1215, O41.1219-O41.1225, O41.1229-O41.1235, O41.1239, O41.1290-O41.1295, O41.1299, O41.1410-O41.1415, O41.1419-O41.1425, O41.1429-O41.1435, O41.1439, O41.1490-O41.1495, O41.1499, |

| Exclusions | Applicable Measures | Codes* |
|---------------------------------|---------------------|---|
| Pregnancy Diagnosis (continued) | | O41.8X10-O41.8X15, O41.8X19-O41.8X25, O41.8X29-O41.8X35, O41.8X39, O41.8X91-O41.8X95, O41.8X99, O41.90X0-O41.90X5, O41.90X9, O41.91X0-O41.91X5, O41.91X9, O41.92X0-O41.92X5, O41.92X9, O41.93X0-O41.93X5, O41.93X9, O42.00, O42.011-O42.013, O42.019, O42.02, O42.10, O42.111-O42.113, O42.119, O42.12, O42.011-O42.013, O42.90, O42.911-O42.913, O42.919, O42.92, O43.011-O43.013, O43.019, O43.021-O43.023, O43.029, O43.101-O43.103, O43.109, O43.111-O43.113, O43.119, O43.121-O43.123, O43.129, O43.191-O43.193, O43.199, O43.211-O43.213, O43.219, O43.221-O43.223, O43.229, O43.231-O43.233, O43.239, O43.811-O43.813, O43.819, O43.891-O43.893, O43.899, O43.90-O43.93, O44.00-O44.03, O44.10-O44.13, O44.20-O44.23, O44.30-O44.33, O44.40-O44.43, O44.50-O44.53, O45.001-O45.003, O45.009, O45.011-O45.013, O45.019, O45.021-O45.023, O45.029, O45.091-O45.093, O45.099, O45.8X1-O45.8X3, O45.8X9, O45.90-O45.93, O46.001-O46.003, O46.009, O46.011-O46.013, O46.019, O46.021-O46.023, O46.029, O46.091-O46.093, O46.099, O46.8X1-O46.8X3, O46.8X9, O46.90-O46.93, O47.00-O47.03, O47.1, O47.9, O48.0-O48.1, O60.00, O60.02-O60.03, O71.00-O71.02-O71.03, O71.1-O71.7, O71.81-O71.82, O71.89, O71.9, O88.011-O88.013, O88.019, O88.111-O88.113, O88.119, O88.211-O88.213, O88.219, |

| Exclusions | Applicable Measures | Codes* |
|---------------------------------|---------------------|---|
| Pregnancy Diagnosis (continued) | | O88.311-O88.313, O88.319, O88.811-O88.813, O88.819, O91.011-O91.013, O91.019, O91.13, O91.211-O91.213, O91.219, O91.23, O92.011-O92.013, O92.019, O92.03, O92.111-O92.113, O92.119, O92.3-O92.6, O92.70, O92.79, O98.011-O98.013, O98.019, O98.111-O98.113, O98.119, O98.211-O98.213, O98.219, O98.311-O98.313, O98.319, O98.411-O98.413, O98.419, O98.511-O98.513, O98.519, O98.611-O98.613, O98.619, O98.711-O98.713, O98.719, O98.811-O98.813, O98.819, O98.911-O98.913, O98.919, O99.011-O99.013, O99.019, O99.111-O99.113, O99.119, O99.210-O99.213, O99.280-O99.283, O99.310-O99.313, O99.320-O99.323, O99.330-O99.333, O99.340-O99.343, O99.350-O99.353, O99.411-O99.413, O99.419, O99.511-O99.513, O99.519, O99.611-O99.613, O99.619, O99.711-O99.713, O99.719, O99.810, O99.820, O99.830, O99.840-O99.843, O99.891, O9A.111-O9A.113, O9A.119, O9A.211-O9A.213, O9A.219, O9A.311-O9A.313, O9A.319, O9A.411-O9A.413, O9A.419, O9A.511-O9A.513, O9A.519, Z03.71-Z03.75, Z03.79, Z32.01, Z34.00-Z34.03, Z34.80-Z34.83, Z34.90-Z34.93, Z36, Z36.0-Z36.5, Z36.81-Z36.89, Z36.8A, Z36.9 |
| Dialysis Procedure | KED, SPC, SPD | CPT: 90935, 90937, 90945, 90947, 90997, 091999 HCPCS: G0257, S9339 ICD-10: 3E1M39Z, 5A1D00Z, 5A1D50Z, 5A1D70Z, 5A1D80Z, 5A1D90Z |
| Narcolepsy | ADD | ICD-10: G47.411, G47.419, G47.421, G47.429 |

| Exclusions | Applicable Measures | Codes* |
|---|---------------------|---|
| Contraindications to Childhood Vaccines | | <p>ICD10CM: B20, B97.35, C81.00, C81.01-C81.49, C81.70-C81.79, C81.90-C81.99, C82.00-C82.69, C82.80-C82.99, C83.00-C83.19, C83.30-C83.39, C83.50-C83.59, C83.70-C83.99, C84.00-C84.19, C84.40-C84.49, C84.60-C84.79, C84.7A, C84.90-C84.99, C84.A0-C84.A9, C84.Z0-C84.Z9, C85.10-C85.29, C85.80-C85.99, C86.0-C88.9, C90.00-C90.02, C90.10-C90.12, C90.20-C90.22, C90.30-C90.32, C91.00-C91.02, C91.10-C91.12, C91.30-C91.32, C91.40-C91.42, C91.50-C91.52, C91.60-C91.62, C91.90-C91.92, C91.A0-C91.A2, C91.Z0-C91.Z2, C92.00-C92.02, C92.10-C92.12, C92.20-C92.22, C92.30-C92.32, C92.40-C92.42, C92.50-C92.52, C92.60-C92.62, C92.90-C92.92, C92.A0-C92.A2, C92.Z0-C92.Z2, C93.00-C93.02, C93.10-C93.12, C93.30-C93.32, C93.90-C93.92, C93.Z0-C93.Z2, C94.00-C94.02, C94.20-C94.22, C94.30-C94.32, C94.80-C94.82, C95.00-C95.02, C95.10-C95.12, C95.90-C95.92, C96.0, C96.20-C96.22, C96.29, C96.4, C96.9, C96.A, C96.Z, D80.0-D80.9, D81.0, D81.1, D81.2, D81.4, D81.6, D81.7, D81.82, D81.89, D81.9, D82.0-D82.4, D82.8-D82.9, D83.0-D83.2, D83.8-D83.9, D84.0-D84.1, D84.8, D84.81, D84.821, D84.822, D84.89, D84.9, D89.3, D89.810, D89.811, D89.812, D89.813, D89.82, D89.831, D89.832, D89.833, D89.834, D89.835, D89.839, D89.89, D89.9, K56.1, Z21</p> |

*Codes listed are subject to change. Meridian recognizes that the circumstances around the services provided may not always directly support/match the codes. It is crucial that the medical record documentation describes the services rendered in order to support the medical necessity and use of these codes.

Point of Service Code Definitions

| Code | Description |
|------|--|
| 02 | Telehealth Provided Other than in Patient's Home |
| 03 | School |
| 05 | Indian Health Service Free-standing Facility |
| 07 | Tribal 638 Free-standing Facility |
| 09 | Prison/Correctional Facility |
| 10 | Telehealth Provided in Patient's Home |
| 11 | Office |
| 12 | Home |
| 13 | Assisted Living Facility |
| 14 | Group Home |
| 15 | Mobile Unit |
| 16 | Temporary Lodging |
| 17 | Walk-in Retail Health Clinic |
| 18 | Place of Employment-Worksite |
| 19 | Off Campus-Outpatient Hospital |
| 20 | Urgent Care Facility |
| 21 | Inpatient Hospital |
| 22 | On Campus-Outpatient Hospital |
| 31 | Skilled Nursing Facility |
| 32 | Nursing Facility |
| 33 | Custodial Care Facility |
| 49 | Independent Clinic |
| 50 | Federally Qualified Health Center |
| 51 | Inpatient Psychiatric Facility |
| 56 | Psychiatric Residential Treatment Center |
| 57 | Non-residential Substance Abuse Treatment Facility |
| 58 | Non-residential Opioid Treatment Facility |
| 71 | Public Health Clinic |
| 72 | Rural Health Clinic |
| 81 | Independent Laboratory |